

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63/221,819, filed July 14, 2021, which is incorporated by reference herein in
5 its entirety.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in Sequence Listing XML format in lieu of a paper copy and is hereby incorporated by reference into the specification. The name of the XML file containing the Sequence Listing is 137080-
10 03620_SL.xml. The text file is 198,833 bytes in size, created on July 14, 2022, and is being submitted electronically via Patent Center, concurrent with the filing of the specification.

BACKGROUND

Technical Field

The present invention relates to engineered T cell receptors (TCRs). Particularly, the
15 present invention relates to TCR-based constructs and complexes engineered to comprise one or more additional antigen-binding domains, and methods of using the same. In certain embodiments, the one or more antigen-binding domains are linked to the TCR α , TCR β , TCR γ , and/or TCR δ variable domains. In particular embodiments, the one or more additional antigen-binding domains are linked to the TCR variable domain via one or more polypeptide linkers.

Description of the Related Art

Adoptive T cell therapies can be engineered to target either cell surface antigens (via chimeric antigen receptors; CAR) or intracellular antigens (via engineered T cell receptors; TCR). CAR T cell activation and anti-tumor activity is achieved through linking targeting moieties to a compound intracellular signaling region comprising one or more costimulatory signaling domains
25 fused to the CD3-zeta signaling domain. Conversely, engineered TCR T cells become activated

through the natural intracellular signaling events coordinated by the CD3 complex and other proximal signaling molecules, resulting in increased sensitivity over CAR T cells.

While the response sensitivity of TCR T cells over CAR T cells is desirable, TCR T cells are limited by other characteristics. For example, since target recognition is governed by MHC-
5 restriction, TCRs are usually developed toward HLA haplotypes that are present in less than 40% of the general population. This represents a ceiling for patient eligibility/recruitment, prior to standard cuts stemming from target expression and other exclusions and limitations. MHC-
restriction also creates ample opportunity for target cells (*e.g.*, tumors) to evolve escape routes via genetic mutation or suppression of antigen processing and presentation machinery.

10 Accordingly, there remains a need for improved TCR-based constructs and therapies to treat disease.

BRIEF SUMMARY

The present disclosure generally relates, in part, to engineered T cell receptors, fusion proteins, polynucleotides, compositions, medicaments and uses thereof.

15 In one aspect an engineered T cell receptor (TCR) is provided, wherein the engineered TCR receptor comprises one or more antigen-binding domain(s) linked to one or both TCR variable domains.

In another aspect, an engineered T cell receptor (TCR) is provided comprising (a) a TCR α polypeptide comprising a TCR α variable domain; (b) a TCR β polypeptide comprising a
20 TCR β variable domain; and (c) one or more antigen-binding domains linked to the TCR α variable domain and/or TCR β variable domain.

In another aspect, an engineered T cell receptor (TCR) is provided comprising (a) a TCR γ polypeptide comprising a TCR γ variable domain; (b) a TCR δ polypeptide comprising a TCR δ variable domain; and (c) one or more antigen-binding domains linked to the TCR γ variable
25 domain and/or TCR δ variable domain.

In another aspect a fusion polypeptide is provided comprising (a) a TCR β polypeptide comprising a TCR β variable domain; (b) a polypeptide cleavage signal; and (c) a TCR α polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR α variable domain.

In another aspect a fusion polypeptide is provided comprising (a) a TCR β polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR β variable domain; (b) a polypeptide cleavage signal; and (c) a TCR α polypeptide comprising a TCR α variable domain.

5 In another aspect a fusion polypeptide is provided comprising (a) a TCR β polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR β variable domain; (b) a polypeptide cleavage signal; and (c) a TCR α polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR α variable domain.

10 In another aspect a fusion polypeptide is provided comprising (a) a TCR γ polypeptide comprising a TCR γ variable domain; (b) a polypeptide cleavage signal; and (c) a TCR δ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR δ variable domain.

15 In another aspect a fusion polypeptide is provided comprising (a) a TCR γ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR γ variable domain; (b) a polypeptide cleavage signal; and (c) a TCR δ polypeptide comprising a TCR δ variable domain.

20 In another aspect a fusion polypeptide is provided comprising (a) a TCR γ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR γ variable domain; (b) a polypeptide cleavage signal; and (c) a TCR δ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR δ variable domain.

In various embodiments, the TCR α polypeptide comprises a TCR α constant domain and the TCR β polypeptide comprises a TCR β constant domain.

In various embodiments, the TCR γ polypeptide comprises a TCR γ constant domain and the TCR δ polypeptide comprises a TCR δ constant domain.

25 In various embodiments, the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR α or TCR γ variable domain. In some embodiments, the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR β or TCR δ variable domain. In some embodiments, the one or more antigen-binding domains comprise: (i) a first antigen-binding domain linked to the TCR α or TCR γ variable domain, and (ii) a first antigen-binding domain linked to the TCR β or TCR δ variable domain. In some embodiments, the first antigen-binding domains are linked to the N-terminus of the variable

30

domains. In some embodiments, the first antigen-binding domains are the same or different, and/or bind to the same or different target antigens.

In various embodiments, the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain. In various embodiments, the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α or TCR γ variable domain. In some embodiments, the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR β or TCR δ variable domain. In some embodiments, the one or more antigen-binding domains comprises: (i) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α or TCR γ variable domain, and (ii) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR β or TCR δ variable domain.

In various embodiments, the second antigen-binding domains are linked to the N-terminus of the first antigen-binding domain. In some embodiments, the second antigen-binding domains are the same or different, and/or bind to the same or different target antigens. In some embodiments, the first and second antigen-binding domains are the same or different, and/or bind to the same or different target antigens.

In various embodiments, the one or more antigen-binding domains bind a target antigen selected from the group consisting of: alpha folate receptor (FR α), $\alpha_v\beta_6$ integrin, ADGRE2, BACE2, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H4, B7-H6, CA19.9, carbonic anhydrase IX (CAIX), CCR1, CD7, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CD244, carcinoembryonic antigen (CEA), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), CLDN6, cMET, chondroitin sulfate proteoglycan 4 (CSPG4), CLDN18.2, cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), DLL3, epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), EGFR806, epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), EPHB2, ERBB4, epithelial cell adhesion molecule (EPCAM), ephrin type-A receptor 2 (EPHA2), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AChR), FLT3, FN, FN-EDB, FRBeta, ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), HER2p95, EGFRv3, IL-10R α , IL-13R α 2, Kappa, cancer/testis antigen 2 (LAGE-1A), K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, LY6G6GD, melanoma antigen recognized by T cells 1

- (MelanA or MART1), Mesothelin (MSLN), MMP10, MUC1, MUC16, MHC class I chain related proteins A (MICA), MHC class I chain related proteins B (MICB), neural cell adhesion molecule (NCAM), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X
- 5 breakpoint 2 (SSX2), Survivin, tumor associated glycoprotein 72 (TAG72), transmembrane activator and CAML interactor (TACI), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), TIM3, trophoblast glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, and vascular endothelial growth factor receptor 2 (VEGFR2).
- 10 In various embodiments, the one or more antigen-binding domains bind a target polypeptide derived from a protein selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell
- 15 (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-
- 20 Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1
- 25 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X
- 30 Antigen Family Member 2 (XAGE2).

In some embodiments, the one or more antigen-binding domains bind CD33, CLL1, CD19, CD20, CD22, CD79A, CD79B, or BCMA. In some embodiments, the one or more antigen-binding domains bind CD19, CD20, CD22, CD33, CD79A, CD79B, B7H3, Muc16,

Her2, EGFR, FN-EDB, CLDN18.2, DLL3, FLT3, CLL1, CD123, or BCMA. In some embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 95% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32.

In various embodiments, the one or more antigen-binding domains comprise an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')₂ fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein ("scFv"), a bis-scFv, (scFv)₂, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein ("dsFv"), and a single-domain antibody (sdAb, a camelid VHH, Nanobody). In some embodiments, the one or more antigen-binding domains comprise one or more single-chain variable fragments (scFv). In some embodiments, the one or more antigen-binding domains comprise one or more single domain antibodies (sdAb). In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In some embodiments, the sdAb is a camelid VHH. In some embodiments, the antibody or antigen binding fragment thereof is human or humanized.

In various embodiments, the one or more antigen-binding domains comprise a ligand.

In various embodiments, the one or more antigen-binding domains are linked to the TCR variable domains by one or more polypeptide linkers. In some embodiments, the one or more polypeptide linkers comprise a linker from about 2 to about 25 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker from about 4 to about 15 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker from about 4 to about 10 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 9 or about 10 amino acids long.

In various embodiments, the one or more polypeptide linkers comprise a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), a linker from a marsupial $\gamma\mu$ TCR (*e.g.*, LEKT; SEQ ID NO: 33), and any combination thereof. In some embodiments, the one or more polypeptide linkers comprises a linker from a marsupial $\gamma\mu$ TCR, comprising an amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the one or more polypeptide linkers comprise a GGGGS (SEQ ID NO: 35) linker (G4S). In some embodiments, the one or more polypeptide linkers comprise a marsupial $\gamma\mu$ TCR linker and a G4S linker as set forth in

SEQ ID NO: 34. In some embodiments, the one or more polypeptide linkers comprise two GGGGS linkers (2xG4S) (SEQ ID NO: 36). In some embodiments, the one or more polypeptide linkers comprise three GGGGS linkers (3xG4S) (SEQ ID NO: 37). In particular embodiments, the one or more polypeptide linkers comprise an amino acid sequence as set forth in any one of
 5 SEQ ID NOs: 33-53.

In various embodiments, the first and second antigen-binding domains are separated by a second polypeptide linker. In some embodiments, the second polypeptide linker is about 2 to about 25 amino acids long. In some embodiments, the second polypeptide linker is about 4 to about 15 amino acids long.

10 In various embodiments, the second polypeptide linker comprises a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), and any combination thereof. In particular embodiments, the second polypeptide linker comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

15 In various embodiments, the TCR variable domains bind a target polypeptide presented by an MHC complex.

In various embodiments, the TCR variable domains bind a target polypeptide derived from a protein selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-
 20 testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-
 25 structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1),
 30 Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen

PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X
 5 Antigen Family Member 2 (XAGE2). In some embodiments, the TCR variable domains bind a target polypeptide derived from MAGE-A4, PRAME, K-Ras, TP53R175H, PSA, or IGF2BP3. In some embodiments, the TCR variable domains bind a target polypeptide derived from MAGE-A4.

In various embodiments, the TCR α constant domain comprises an amino acid sequence at
 10 least 90% identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88, and/or the TCR β constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87.

In various embodiments, the TCR γ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84, and/or the
 15 TCR δ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NO: 85.

In various embodiments, the TCR α or TCR γ polypeptide comprises (i) an amino acid sequence as set forth in any one of SEQ ID NOs: 105-111, or (ii) a TCR α or TCR γ variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 62, 64, 66,
 20 68, 70, 72, 74, 76, and 78.

In various embodiments, the TCR β or TCR δ polypeptide comprises (i) an amino acid sequence as set forth in SEQ ID NO: 103 or 104, or (ii) a TCR β or TCR δ variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 63, 65, 67, 69, 71, 73, 75, 77, and 79.

In various embodiments, the polypeptide cleavage signal of the fusion polypeptide is a
 25 viral self-cleaving peptide or ribosomal skipping sequence. In some embodiments, the polypeptide cleavage signal is a viral 2A peptide. In some embodiments, the polypeptide cleavage signal is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide. In some embodiments, the polypeptide cleavage signal is a viral 2A peptide selected from the
 30 group consisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thosa asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide. In

some embodiments, the polypeptide cleavage signal comprises a furin recognition site upstream of the self-cleaving peptide, optionally wherein the furin recognition site comprises the amino acid sequence as set forth in SEQ ID NO: 112. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 113-137.

5 In various embodiments, the TCR β or TCR δ polypeptide of the fusion polypeptide is N-terminal of the TCR α or TCR γ polypeptide.

In various embodiments, the TCR α or TCR γ polypeptide of the fusion polypeptide is N-terminal of the TCR β or TCR δ polypeptide.

10 In various embodiments, the TCR α and TCR β polypeptides each comprise an N-terminal signal sequence. In various embodiments, the TCR γ and TCR δ polypeptides each comprises an N-terminal signal sequence. In some embodiments, the signal sequences are the same or different. In some embodiments, the signal sequence is an IgK or TCR α signal sequence. In some embodiments, the signal sequence is an CD8 α signal sequence.

15 In various embodiments, the fusion polypeptide comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102.

In another aspect, a polynucleotide encoding an engineered TCR or fusion polypeptide contemplated herein is provided.

20 In another aspect, a vector comprising one or more polynucleotides contemplated herein is provided. In some embodiments, the vector is an expression vector, retroviral vector, or a lentiviral vector.

25 In another aspect, a cell comprising an engineered TCR, fusion polypeptide, polynucleotide, or vector contemplated herein is provided. In some embodiments, the cell is a hematopoietic cell. In some embodiments, the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell. In some embodiments, the cell is a CD3 $^{+}$, CD4 $^{+}$, and/or CD8 $^{+}$ cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a cytotoxic T lymphocytes (CTLs), a tumor infiltrating lymphocytes (TILs), or a helper T cell. In some embodiments, the cell is a T cell, a natural killer (NK) cell, or a natural killer T (NKT) cell. In some embodiments, the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors. In some embodiments, the cell is an isolated non-natural cell. In some embodiments, the cell is obtained from a subject. In some embodiments, the cell is a human cell.

In another aspect, a composition comprising an engineered TCR, fusion polypeptide, polynucleotide, vector, or cell contemplated herein is provided.

In another aspect, a pharmaceutical composition comprising an engineered TCR, fusion polypeptide, polynucleotide, vector, or cell contemplated herein is provided.

- 5 In another aspect, a method of treating a subject in need thereof is provided, comprising administering the subject an effective amount of a cell, composition, or a pharmaceutical composition contemplated herein.

- In another aspect, a method of treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and
10 immunodeficiency, or condition associated therewith is provided, comprising administering to the subject an effective amount a cell, composition, or a pharmaceutical composition contemplated herein.

- In another aspect, a method of treating a solid cancer is provided, comprising administering to the subject an effective amount of a cell, composition, or a pharmaceutical
15 composition contemplated herein. In various embodiments, the solid cancer is selected from the group consisting of: lung cancer, squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, brain cancer, or sarcoma. In some embodiments, the solid cancer is a non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), head and
20 neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, oligodendroglioma, sarcoma, or osteosarcoma.

- In another aspect, a method of treating a hematological malignancy comprising administering to the subject an effective amount of a cell, composition, or a pharmaceutical
25 composition contemplated herein. In various embodiments, the hematological malignancy is a leukemia, lymphoma, or multiple myeloma. In some embodiments, the hematological malignancy is selected from the group consisting of non-Hodgkin's lymphoma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL).

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

Figure 1A shows illustrative MAGE TCR, CD33 DARIC, and engineered TCR (VHH-TCR) construct designs.

Figure 1B shows an illustrative engineered TCR having a VHH linked to a TCR.

5 **Figure 2A** shows VHH expression on immune effector cells.

Figure 2B shows engineered TCR/receptor cytokine response against A549.CD33 cells.

Figure 2C shows engineered TCR/receptor cytotoxicity against A549.CD33 cells.

Figure 3A shows engineered TCR/receptor expression on immune effector cells.

10 **Figure 3B** shows engineered TCR/receptor cytokine response against A549.A2.MAGEA4 cells.

Figure 3C shows engineered TCR/receptor cytotoxicity against A549.A2.MAGEA4 cells.

Figure 4A shows engineered TCR cytokine response against MAGEA4 peptide.

15 **Figures 4B and 4C** show engineered TCR cytokine response against cells electroporated with varying amounts of CD33 mRNA.

Figures 5A-5C show engineered TCR and DARIC cytotoxicity against HL-60, Kasumi1, and OCI-AML3 cells.

Figure 6 shows illustrative engineered TCR constructs.

Figure 7A shows VHH expression on immune effector cells.

20 **Figure 7B** shows engineered TCR/receptor cytokine response against A549.CD33 cells.

Figure 7C shows engineered TCR/receptor cytotoxicity against A549.CD33 cells.

Figure 8A shows VHH expression on immune effector cells.

Figure 8B shows engineered TCR/receptor cytokine response against A549.MAGEA4.A2 cells.

25 **Figure 8C** shows engineered TCR/receptor cytotoxicity against A549.MAGEA4.A2 cells.

Figure 9 shows illustrative engineered TCR constructs.

Figure 10A shows VHH expression on immune effector cells.

Figure 10B shows engineered TCR/receptor cytokine response against A549.CD33 cells.

Figure 10C shows engineered TCR/receptor cytotoxicity against A549.CD33 cells.

Figure 11A shows VHH expression on immune effector cells.

5 **Figure 11B** shows engineered TCR cytokine response against A549.MAGEA4.A2 cells.

Figure 11C shows engineered TCR/receptor cytotoxicity against A549.MAGEA4.A2 cells.

Figure 12A shows illustrative MAGE TCR, CD33 DARIC, CLL1 DARIC, CLL1-CD33 DARIC, and engineered TCR (CLL1-CD33 VHH TCR) construct designs.

10 **Figure 12B** shows an illustrative engineered TCR having two VHHs linked to the TCR.

Figure 13A shows CD33-based receptor expression on immune effector cells.

Figure 13B shows engineered TCR/receptor cytokine response against A549.CD33 cells.

Figure 14A shows CLL1-based receptor expression on immune effector cells.

Figure 14B shows engineered TCR/receptor cytokine response against A549.CLL1 cells.

15 **Figure 15A** shows TCR expression on immune effector cells.

Figure 15B shows engineered TCR/receptor cytokine response against A549.MAGEA4 cells.

Figure 16 shows TCR and CAR expression on immune effector cells.

20 **Figure 17** shows engineered TCR and CAR cytokine responses against A375.NLR (MAGEA4+; BCMA-) cells.

Figure 18A shows engineered TCR and CAR IFN γ cytokine response against Toledo cells.

Figure 18B shows engineered TCR and CAR IL-2 cytokine response against Toledo cells.

25 **Figure 19** shows antigen-independent IFN γ cytokine response with engineered TCR and CAR T cells alone.

Figure 20A shows illustrative MAGEA4 TCR, scFv CAR, and engineered TCR (scFv TCR) construct designs.

Figure 20B shows an illustrative engineered TCR having an scFv linked to the TCR.

Figure 21A shows BCMA-based receptor expression on immune effector cells.

Figure 21B shows engineered TCR/receptor IFN γ cytokine response against HT1080.BCMA, RPMI-8226, and Toledo cells.

5 **Figure 21C** shows engineered TCR/receptor IL-2 cytokine response against HT1080.BCMA, RPMI-8226, and Toledo cells.

Figure 21D shows engineered TCR/receptor TNF α cytokine response against HT1080.BCMA, RPMI-8226, and Toledo cells.

Figure 21E shows engineered TCR/receptor cytotoxicity against HT1080.BCMA cells.

10 **Figure 22A** shows TCR expression on immune effector cells.

Figure 22B shows engineered TCR/receptor IFN γ , IL2, and TNF α cytokine response against A375 cells.

Figure 23 shows HL-60.FP (CD33+ MAGEA4-) tumor growth in an NGS systemic tumor model treated with UTD T cells, CD33 DARIC T cells, MAGEA4 TCR T cells, or VHH-
15 TCR T cells.

Figure 24 shows NCI-H2023 (CD33- MAGEA4+) tumor growth in an NGS subcutaneous tumor model treated with UTD T cells, CD33 DARIC T cells, MAGEA4 TCR T cells, or VHH-TCR T cells.

Figure 25A shows TCR/ATOMIC expression on immune effector cells.

20 **Figure 25B** shows engineered TCR/ATOMIC IFN γ cytokine response against RPMI-8226 cells.

Figure 25C shows engineered TCR/ATOMIC IFN γ cytokine response against K562.CD19 cells.

BRIEF DESCRIPTION OF THE SEQUENCE IDENTIFIERS

25 **SEQ ID NOs: 1-32** set forth the amino acid sequences for representative target antigen binding domains.

SEQ ID NOs: 33-53 set forth the amino acid sequences for representative polypeptide linkers.

SEQ ID NOs: 54-79 set forth the amino acid sequences for representative TCR components (*e.g.*, TCR variable regions).

SEQ ID NOs: 80-88 set forth the amino acid sequences for representative TCR constant domains.

5 **SEQ ID NO: 89** sets forth the amino acid sequence for a representative MAGEA4-targeting TCR.

SEQ ID NOs: 90, 98, and 99 set forth the amino acid sequences for representative DARICs.

10 **SEQ ID NO: 91-97, 100, and 102** set forth the amino acid sequences for representative engineered TCR constructs/ATOMICs.

SEQ ID NO: 101 sets forth the amino acid sequences for a representative anti-BCMA CAR.

SEQ ID NOs: 103-111 set forth the amino acid sequences for representative TRA or TRB polypeptides.

15 **SEQ ID NO: 112** sets forth the amino acid sequence for a representative furin cleavage site.

SEQ ID NO: 113-137 set forth the amino acid sequences for representative polypeptide cleavage signal (*e.g.*, self-cleaving peptides).

20 In the foregoing sequences, X, if present, refers to any amino acid or the absence of an amino acid.

DETAILED DESCRIPTION

A. OVERVIEW

25 The present disclosure generally relates to, in part, TCR-based constructs engineered to comprise one or more additional binding domains (*e.g.*, antigen-binding domains), and methods of using the same. Without wishing to be bound by any particular theory, the inventors have unexpectedly discovered that TCRs engineered to comprise both a TCR binding domain (*e.g.*, a TCR variable domain) and one or more additional antigen-binding domains are surprisingly effective at cell killing, and can target cells expressing either a TCR antigen, a non-TCR antigen,
30 or both.

The multi-chain architecture of the TCR poses significant structural hurdles to grafting secondary binders into the TCR architecture, and success has primarily been achieved through co-expressing scFv-CD3 chain fusions or replacing the TCR variable regions with antibody-based binders. Overall, the complexity and MHC-restricted nature of the TCR architecture has stymied the development of broadly applicable technologies that achieve high levels of sensitivity and/or multiplexing. At minimum, there are very few potential solutions to these important challenges that do not consume the majority of available vector (*e.g.*, lentiviral) payload space.

Thus, disclosed herein is an efficient and effective engineered/hybrid TCR architecture that enables concurrent TCR targeting and secondary binder targeting. Specifically, an antigen-binding domain (*e.g.*, a VHH or scFv) is linked to a TCR component, *e.g.*, a TCR α , TCR β , TCR γ , and/or TCR δ variable domain / chain, in a manner that preserves TCR function. In certain embodiments, the engineered TCRs comprise a linker between the antigen-binding domain and the TCR component, such that the function of each targeting molecule (*i.e.*, the TCR component and secondary antigen-binding domain) is preserved. Accordingly, the invention enables simultaneous targeting of intracellular and extracellular antigens.

In various embodiments, the engineered/hybrid TCR comprises one or more additional antigen-binding domains. In some embodiments, the engineered/hybrid TCR comprises two or more additional antigen-binding domains. In some embodiments, the two or more additional antigen-binding domains target the same or different antigens.

In various embodiments, the one or more antigen-binding domains are selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')₂ fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein ("scFv"), a bis-scFv, (scFv)₂, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein ("dsFv"), and a single-domain antibody (sdAb, a camelid VHH, Nanobody). In particular embodiments, the one or more antigen-binding domains comprise one or more single-chain variable fragments (scFv) or single domain antibodies (sdAb, *e.g.*, camelid VHHs).

In various embodiments, the linker is a polypeptide linker from about 2 to about 25 amino acids long. In some embodiments, the linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), a linker from a marsupial $\gamma\mu$ TCR (*e.g.*, LEKT; SEQ ID NO: 33), and any combination thereof. In particular embodiments, the linker comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

In various embodiments, the engineered TCR comprises one or more TCR components comprising one or more TCR variable domains that bind a target polypeptide presented by an MHC complex.

In various embodiments, the TCR component of the engineered TCR comprises a TCR
5 constant region. In some embodiments, the TCR constant region is selected from a TCR α , TCR β , TCR γ , or TCR δ constant region. In some embodiments, the TCR constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80-88.

In some embodiments, a non-functioning TCR can be used if antibody-based targeting
10 alone is sufficient.

Techniques for recombinant (*i.e.*, engineered) DNA, peptide and oligonucleotide synthesis, immunoassays, tissue culture, transformation (*e.g.*, electroporation, lipofection), enzymatic reactions, purification and related techniques and procedures may be generally performed as described in various general and more specific references in microbiology,
15 molecular biology, biochemistry, molecular genetics, cell biology, virology and immunology as cited and discussed throughout the present specification. See, *e.g.*, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (John Wiley and Sons, updated July 2008); Short Protocols in Molecular Biology: A Compendium of Methods from Current
20 Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Glover, DNA Cloning: A Practical Approach, vol. I & II (IRL Press, Oxford Univ. Press USA, 1985); Current Protocols in Immunology (Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober 2001 John Wiley & Sons, NY, NY); Real-Time PCR: Current Technology and Applications, Edited by Julie Logan, Kirstin Edwards and Nick
25 Saunders, 2009, Caister Academic Press, Norfolk, UK; Anand, Techniques for the Analysis of Complex Genomes, (Academic Press, New York, 1992); Guthrie and Fink, Guide to Yeast Genetics and Molecular Biology (Academic Press, New York, 1991); Oligonucleotide Synthesis (N. Gait, Ed., 1984); Nucleic Acid The Hybridization (B. Hames & S. Higgins, Eds., 1985); Transcription and Translation (B. Hames & S. Higgins, Eds., 1984); Animal Cell Culture (R.
30 Freshney, Ed., 1986); Perbal, A Practical Guide to Molecular Cloning (1984); Next-Generation Genome Sequencing (Janitz, 2008 Wiley-VCH); PCR Protocols (Methods in Molecular Biology) (Park, Ed., 3rd Edition, 2010 Humana Press); Immobilized Cells And Enzymes (IRL Press, 1986); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For

Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Harlow and Lane, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and CC Blackwell, eds., 1986); Roitt, Essential Immunology, 6th Edition, (Blackwell Scientific Publications, Oxford, 1988); Current Protocols in Immunology (Q. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991); Annual Review of Immunology; as well as monographs in journals such as Advances in Immunology.

Methods and techniques for generating and modifying novel TCRs are also known in the art, see, e.g., Linnemann, C. *et al.*, *Nat. Med.*, 19, 1534–1541 (2013); Scheper, W. *et al.*, *Nat. Med.*, 25, 89–94 (2019); Yossef, R. *et al.*, *JCI Insight*, 3, 122467 (2018); Hu, Z. *et al.*, *Blood*, 132, 1911–1921 (2018); Li, Y. *et al.*, *Nat. Biotechnol*, 23, 349–354 (2005); Wagner, E. K. *et al.* *J. Biol. Chem*, 294, 5790–5804 (2019); Guo, X.-Z. J. *et al.*, *Mol. Ther. Methods Clin. Dev*, 3, 15054 (2016); Azizi, E. *et al.*, *Cell*, 174, 1293–1308 (2018); Kieke, M. C. *et al.*, *Proc. Natl Acad. Sci. USA*, 96, 5651–5656 (1999); Smith, S. N. *et al.*, 1319, 95–141 (Springer, 2015); Tsuji, T. *et al.*, *Cancer Immunol. Res*, 6, 594–604 (2018); and Spindler, M.J., *et al.*, *Nat Biotechnol*, 38, 609–619 (2020).

B. DEFINITIONS

Prior to setting forth this disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of particular embodiments, preferred embodiments of compositions, methods and materials are described herein. For the purposes of the present disclosure, the following terms are defined below.

The articles “a,” “an,” and “the” are used herein to refer to one or to more than one (*i.e.*, to at least one, or to one or more) of the grammatical object of the article. By way of example, “an element” means one element or one or more elements.

The use of the alternative (*e.g.*, “or”) should be understood to mean either one, both, or any combination thereof of the alternatives.

The term “and/or” should be understood to mean either one, or both of the alternatives.

As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level, value,

5 number, frequency, percentage, dimension, size, amount, weight or length. In one embodiment, the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length $\pm 15\%$, $\pm 10\%$, $\pm 9\%$, $\pm 8\%$, $\pm 7\%$, $\pm 6\%$, $\pm 5\%$, $\pm 4\%$, $\pm 3\%$, $\pm 2\%$, or $\pm 1\%$ about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

10 In one embodiment, a range, *e.g.*, 1 to 5, about 1 to 5, or about 1 to about 5, refers to each numerical value encompassed by the range. For example, in one non-limiting and merely illustrative embodiment, the range “1 to 5” is equivalent to the expression 1, 2, 3, 4, 5; or 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0; or 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5,
15 4.6, 4.7, 4.8, 4.9, or 5.0.

As used herein, the term “substantially” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In one
20 embodiment, “substantially the same” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that produces an effect, *e.g.*, a physiological effect, that is approximately the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

Throughout this specification, unless the context requires otherwise, the words
25 “comprise”, “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of” is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting
30 essentially of” is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed

elements are required or mandatory, but that no other elements are present that materially affect the activity or action of the listed elements.

Reference throughout this specification to “one embodiment,” “an embodiment,” “a particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional
5 embodiment,” or “a further embodiment” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one
10 or more embodiments. It is also understood that the positive recitation of a feature in one embodiment, serves as a basis for excluding the feature in a particular embodiment.

As used herein, the term “TCR complex” refers to a complex formed by the association of CD3 with a TCR. For example, a TCR complex can be composed of a CD3 γ chain, a CD3 δ chain, two CD3 ϵ chains, a homodimer of CD3 ζ chains, a TCR α chain, and a
15 TCR β chain. In some embodiments, a TCR complex can be composed of a CD3 γ chain, a CD3 δ chain, two CD3 ϵ chains, a homodimer of CD3 ζ chains, a TCR γ chain, and a TCR δ chain.

A “component of a TCR complex,” as used herein, refers to a TCR chain (*i.e.*, TCR α , TCR β , TCR γ or TCR δ), a CD3 chain (*i.e.*, CD3 γ , CD3 δ , CD3 ϵ or CD3 ζ), or a complex
20 formed by two or more TCR chains or CD3 chains (*e.g.*, a complex of TCR α and TCR β , a complex of TCR γ and TCR δ , a complex of CD3 ϵ and CD3 δ , a complex of CD3 γ and CD3 ϵ , or a sub-TCR complex of TCR α , TCR β , CD3 γ , CD3 δ , and two CD3 ϵ chains).

As used herein, the terms, “binding domain,” “extracellular domain,” “antigen binding domain,” “extracellular binding domain,” “extracellular antigen binding domain,”
25 “antigen-specific binding domain,” “extracellular antigen specific binding domain,” “binder,” and “antigen binder” are used interchangeably and provide a polypeptide with the ability to specifically bind to the target antigen of interest. The binding domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.

The term “antibody” refers to a binding agent that is a polypeptide comprising at least
30 a light chain or heavy chain immunoglobulin variable region or fragment thereof which specifically recognizes and binds one or more epitopes of an antigen, such as a peptide, lipid,

polysaccharide, or nucleic acid containing an antigenic determinant, such as those recognized by an immune cell.

The term “antibody” encompasses any naturally-occurring, recombinant, modified or engineered immunoglobulin or immunoglobulin-like structure or antigen-binding fragment or portion thereof, or derivative thereof, as further described elsewhere herein. Thus, the term refers to an immunoglobulin molecule that specifically binds to a target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An intact antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camelids which can comprise only heavy chains. Antibodies can be derived solely from a single source, or can be “chimeric,” that is, different portions of the antibody can be derived from two different antibodies. Antibodies, or antigen-binding portions thereof, can be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies.

The term “antigen binding fragment” or “antigen binding portion” refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Antigen binding fragments include, but are not limited to, any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. In some embodiments, an antigen-binding portion of an antibody may be derived, *e.g.*, from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains.

A “Single-chain Fv” or “scFv” antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain and in either orientation (*e.g.*, VL-VH or VH-VL). For example, in some embodiments, the scFv variable light chain is positioned c-terminal to that of the variable heavy chain. In some embodiments, the scFv variable heavy chain is positioned c-terminal to that of the variable light chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see, *e.g.*, Pluckthün, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., (Springer-Verlag, New York, 1994), pp. 269-315.

A “V_HH,” “V_HH antibody,” or “V_HH domain” as used herein refers an antibody fragment that contains the smallest known antigen-binding unit of the variable region of a heavy chain antibody (Koch-Nolte, *et al*, *FASEB J.*, 21: 3490-3498 (2007)).

5 An “isolated antibody or antigen binding fragment thereof” refers to an antibody or antigen binding fragment thereof which has been identified and separated and/or recovered from a component of its natural environment.

The terms “Antigen (Ag),” “target antigen,” and “polypeptide antigen” are used interchangeably and broadly include any molecules comprising an antigenic determinant within a binding region(s) to which an TCR or antibody or a fragment specifically binds. In
10 particular embodiments, an “antigen (Ag)” refers to a compound, composition, or substance that can stimulate the production of antibodies or a T cell response in an animal, including compositions (such as one that includes a cancer-specific protein) that are injected or absorbed into an animal. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous antigens, such as the disclosed antigens.

15 An antigen can be a single-unit molecule (such as a protein monomer or a fragment) or a complex comprised of multiple components. An antigen provides an epitope, *e.g.*, a molecule or a portion of a molecule, or a complex of molecules or portions of molecules, capable of being bound by a selective binding agent, such as an antigen-binding protein (including, *e.g.*, an antibody and/or a TCR). Thus, a selective binding agent may specifically
20 bind to an antigen that is formed by two or more components in a complex. In some embodiments, the antigen is capable of being used in an animal to produce antibodies capable of binding to that antigen. An antigen can possess one or more epitopes that are capable of interacting with different antigen-binding proteins, *e.g.*, antibodies. In preferred TCR-related embodiments, the terms “antigen (Ag),” “target antigen,” and “polypeptide antigen” are
25 collective refer to a naturally processed or synthetically produced portion of an antigenic protein, *e.g.*, a tumor associated antigen (TAA) or tumor specific antigen (TSA), ranging in length from about 7 amino acids to about 15 amino acids, which can form a complex with a MHC (*e.g.*, HLA) molecule forming a target antigen:MHC (*e.g.*, HLA) complex.

A “target antigen” or “target antigen of interest” refers to a molecule expressed on the cell
30 surface of a target cell that a binding domain contemplated herein, is designed to bind. In particular embodiments, the target antigen is an epitope of a polypeptide expressed on the surface of a cancer cell. An “epitope” or “antigenic determinant” refers to the region of an antigen to

which a binding agent binds. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5, about 9, or about 8-10 amino acids in a unique spatial conformation.

The terms “selectively binds” or “selectively bound” or “selectively binding” or “selectively targets”, “specific binding affinity” or “specifically binds” or “specifically bound” or “specific binding” or “specifically targets” as used herein, describes preferential binding of one molecule to a target molecule (on-target binding) in the presence of a plurality of off-target molecules. In particular embodiments, the terms refer to binding of a TCR, antibody, or antigen binding fragment thereof to an antigen at greater binding affinity than background binding. A binding domain “specifically binds” to an antigen if it binds to or associates with the antigen With an affinity or K_a (*i.e.*, an equilibrium association constant of a particular binding interaction with units of $1/M$) of, for example, greater than or equal to about $10^5 M^{-1}$. In certain embodiments, a binding domain (or a fusion protein thereof) binds to a target with a K_a greater than or equal to about $10^6 M^{-1}$, $10^7 M^{-1}$, $10^8 M^{-1}$, $10^9 M^{-1}$, $10^{10} M^{-1}$, $10^{11} M^{-1}$, $10^{12} M^{-1}$, or $10^{13} M^{-1}$. “High affinity” binding domains (or single chain fusion proteins thereof) refers to those binding domains with a K_a of at least $10^7 M^{-1}$, at least $10^8 M^{-1}$, at least $10^9 M^{-1}$, at least $10^{10} M^{-1}$, at least $10^{11} M^{-1}$, at least $10^{12} M^{-1}$, at least $10^{13} M^{-1}$, or greater.

Alternatively, affinity may be defined as an equilibrium dissociation constant (K_d) of a particular binding interaction with units of M (*e.g.*, $10^{-5} M$ to $10^{-13} M$, or less). Affinities of binding domain polypeptides and CAR proteins according to the present disclosure can be readily determined using conventional techniques, *e.g.*, by competitive ELISA (enzyme-linked immunosorbent assay), or by binding association, or displacement assays using labeled ligands, or using a surface-plasmon resonance device such as the Biacore T100, which is available from Biacore, Inc., Piscataway, NJ, or optical biosensor technology such as the EPIC system or EnSpire that are available from Corning and Perkin Elmer respectively (*see also, e.g.*, Scatchard *et al.* (1949) Ann. N.Y. Acad. Sci. 51:660; and U.S. Patent Nos. 5,283,173; 5,468,614, or the equivalent).

In one embodiment, the affinity of specific binding is about 2 times greater than background binding, about 5 times greater than background binding, about 10 times greater than background binding, about 20 times greater than background binding, about 50 times

greater than background binding, about 100 times greater than background binding, or about 1000 times greater than background binding or more.

In particular embodiments, the engineered/hybrid TCR comprises an antibody or antigen binding fragment thereof. In the context of an engineered TCR, an “antibody” refers
5 to a binding agent that is a polypeptide comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen, such as a peptide, lipid, polysaccharide, or nucleic acid containing an antigenic determinant, such as those recognized by an immune cell.

As would be understood by the skilled person and as described elsewhere herein, a
10 complete antibody comprises two heavy chains and two light chains. Each heavy chain consists of a variable region and a first, second, and third constant region, while each light chain consists of a variable region and a constant region.

Light and heavy chain variable regions contain a “framework” region interrupted by three hypervariable regions, also called “complementarity-determining regions” or “CDRs.”
15 The CDRs can be defined or identified by conventional methods, such as by sequence according to Kabat *et al* (Wu, TT and Kabat, E. A., *J Exp Med.* 132(2):211-50, (1970); Borden, P. and Kabat E. A., *PNAS*, 84: 2440-2443 (1987); (see, Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, U.S. Department of Health and Human Services, 1991, which is hereby incorporated by reference), or by structure according to Chothia *et al*
20 (Chothia, C. and Lesk, A.M., *J Mol. Biol.*, 196(4): 901-917 (1987), Chothia, C. *et al*, *Nature*, 342: 877 – 883 (1989)).

Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (1995) *FASEB J.* 9: 133-139 and MacCallum (1996) *J. Mol. Biol.* 262(5): 732-45. Still other CDR boundary definitions may not strictly follow one of the
25 herein systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen-binding. For example, the CDRs of an antibody can be determined according to the AbM numbering scheme, which refers to AbM hypervariable regions, which represent a compromise between the Kabat
30 CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software (Oxford Molecular Group, Inc.).

Additionally, the CDRs of an antibody can be determined according to the IMGT numbering system as described in Lefranc M-P, (1999) *The Immunologist* 7: 132-136 and Lefranc M-P *et al.*, (1999) *Nucleic Acids Res* 27: 209-212.

Still other methods of CDR determination are disclosed in MacCallum R M *et al.*,
5 (1996) *J Mol Biol* 262: 732-745. See also, *e.g.*, Martin A. "Protein Sequence and Structure Analysis of Antibody Variable Domains," in *Antibody Engineering*, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001). Proprietary and publicly available programs are known to those skilled in the art which can be used to determine CDRs base on any of the CDR definitions described herein, for example, abYsis
10 (abysis.org/abysis/) and IMGT/V-QUEST (imgt.org/IMGT_vquest).

Illustrative examples of rules for predicting light chain CDRs include: CDRL1 starts at about residue 24, is preceded by a Cys, is about 10-17 residues, and is followed by a Trp (typically Trp-Tyr-Gln, but also, Trp-Leu-Gln, Trp-Phe-Gln, Trp-Tyr-Leu); CDRL2 starts about 16 residues after the end of CDRL1, is generally preceded by Ile-Tyr, but also, Val-
15 Tyr, Ile-Lys, Ile-Phe, and is 7 residues; and CDRL3 starts about 33 residues after the end of CDRL2, is preceded by a Cys, is 7-11 residues, and is followed by Phe-Gly-XXX-Gly (XXX is any amino acid).

Illustrative examples of rules for predicting heavy chain CDRs include: CDRH1 starts at about residue 26, is preceded by Cys-XXX-XXX-XXX, is 10-12 residues and is
20 followed by a Trp (typically Trp-Val, but also, Trp-Ile, Trp-Ala); CDRH2 starts about 15 residues after the end of CDRH1, is generally preceded by Leu-Glu-Trp-Ile-Gly (SEQ ID NO: 138), or a number of variations, is 16-19 residues, and is followed by Lys/Arg-Leu/Ile/Val/Phe/Thr/Ala-Thr/Ser/Ile/Ala, AbM definition ends 7 residues earlier; and CDRH3 starts about 33 residues after the end of CDRH2, is preceded by Cys-XXX-XXX
25 (typically Cys-Ala-Arg), is 3 to 25 residues, and is followed by Trp-Gly-XXX-Gly.

References to "V_H" or "VH" refer to the variable region of an immunoglobulin heavy chain, including that of an antibody, Fv, scFv, dsFv, Fab, or other antibody fragment as disclosed herein. References to "V_L" or "VL" refer to the variable region of an immunoglobulin light chain, including that of an antibody, Fv, scFv, dsFv, Fab, or other
30 antibody fragment as disclosed herein.

Additional definitions are set forth throughout this disclosure.

C. ENGINEERED T CELL RECEPTORS

T cell receptors (TCRs) recognize a peptide fragment of a target antigen when it is presented by a major histocompatibility complex (MHC) molecule. There are two different classes of MHC molecules, MHC I and MHC II, that deliver peptides from different cellular compartments to the cell surface. Engagement of the TCR with antigen and MHC results in immune effector cell activation through a series of biochemical events mediated by associated enzymes, co-receptors, and specialized accessory molecules.

A TCR contemplated herein is a heterodimeric complex comprising a TCR alpha (TCR α) polypeptide / chain and a TCR beta (TCR β) polypeptide / chain; or a TCR gamma (TCR γ) polypeptide / chain and a TCR delta (TCR δ) polypeptide / chain.

The human TCR α locus is located on chromosome 14 (14q11.2). The mature TCR α chain comprises a variable domain derived from recombination of a variable (V) segment and a joining (J) segment, and a constant (C) domain. The term "variable TCR α region" or "TCR α variable region" or "variable TCR α chain" or "TCR α variable chain" or "variable TCR α domain" or "TCR α variable domain" refers to the variable region of a TCR α chain.

The human TCR β locus is located on chromosome 7 (7q34). The mature TCR β chain comprises a variable domain derived from recombination of a variable (V) segment, a diversity (D) segment, and a joining (J) segment, and one of two constant (C) domains. The term "variable TCR β region" or "TCR β variable region" or "variable TCR β chain" or "TCR β variable chain" or "variable TCR β domain" or "TCR β variable domain" refers to the variable region of a TCR β chain.

The human TCR γ locus is located on chromosome 7 (7p14.1). The mature TCR γ chain comprises a variable domain derived from recombination of a variable (V) segment and a joining (J) segment, and a constant (C) domain. The term "variable TCR γ region" or "TCR γ variable region" or "variable TCR γ chain" or "TCR γ variable chain" or "variable TCR γ domain" or "TCR γ variable domain" refers to the variable region of a TCR γ chain.

The human TCR δ locus is located on chromosome 14 (14q11.2). The mature TCR δ chain comprises a variable domain derived from recombination of a variable (V) segment, a diversity (D) segment, and a joining (J) segment, and one of two constant (C) domains. The term "variable TCR δ region" or "TCR δ variable region" or "variable TCR δ chain" or "TCR δ variable chain" or "variable TCR δ domain" or "TCR δ variable domain" refers to the variable region of a TCR δ chain.

The rearranged V(D)J regions of both the TCR α , TCR β , TCR γ , and TCR δ chains each contain three hypervariable regions known as complementarity determining regions (CDRs). CDR3 is the main CDR responsible for recognizing processed antigen, although CDR1 of the alpha chain has also been shown to interact with the N-terminal part of the antigenic peptide, whereas CDR1 of the beta chain interacts with the C-terminal part of the peptide. CDR2 is thought to recognize the MHC molecule. Framework regions (FRs) are positioned between the CDRs. These regions provide the structure of the TCR variable region.

The constant domain or constant region of the TCR chain also contributes to TCR structure and consists of an extracellular domain, a transmembrane domain and a short cytoplasmic domain. The TCR structure allows the formation of a TCR complex that includes the TCR α or TCR γ chain, the TCR β or TCR δ chain, and accessory molecules CD3 γ , CD3 δ , CD3 ϵ , and CD3 ζ . The signal from the T cell complex is enhanced by simultaneous binding of the MHC molecules by a specific co-receptor. CD4 is the co-receptor for MHC II molecules expressed on helper T cells and CD8 is the co-receptor for MHC I molecules expressed on cytotoxic T cells. The co-receptor not only ensures the specificity of the TCR for an antigen, but also allows prolonged engagement between the antigen presenting cell and the T cell and recruits essential molecules (*e.g.*, LCK) inside the cell involved in the signaling of the activated T lymphocyte.

Engineered TCRs contemplated herein can be used to redirect immune effector cells to target cells. Additionally, the TCRs contemplated herein are engineered to comprise a functional antigen binding domain. In particular embodiments, the engineered TCR comprises both functional TCR binding domains (*e.g.*, functional TCR variable regions) and one or more separate antigen-binding domains linked to one or both of the TCR polypeptides/chains. Accordingly, in some embodiments, the engineered TCR variable domains and the additional antigen binding domains can bind the same antigen or two different antigens, or more. In some embodiments, the engineered TCR can bind both an intracellular antigen presented on MHC molecules and a second antigen (*e.g.*, receptor, ligand, or cancer antigen). In some embodiments, the engineered TCR can bind three different antigens.

The TCRs contemplated herein are sometimes referred to as engineered TCRs, hybrid TCRs, dual targeting TCRs, multi-targeting TCRs, or ATOMICs (**A**ntibody **T**ethered **O**rthogonal **M**ultiplexing **C**ompatible) and comprise one or more antigen-binding domain components (“A” component) and one or more TCR components (“C” component), with or without one or more linkers (“B” component), each of which are described in more detail in the subsections below.

The data in the Examples demonstrate that the engineered TCRs and fusion proteins disclosed herein may comprise an antigen-binding domain ("A" component) and/or TCR component ("C" component) specific for any antigen(s). One of ordinary skill in the art would readily understand that an antigen-binding domain component and TCR component, irrespective
5 of the antigen specificity or any specific sequence, *e.g.*, of its variable domain or CDR sequences, may be linked to produce an engineered TCR or fusion protein meeting the characteristics of the engineered TCRs disclosed herein.

This is because the inventors have unexpectedly discovered that the disclosed engineered TCRs and fusion proteins, which comprise an antigen-binding domain ("A" component) linked to
10 one or more TCR binding domains ("C" component), have an efficient and effective architecture that enables concurrent TCR targeting and secondary antigen-binder targeting, in a manner that preserves the function of both components. The antigen specificity of the component, as well as the sequences of the component, *e.g.*, variable domain or CDR sequences, can be varied by one of ordinary skill in the art using the illustrative general engineered TCR formulas provided
15 herein. Therefore, although the present disclosure and Examples provide a plethora of engineered TCRs and fusion proteins comprising (i) antigen-binding domain components and TCR components to different antigens, as well as (ii) different antigen-binding domains directed to the same antigen, one of ordinary skill in the art would understand that the engineered TCRs and fusion proteins disclosed and claimed herein should not be limited by antigen-specificity or
20 by sequence, *e.g.*, variable region sequences or CDR sequences.

1. ANTIGEN-BINDING DOMAIN COMPONENT ("A" COMPONENT)

Provided herein are engineered TCRs, and related fusion polypeptides, comprising (a) a TCR α or TCR γ polypeptide comprising a TCR α or TCR γ variable domain; (b) a TCR β or TCR δ polypeptide comprising a TCR β or TCR δ variable domain; and (c) one or more
25 antigen-binding domains ("A" components) linked to the TCR α , TCR β , TCR γ and/or TCR δ variable domains.

In various embodiments, the one or more antigen-binding domains (also referred to herein as binders or antigen-binders) comprises one or more, two or more, or three or more antigen-binding domains. In some embodiments, the one or more antigen-binding domains comprises
30 one or more first antigen-binding domains linked to any one or more of the TCR α , TCR β , TCR γ , and/or TCR δ variable domains. In some embodiments, the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR α variable domain. In some

embodiments, the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR β variable domain. In some embodiments, the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR γ variable domain. In some embodiments, the one or more antigen-binding domains comprises a first antigen-binding domain
5 linked to the TCR δ variable domain. In some embodiments, the one or more antigen-binding domains comprise: (i) a first antigen-binding domain linked to the TCR α variable domain, and (ii) a first antigen-binding domain linked to the TCR β variable domain. In some embodiments, the one or more antigen-binding domains comprise: (i) a first antigen-binding domain linked to the TCR γ variable domain, and (ii) a first antigen-binding domain linked to the TCR δ variable
10 domain. In some embodiments, the first antigen-binding domains are the same or different, and/or bind to the same or different target antigens.

In various embodiments, the first antigen-binding domains are linked to the N-terminus of the variable domains.

In various embodiments, the one or more antigen-binding domains comprises a second
15 antigen-binding domain linked to the first antigen-binding domain. In some embodiments, the second antigen-binding domain is N-terminal of the first antigen-binding domain. In some embodiments, the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain which is linked to the TCR α variable domain. In some embodiments, the one or more antigen-binding domains comprises a second antigen-
20 binding domain linked to the first antigen-binding domain which is linked to the TCR β variable domain. In some embodiments, the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain which is linked to the TCR γ variable domain. In some embodiments, the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain which is linked to the
25 TCR δ variable domain.

In various embodiments, the one or more antigen-binding domains comprises: (i) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α variable domain, and (ii) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR β variable domain.

30 In various embodiments, the one or more antigen-binding domains comprises: (i) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR γ

variable domain, and (ii) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR δ variable domain.

In various embodiments, the second antigen-binding domains are the same or different, and/or bind to the same or different target antigens. In some embodiments, the second antigen-binding domains are the same. In some embodiments, the second antigen-binding domains are different.

In various embodiments, the one or more antigen-binding domains (*e.g.*, the first and/or second antigen-binding domains) bind a target antigen selected from the group consisting of: alpha folate receptor (FR α), $\alpha_v\beta_6$ integrin, ADGRE2, BACE2, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H4, B7-H6, CA19.9, carbonic anhydrase IX (CAIX), CCR1, CD7, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CD244, carcinoembryonic antigen (CEA), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), CLDN6, cMET, chondroitin sulfate proteoglycan 4 (CSPG4), CLDN18.2, cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), DLL3, epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), EGFR806, epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), EPHB2, ERBB4, epithelial cell adhesion molecule (EPCAM), ephrin type-A receptor 2 (EPHA2), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AchR), FLT3, FN, FN-EDB, FRBeta, ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), HER2p95, EGFRv3, IL-10R α , IL-13R α 2, Kappa, cancer/testis antigen 2 (LAGE-1A), K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, LY6G6GD, melanoma antigen recognized by T cells 1 (MelanA or MART1), Mesothelin (MSLN), MMP10, MUC1, MUC16, MHC class I chain related proteins A (MICA), MHC class I chain related proteins B (MICB), neural cell adhesion molecule (NCAM), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X breakpoint 2 (SSX2), Survivin, tumor associated glycoprotein 72 (TAG72), transmembrane activator and CAML interactor (TACI), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), TIM3, trophoblast glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, and vascular endothelial growth factor receptor 2 (VEGFR2).

In various embodiments, the one or more antigen-binding domains (*e.g.*, the first and/or second antigen-binding domains) bind a target polypeptide derived from a protein selected from

the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma

5 (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane

10 protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1), Preferentially expressed antigen

15 in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

20 In various embodiments, the one or more antigen-binding domains bind CD33, CLL1, CD19, CD20, CD22, CD79A, CD79B, or BCMA. In some embodiments, the one or more antigen-binding domains bind CD19, CD20, CD22, CD33, CD79A, CD79B, B7H3, Muc16, Her2, EGFR, FN-EDB, CLDN18.2, DLL3, FLT3, CLL1, CD123, or BCMA.

In various embodiments, the one or more antigen-binding domains comprises an amino

25 acid sequence at least 85% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32. In various embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32. In various embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 95% identical to an amino acid sequence as set forth in

30 any one of SEQ ID NOs: 1-32. In some embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 96% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32. In some embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 97% identical to an amino acid sequence as set forth in

any one of SEQ ID NOs: 1-32. In some embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 98% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32. In some embodiments, the one or more antigen-binding domains comprises an amino acid sequence at least 99% identical to an amino acid sequence as set forth in
5 any one of SEQ ID NOs: 1-32. In some embodiments, the one or more antigen-binding domains comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32.

In various embodiments, the one or more antigen-binding domains comprise an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')₂ fragment, a bispecific Fab dimer (Fab₂), a
10 trispecific Fab trimer (Fab₃), an Fv, an single chain Fv protein ("scFv"), a bis-scFv, (scFv)₂, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein ("dsFv"), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

In various embodiments, the one or more antigen-binding domains comprise one or more single-chain variable fragments (scFv).

15 In various embodiments, the one or more antigen-binding domains comprise one or more single domain antibodies (sdAb). In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In particular embodiments, the sdAb is a camelid VHH.

In various embodiments, the antibody or antigen binding fragment thereof is human or humanized.

20 Numerous methods may be used for obtaining antibodies, or antigen-binding fragments thereof. For example, antibodies can be produced using recombinant DNA methods. Monoclonal antibodies may also be produced by generation of hybridomas (see *e.g.*, Kohler and Milstein (1975) *Nature*, 256: 495-499) in accordance with known methods. Hybridomas formed in this manner are then screened using standard methods, such as enzyme-linked immunosorbent
25 assay (ELISA) and surface plasmon resonance (*e.g.*, OCTET or BIACORE) analysis, to identify one or more hybridomas that produce an antibody that specifically binds to a specified antigen. Any form of the specified antigen may be used as the immunogen, *e.g.*, recombinant antigen, naturally occurring forms, any variants or fragments thereof, as well as antigenic peptide thereof (*e.g.*, any of the epitopes described herein as a linear epitope or within a scaffold as a
30 conformational epitope). One exemplary method of making antibodies includes screening protein expression libraries that express antibodies or fragments thereof (*e.g.*, scFv), *e.g.*, phage or ribosome display libraries. Phage display is described, for example, in Ladner *et al.*, U.S. Pat.

No. 5,223,409; Smith (1985) *Science* 228:1315-1317; Clackson *et al.* (1991) *Nature*, 352: 624-628; Marks *et al.* (1991) *J. Mol. Biol.*, 222: 581-597; WO 92/18619; WO 91/17271; WO92/20791; WO92/15679; WO93/01288; WO92/01047; WO92/09690; and WO90/02809.

In some embodiments, a monoclonal antibody is obtained from the non-human animal,
 5 and then modified, *e.g.*, chimeric, using suitable recombinant DNA techniques. A variety of approaches for making chimeric antibodies have been described. See *e.g.*, Morrison *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 81:6851, 1985; Takeda *et al.*, *Nature* 314:452, 1985; Cabilly *et al.*, U.S. Pat. No. 4,816,567; Boss *et al.*, U.S. Pat. No. 4,816,397; Tanaguchi *et al.*, European Patent Publication EP171496; European Patent Publication 0173494; and United Kingdom Patent GB
 10 2177096B.

For additional antibody production techniques, see *Antibodies: A Laboratory Manual*, eds. Harlow *et al.*, Cold Spring Harbor Laboratory, 1988. The present disclosure is not necessarily limited to any particular source, method of production, or other special characteristics of an antibody.

15 In various embodiments, the one or more antigen-binding domains comprise a ligand.

2. LINKERS (“B” COMPONENT)

As contemplated herein, the engineered TCRs may or may not comprise linker residues (“B” component) between the various domains, *e.g.*, added for appropriate spacing and conformation of the molecule. Particularly, the engineered TCRs comprise a linker between
 20 the one or more antigen-binding domains and the TCR component, *e.g.*, TCR variable domain. In various embodiments, the one or more antigen-binding domains are linked to the TCR component, *e.g.*, TCR variable domains, by one or more polypeptide linkers. In some embodiments, the TCR comprises two or more linkers between the antigen-binding domain and the TCR variable domain. In some embodiments, the engineered TCR does not comprise a
 25 polypeptide linker (“B” component) between the antigen-binding domain and the TCR component.

A “linker” or “polypeptide linker” or “linker polypeptide” is an amino acid sequence that connects adjacent domains of a polypeptide or fusion polypeptide. Illustrative examples of linkers include glycine polymers (G)_n; glycine-serine polymers (G₁₋₅S₁₋₅)_n,
 30 where n is an integer of at least one, two, three, four, or five; glycine-alanine polymers; alanine-serine polymers; and other flexible linkers known in the art. Glycine accesses significantly more phi-psi space than even alanine, and is much less restricted than residues

with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). A linker may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more amino acids long.

In particular embodiments, the engineered TCRs and/or antigen-binding domains
5 comprise one, two, three, four, or five or more linkers. The linker may be between the TCR variable domain and the antigen-binding domain, between two or more antigen binding domains, or between VH and VL sequences within an antigen binding domain (*e.g.*, scFv). In particular embodiments, the length of a linker is about 2 to about 25 amino acids, about 5 to about 20 amino acids, or about 10 to about 20 amino acids, or any intervening length of
10 amino acids. In some embodiments, the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more amino acids long.

In various embodiments, the one or more polypeptide linkers comprise a linker from about 2 to about 25 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker from about 3 to about 20 amino acids long. In some embodiments, the one or
15 more polypeptide linkers comprise a linker from about 4 to about 15 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker from about 4 to about 10 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 4 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 5 amino acids long. In some embodiments, the one or more
20 polypeptide linkers comprise a linker of about 6 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 7 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 8 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 9 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about
25 10 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 11 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 12 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 13 amino acids long. In some embodiments, the one or more polypeptide linkers comprise a linker of about 14 amino acids long. In some
30 embodiments, the one or more polypeptide linkers comprise a linker of about 15 amino acids long.

Illustrative examples of linkers include glycine polymers (G)_n; glycine-serine polymers (G₁₋₅S₁₋₅)_n, where n is an integer of at least one, two, three, four, or five; glycine-

alanine polymers; alanine-serine polymers; and other flexible linkers are known in the art. Glycine and glycine-serine polymers are relatively unstructured, and therefore may be able to serve as a neutral tether between domains of fusion proteins such as the engineered/hybrid TCRs described herein. Glycine accesses significantly more phi-psi space than even alanine, and is much less restricted than residues with longer side chains (see Scheraga, *Rev. Computational Chem.* 11173-142 (1992)). The ordinarily skilled artisan will recognize that design of an engineered/hybrid TCR in particular embodiments can include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure to provide for a desired TCR/hybrid structure.

Other illustrative linkers include, but are not limited to the following amino acid sequences: DGGGS (SEQ ID NO: 40); TGEKP (SEQ ID NO: 41) (see, *e.g.*, Liu *et al.*, PNAS 5525-5530 (1997)); GGRR (SEQ ID NO: 42) (Pomerantz *et al.* 1995, *supra*); (GGGGS)_n where n = 1, 2, 3, 4 or 5 (SEQ ID NOs: 35-39) (Kim *et al.*, PNAS 93, 1156-1160 (1996.); EGKSSGSGSESKVD (SEQ ID NO: 43) (Chaudhary *et al.*, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070); KESGSVSSEQLAQFRSLD (SEQ ID NO: 44) (Bird *et al.*, 1988, Science 242:423-426), GGRRGGGS (SEQ ID NO: 45); LRQDGERP (SEQ ID NO: 46); LRQKDGGGSERP (SEQ ID NO: 47); LRQKD(GGGGS)₂ ERP (SEQ ID NO: 48). Alternatively, flexible linkers can be rationally designed using a computer program capable of modeling both DNA-binding sites and the peptides themselves (Desjarlais & Berg, PNAS 90:2256-2260 (1993), PNAS 91:11099-11103 (1994) or by phage display methods. In particular embodiments, a linker comprises the amino acid sequence: GSTSGSGKPGSGEGSTKG (SEQ ID NO: 49) or GSTSGSGKSSEGSSTKG (SEQ ID NO: 50) (Cooper *et al.*, Blood, 101(4): 1637-1644 (2003) and Whitlow *et al.*, Protein Eng., 6(8): 989-95 (1993)). Other linkers include GSTSGSGKSSEGKG (SEQ ID NO: 51), GSTSGSGKPGSGEGS (SEQ ID NO: 52), or GGGGS (SEQ ID NO: 53).

In various embodiments, the one or more polypeptide linkers comprise a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), a linker from a marsupial $\gamma\mu$ TCR (*e.g.*, LEKT; SEQ ID NO: 33), and any combination thereof.

In various embodiments, the one or more polypeptide linkers comprise a linker from a marsupial $\gamma\mu$ TCR. In particular embodiments, the marsupial $\gamma\mu$ TCR linker is a μ LNK comprising an amino acid sequence as set forth in SEQ ID NO: 33. In various embodiments, the

one or more polypeptide linkers comprise a marsupial $\gamma\mu$ TCR linker and a G4S linker as set forth in SEQ ID NO: 34.

In various embodiments, the one or more polypeptide linkers comprise a GGGGS (SEQ ID NO: 35) linker (G4S). In various embodiments, the one or more polypeptide linkers comprise
5 two GGGGS linkers (2xG4S) (SEQ ID NO: 36). In various embodiments, the one or more polypeptide linkers comprise three GGGGS linkers (3xG4S) (SEQ ID NO: 37). In various embodiments, the one or more polypeptide linkers comprise four GGGGS linkers (4xG4S) (SEQ ID NO: 38). In various embodiments, the one or more polypeptide linkers comprise five GGGGS linkers (5xG4S) (SEQ ID NO: 39).

10 In various embodiments, the one or more polypeptide linkers comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

In particular embodiments, the first and second antigen-binding domains are separated by a second polypeptide linker. In some embodiments, the second polypeptide linker comprises a linker from about 2 to about 25 amino acids long. In some embodiments, the second polypeptide
15 linker comprises a linker from about 3 to about 20 amino acids long. In some embodiments, the second polypeptide linker comprises a linker from about 4 to about 15 amino acids long. In some embodiments, the second polypeptide linker comprises a linker from about 4 to about 10 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 4 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 5 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 6 amino acids long. In some embodiments, the second polypeptide linker
20 comprises a linker of about 7 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 8 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 9 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 10 amino acids long. In some
25 embodiments, the second polypeptide linker comprises a linker of about 11 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 12 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 13 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of about 14 amino acids long. In some embodiments, the second polypeptide linker comprises a linker of
30 about 15 amino acids long.

In various embodiments, the second polypeptide linker comprises a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), and any combination thereof. In some embodiments, the second polypeptide linker comprises a GGGGS (SEQ ID NO: 35) linker

5 (G4S). In some embodiments, the one or more polypeptide linkers comprise two GGGGS linkers (2xG4S) (SEQ ID NO: 36). In some embodiments, the second polypeptide linker comprises three GGGGS linkers (3xG4S) (SEQ ID NO: 37). In some embodiments, the second polypeptide linker comprises four GGGGS linkers (4xG4S) (SEQ ID NO: 38). In some embodiments, the second polypeptide linker comprises five GGGGS linkers (5xG4S) (SEQ ID NO: 39).

10 In various embodiments, the second polypeptide linker comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53, or combination thereof.

3. T CELL RECEPTOR COMPONENT ("C" COMPONENT)

The engineered T cell receptors (TCRs) contemplated herein bind a polypeptide antigen presented by a major histocompatibility complex (MHC) class I or MHC class II molecule,

15 preferentially a polypeptide antigen presented by an MHC class I molecule.

"Major histocompatibility complex" (MHC) refers to glycoproteins that deliver peptide antigens to a cell surface. MHC class I molecules are heterodimers having a membrane spanning α chain (with three α domains) and a non-covalently associated β 2 microglobulin. MHC class II molecules are composed of two transmembrane glycoproteins, α and β , both of which span the

20 membrane. Each chain has two domains. MHC class I molecules deliver peptides originating in the cytosol to the cell surface, where a peptide:MHC complex is recognized by CD8⁺ T cells. MHC class II molecules deliver peptides originating in the vesicular system to the cell surface, where they are recognized by CD4⁺ T cells. Human MHC is referred to as human leukocyte antigen (HLA).

25 Principles of antigen processing by antigen presenting cells (APC) (such as dendritic cells, macrophages, lymphocytes or other cell types), and of antigen presentation by APC to T cells, including major histocompatibility complex (MHC)-restricted presentation between immunocompatible (*e.g.*, sharing at least one allelic form of an MHC gene that is relevant for antigen presentation) APC and T cells, are well established (*see, e.g.*, Murphy, Janeway's

30 Immu^{no}biology (8th Ed.) 2011 Garland Science, NY; chapters 6, 9 and 16). For example, processed antigen peptides originating in the cytosol (*e.g.*, tumor antigen, intracellular pathogen) are generally from about 7 amino acids to about 11 amino acids in length and will associate with

class I MHC molecules, whereas peptides processed in the vesicular system (*e.g.*, bacterial, viral) will generally vary in length from about 10 amino acids to about 25 amino acids and associate with class II MHC molecules.

In particular embodiments, an engineered TCR contemplated herein binds a tumor antigen, *e.g.*, a TAA or TSA. “Tumor associate antigens” or “TAAs” include but are not limited to oncofetal antigens, overexpressed antigens, lineage restricted antigens, and cancer-testis antigens. TAAs are relatively restricted to tumor cells. TAAs have elevated expression levels on tumor cells, but are also expressed at lower levels on healthy cells. “Tumor-specific antigens” or “TSAs” include but are not limited to neoantigens and oncoviral antigens. TSAs are unique to tumor cells. TSAs are expressed in cancer cells and not normal cells.

In particular embodiments, engineered TCRs contemplated herein bind an antigenic portion of a polypeptide selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2). In some embodiments, the TCR variable domains bind a target polypeptide

derived from MAGE-A4, PRAME, K-Ras, TP53R175H, PSA, or IGF2BP3. In some embodiments, the TCR variable domains bind a target polypeptide derived from MAGE-A4.

As contemplated herein, the engineered TCRs comprise a TCR component ("C" component). In some embodiments, the TCR component comprises a TCR α polypeptide comprising a TCR α variable domain. In some embodiments, the TCR component comprises a TCR β polypeptide comprising a TCR β variable domain. In some embodiments, the TCR component comprises a TCR γ polypeptide comprising a TCR γ variable domain. In some embodiments, the TCR component comprises a TCR δ polypeptide comprising a TCR δ variable domain.

10 In one embodiment, the TCR component ("C" component) comprises a TCR α polypeptide comprising a TCR α variable domain; and a TCR β polypeptide comprising a TCR β variable domain. In a particular embodiment, the TCR component comprises a TCR α polypeptide comprising a TCR α variable domain; a TCR β polypeptide comprising a TCR β variable domain; and one or more antigen-binding domains linked to the TCR γ variable domain
15 and/or TCR δ variable domain.

In one embodiment, the TCR component ("C" component) a TCR γ polypeptide comprising a TCR γ variable domain; and a TCR δ polypeptide comprising a TCR δ variable domain. In a particular embodiment, the TCR component comprises a TCR γ polypeptide comprising a TCR γ variable domain; a TCR δ polypeptide comprising a TCR δ variable domain;
20 and one or more antigen-binding domains linked to the TCR γ variable domain and/or TCR δ variable domain.

In various embodiments, the TCR component ("C" component) comprises a TCR constant domain. One of skill in the art would understand that a given TCR variable domains can be paired with any one of several different constant domains. For example, any one of the TCR α ,
25 TCR β , TCR γ , or TCR δ variable domains can be paired with any one of the TCR α , TCR β , TCR γ , or TCR δ constant domains. In some embodiments, the TCR α polypeptide comprises a TCR α constant domain. In some embodiments, the TCR β polypeptide comprises a TCR β constant domain. In some embodiments, the TCR γ polypeptide comprises a TCR γ constant domain. In some embodiments, the TCR δ polypeptide comprises a TCR δ constant domain. In some
30 embodiments a TCR α variable domain is paired with a TCR γ constant domain. In some embodiments a TCR α variable domain is paired with a TCR δ constant domain. In some embodiments a TCR β variable domain is paired with a TCR γ constant domain. In some

embodiments a TCR β variable domain is paired with a TCR δ constant domain. In some
embodiments a TCR γ variable domain is paired with a TCR α constant domain. In some
embodiments a TCR γ variable domain is paired with a TCR β constant domain. In some
embodiments a TCR δ variable domain is paired with a TCR α constant domain. In some
5 embodiments a TCR δ variable domain is paired with a TCR β constant domain.

The constant domains can be derived from native constant domains or mutated to
enhance pairing with each other over pairing with native TCRs when expressed, or to increase
stability. Such pairing and stability enhanced TCR are known, see, *e.g.*, WO2021195503A1 and
WO2018102795A1, which is incorporated by reference herein, in its entirety.

10 In various embodiments, the TCR α constant domain comprises an amino acid sequence at
least 85% identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88. In some
embodiments, the TCR α constant domain comprises an amino acid sequence at least 90%
identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88. In some embodiments,
the TCR α constant domain comprises an amino acid sequence at least 95% identical to an amino
15 acid sequence as set forth in SEQ ID NOs: 82 or 88. In some embodiments, the TCR α constant
domain comprises an amino acid sequence at least 96% identical to an amino acid sequence as set
forth in SEQ ID NOs: 82 or 88. In some embodiments, the TCR α constant domain comprises an
amino acid sequence at least 97% identical to an amino acid sequence as set forth in SEQ ID
NOs: 82 or 88. In some embodiments, the TCR α constant domain comprises an amino acid
20 sequence at least 98% identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88.
In some embodiments, the TCR α constant domain comprises an amino acid sequence at least
99% identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88. In some
embodiments, the TCR α constant domain comprises an amino acid sequence as set forth in SEQ
ID NOs: 82 or 88.

25 In various embodiments, the TCR β constant domain comprises an amino acid sequence at
least 85% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86,
or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence at
least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86,
or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence at
30 least 95% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86,
or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence at
least 96% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86,
or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence at

least 97% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence at least 98% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence at least 99% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87. In some embodiments, the TCR β constant domain comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87.

In various embodiments, the TCR γ constant domain comprises an amino acid sequence at least 85% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence at least 95% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence at least 96% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence at least 97% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence at least 98% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence at least 99% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84. In some embodiments, the TCR γ constant domain comprises an amino acid sequence as set forth in SEQ ID NO: 83 or 84.

In various embodiments, the TCR δ constant domain comprises an amino acid sequence at least 85% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the TCR δ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the TCR δ constant domain comprises an amino acid sequence at least 95% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the TCR δ constant domain comprises an amino acid sequence at least 96% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the TCR δ constant domain comprises an amino acid sequence at least 97% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the TCR δ constant domain comprises an amino acid sequence at least 98% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the

TCR δ constant domain comprises an amino acid sequence at least 99% identical to an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the TCR δ constant domain comprises an amino acid sequence as set forth in SEQ ID NO: 85.

In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 105-111. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 105. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 106. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 107. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 108. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 109. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 110. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 111.

In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 62, 64, 66, 68, 70, 72, 74, and 76. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 66. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 68. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 70. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 74. In some embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 76.

In various embodiments, the TCR γ polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NO: 78.

In various embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 103 or 104. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 103. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 104.

In various embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 63, 65, 67, 69, 71, 73, 75, and 77. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 67. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 69. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 73. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 77.

In various embodiments, the TCR δ polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NO: 79.

As discussed herein, one or more antigen-binding domains are linked to one or both TCR variable domains of the TCR component. For example, one or more antigen-binding domains can be linked to any one or more of the TCR α , TCR β , TCR γ , or TCR δ variable domains as the case may be. Various antigen-binding domain / TCR component configurations are contemplated herein. For example, a first antigen binding domain can be linked to the N-terminus of one or both TCR polypeptides (*e.g.*, TCR α/β or TCR γ/δ variable regions). Additionally, a second antigen binding domain can be linked to the N-terminus of the first antigen binding domain, thus generating a tandem antigen binding domain. The first and second antigen-binding domains can be targeted to bind the same or different antigens. Similarly, multiple first binding domains can be targeted to bind the same or different antigens, and multiple second binding domains can be targeted to bind the same or different antigens.

In various embodiments, the TCR component further comprises a signal sequence/peptide. In some embodiments, the TCR α , TCR β , TCR γ , or TCR δ polypeptides comprise an N-terminal signal sequence.

In some embodiments, the TCR α polypeptide comprises an N-terminal TCR α , TCR β , TCR γ , TCR δ , CD8 α , or IgK signal sequence. In some embodiments, the TCR α polypeptide comprises an N-terminal TCR α signal sequence. In some embodiments, the TCR α polypeptide

comprises an N-terminal IgK signal sequence. In some embodiments, the TCR α polypeptide comprises an N-terminal CD8 α signal sequence.

In some embodiments, the TCR β polypeptide comprises an N-terminal TCR α , TCR β , TCR γ , TCR δ , CD8 α , or IgK signal sequence. In some embodiments, the TCR β polypeptide
5 comprises an N-terminal TCR β signal sequence. In some embodiments, the TCR β polypeptide comprises an N-terminal IgK signal sequence. In some embodiments, the TCR β polypeptide comprises an N-terminal CD8 α signal sequence.

In some embodiments, the TCR γ polypeptide comprises an N-terminal TCR α , TCR β , TCR γ , TCR δ , CD8 α , or IgK signal sequence. In some embodiments, the TCR γ polypeptide
10 comprises an N-terminal TCR γ signal sequence. In some embodiments, the TCR γ polypeptide comprises an N-terminal IgK signal sequence. In some embodiments, the TCR γ polypeptide comprises an N-terminal CD8 α signal sequence.

In some embodiments, the TCR δ polypeptide comprises an N-terminal TCR α , TCR β , TCR γ , TCR δ , CD8 α , or IgK signal sequence. In some embodiments, the TCR δ polypeptide
15 comprises an N-terminal TCR δ signal sequence. In some embodiments, the TCR δ polypeptide comprises an N-terminal IgK signal sequence. In some embodiments, the TCR δ polypeptide comprises an N-terminal CD8 α signal sequence.

D. ILLUSTRATIVE ENGINEERED TCR POLYPEPTIDES AND COMPLEXES

Various engineered TCR polypeptides and their related variants and complexes are
20 contemplated herein. As discussed above, the engineered TCRs surprising have multi-specificity, the ability to simultaneously target both intracellular and extracellular targets, and increased sensitivity to non-MHC presented targets.

The engineered TCRs can be constructed in multiple formats, and can be designed and constructed using known components (*e.g.*, antigen-binding domains, polypeptide
25 linkers, and TCR α and TCR β chains) and techniques. For example, one or more antigen-binding domains (*e.g.*, one or more “A” components) can be linked to one or more TCR components (*e.g.*, one or more “C” components) with or without one or more polypeptide linkers (*e.g.*, with or without one or more “B” components) using standard cloning techniques. The “A” component can be linked to either the TCR α or TCR β

polypeptide/chain or both; or the TCR γ or TCR δ or both; of the “C” component, as the case may be. Illustrative engineered TCR formulas are provided below:

$$A - C$$

$$A - B - C$$

5 Illustrative antigen-binding domains, linkers, and TCRs can be found in **Tables 3-5** below. Additionally, **Table 6** provides an illustrative list of engineered TCR/ATOMIC polypeptides and complexes based on the antigen-binding domains, linkers, and TCRs provided in **Tables 3, 4, and 5** (see Example 10). One of skill in the art would understand that other combinations are possible, including combinations using other antigen-binding domains, linkers,
10 and TCRs either known to or newly developed by the skilled artisan.

In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 105. In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 106. In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 107. In various embodiments, the
15 TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 108. In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 109. In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 110. In various embodiments, the TCR α polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 111.

20 In various embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 103. In various embodiments, the TCR β polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 104.

E. POLYPEPTIDES

Various polypeptides, fusion polypeptides, and polypeptide variants are contemplated
25 herein, including, but not limited to, TCR polypeptides, TCR α chain polypeptides, TCR β chain polypeptides, TCR fusion polypeptides, and fragments thereof.

“Polypeptide,” “peptide” and “protein” are used interchangeably, unless specified to the contrary, and according to conventional meaning, *i.e.*, as a sequence of amino acids. Polypeptides are not limited to a specific length, *e.g.*, they may comprise a full-length
30 polypeptide or a polypeptide fragment, and may include one or more post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations

and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

An “isolated polypeptide” and the like, as used herein, refer to *in vitro* synthesis, isolation, and/or purification of a peptide or polypeptide molecule from a cellular
5 environment, and from association with other components of the cell, *i.e.*, it is not significantly associated with *in vivo* substances. In particular embodiments, an isolated polypeptide is a synthetic polypeptide, a recombinant polypeptide, or a semi-synthetic polypeptide, or a polypeptide obtained or derived from a recombinant source.

Polypeptides include “polypeptide variants.” Polypeptide variants may differ from a
10 naturally occurring polypeptide in one or more amino acid substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the polypeptide sequences contemplated herein. For example, in particular embodiments, it may be desirable to improve the binding affinity, stability, expression, specific pairing, functional avidity and/or other
15 biological properties of a TCR by introducing one or more substitutions, deletions, additions and/or insertions into any one or more of the TCR α , TCR β , TCR γ , and/or TCR δ polypeptides, variable domains, and/or constant regions. In particular embodiments, polypeptides include polypeptides having at least about 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,
20 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to any of the polypeptide sequences contemplated herein, typically where the variant maintains at least one biological activity of the reference sequence.

Polypeptides include “polypeptide fragments.” Polypeptide fragments refer to a polypeptide, which can be monomeric or multimeric that has an amino-terminal deletion, a
25 carboxyl-terminal deletion, and/or an internal deletion or substitution of a naturally-occurring or recombinantly-produced polypeptide. As used herein, the term “biologically active fragment” or “minimal biologically active fragment” refers to a polypeptide fragment that retains at least 100%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or at least 5% of the naturally occurring polypeptide
30 activity. In certain embodiments, a polypeptide fragment can comprise an amino acid chain at least 5 to about 500 amino acids long. It will be appreciated that in certain embodiments, fragments are at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,

55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long.

As noted above, in particular embodiments, polypeptides may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of a reference polypeptide can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985, *Proc. Natl. Acad. Sci. USA*. 82: 488-492), Kunkel *et al.*, (1987, *Methods in Enzymol*, 154: 367-382), U.S. Pat. No. 4,873,192, Watson, J. D. *et al.*, (*Molecular Biology of the Gene*, Fourth Edition, Benjamin/Cummings, Menlo Park, Calif., 1987) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff *et al.*, (1978) *Atlas of Protein Sequence and Structure* (Natl. Biomed. Res. Found., Washington, D.C.).

In certain embodiments, a polypeptide variant comprises one or more conservative substitutions. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Modifications may be made in the structure of the polynucleotides and polypeptides contemplated in particular embodiments and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, variant polypeptide, one skilled in the art, for example, can change one or more of the codons of the encoding DNA sequence, *e.g.*, according to Table 1.

TABLE 1- Amino Acid Codons

Amino Acids	One letter code	Three letter code	Codons			
Alanine	A	Ala	GCA	GCC	GCG	GCU
Cysteine	C	Cys	UGC	UGU		
Aspartic acid	D	Asp	GAC	GAU		
Glutamic acid	E	Glu	GAA	GAG		
Phenylalanine	F	Phe	UUC	UUU		

Glycine	G	Gly	GGA	GGC	GGG	GGU
Histidine	H	His	CAC	CAU		
Isoleucine	I	Iso	AUA	AUC	AUU	
Lysine	K	Lys	AAA	AAG		
Leucine	L	Leu	UUA	UUG	CUA	CUC
					CUG	CUU
Methionine	M	Met	AUG			
Asparagine	N	Asn	AAC	AAU		
Proline	P	Pro	CCA	CCC	CCG	CCU
Glutamine	Q	Gln	CAA	CAG		
Arginine	R	Arg	AGA	AGG	CGA	CGC
					CGG	CGU
Serine	S	Ser	AGC	AGU	UCA	UCC
					UCG	UCU
Threonine	T	Thr	ACA	ACC	ACG	ACU
Valine	V	Val	GUA	GUC	GUG	GUU
Tryptophan	W	Trp	UGG			
Tyrosine	Y	Tyr	UAC	UAU		

Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological activity can be found using computer programs well known in the art, such as DNASTAR, DNA Strider, Geneious, Mac Vector, or Vector NTI software.

- 5 Preferably, amino acid changes in the protein variants disclosed herein are conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and generally can be made without altering a biological activity of a resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, *e.g.*, Watson *et al.* Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. Co., p.224).

- As outlined above, amino acid substitutions may be based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.

Polypeptide variants further include glycosylated forms, aggregative conjugates with other molecules, and covalent conjugates with unrelated chemical moieties (*e.g.*, pegylated molecules). Covalent variants can be prepared by linking functionalities to groups which are found in the amino acid chain or at the N- or C-terminal residue, as is known in the art. Variants
5 also include allelic variants, species variants, and muteins. Truncations or deletions of regions which do not affect functional activity of the proteins are also variants.

In particular embodiments, expression of both TCR α and TCR β polypeptides, or TCR γ and TCR δ polypeptides, in the same cell is desired. Polynucleotide sequences encoding TCR polypeptides can be separated by an IRES sequence as discussed elsewhere herein.

10 In preferred embodiments, fusion polypeptides are contemplated herein. Fusion polypeptides and fusion proteins refer to a polypeptide having at least two, three, four, five, six, seven, eight, nine, or ten or more polypeptide segments. Fusion polypeptides are typically linked C-terminus to N-terminus, although they can also be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. In particular
15 embodiments, polypeptides of the fusion protein can be in any order or a specified order.

In a particular preferred embodiment, a TCR polypeptides (*i.e.*, TCR α , TCR β , TCR γ , and/or TCR δ polypeptides) can be expressed as a fusion polypeptide that comprises one or more self-cleaving polypeptide sequences that separate TCR polypeptides.

In particular embodiments, a TCR contemplated herein (*e.g.*, an engineered TCR) is
20 expressed as a fusion polypeptide that comprises a TCR α polypeptide, a polypeptide linker (*e.g.*, self cleaving polypeptide), and a TCR β polypeptide. In particular embodiments, a TCR contemplated herein (*e.g.*, an engineered TCR) is expressed as a fusion polypeptide that comprises a TCR γ polypeptide, a polypeptide linker (*e.g.*, self cleaving polypeptide), and a TCR δ polypeptide.

25 In some embodiments, a TCR (*e.g.*, an engineered TCR) is expressed as a fusion protein that comprises from N-terminus to C-terminus, a TCR α polypeptide, a polypeptide linker (*e.g.*, self cleaving polypeptide), and a TCR β polypeptide. In some embodiments, a TCR (*e.g.*, an engineered TCR) is expressed as a fusion protein that comprises from N-terminus to C-terminus, a TCR β polypeptide, a polypeptide linker (*e.g.*, self cleaving polypeptide), and a
30 TCR α polypeptide.

In some embodiments, a TCR (*e.g.*, an engineered TCR) is expressed as a fusion protein that comprises from N-terminus to C-terminus, a TCR γ polypeptide, a polypeptide

linker (*e.g.*, self cleaving polypeptide), and a TCR δ polypeptide. In some embodiments, a TCR (*e.g.*, an engineered TCR) is expressed as a fusion protein that comprises from N-terminus to C-terminus, a TCR δ polypeptide, a polypeptide linker (*e.g.*, self cleaving polypeptide), and a TCR γ polypeptide.

5 In particular embodiments, an engineered TCR (*e.g.*, an engineered TCR complex) contemplated herein is expressed as a fusion polypeptide comprising: (a) a TCR β polypeptide comprising a TCR β variable domain; (b) a polypeptide cleavage signal; and (c) a TCR α polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR α variable domain.

10 In particular embodiments, an engineered TCR (*e.g.*, an engineered TCR complex) contemplated herein is expressed as a fusion polypeptide comprising (a) a TCR β polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR β variable domain; (b) a polypeptide cleavage signal; and (c) a TCR α polypeptide comprising a TCR α variable domain.

15 In particular embodiments, an engineered TCR (*e.g.*, an engineered TCR complex) contemplated herein is expressed as a fusion polypeptide comprising: (a) a TCR β polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR β variable domain; (b) a polypeptide cleavage signal; and (c) a TCR α polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR α variable domain.

20 In particular embodiments, an engineered TCR (*e.g.*, an engineered TCR complex) contemplated herein is expressed as a fusion polypeptide comprising: (a) a TCR γ polypeptide comprising a TCR γ variable domain; (b) a polypeptide cleavage signal; and (c) a TCR δ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR δ variable domain.

25 In particular embodiments, an engineered TCR (*e.g.*, an engineered TCR complex) contemplated herein is expressed as a fusion polypeptide comprising (a) a TCR γ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR γ variable domain; (b) a polypeptide cleavage signal; and (c) a TCR δ polypeptide comprising a TCR δ variable domain.

30 In particular embodiments, an engineered TCR (*e.g.*, an engineered TCR complex) contemplated herein is expressed as a fusion polypeptide comprising: (a) a TCR γ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR γ

variable domain; (b) a polypeptide cleavage signal; and (c) a TCR δ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR δ variable domain.

The fusion polypeptides can comprise any of the TCR polypeptides contemplated herein.

The fusion proteins contemplated herein also comprise a polypeptide cleavage signal
5 between the TCR polypeptides. Illustrative examples of polypeptide cleavage signals include polypeptide cleavage recognition sites such as protease cleavage sites, nuclease cleavage sites (*e.g.*, rare restriction enzyme recognition sites, self-cleaving ribozyme recognition sites), and self-cleaving viral oligopeptides (*see* deFelipe and Ryan, 2004. *Traffic*, 5(8); 616-26).

Suitable protease cleavages sites and self-cleaving peptides are known to the skilled
10 person (*see, e.g.*, in Ryan *et al.*, 1997. *J. Gener. Virol.* 78, 699-722; Scymczak *et al.* (2004) *Nature Biotech.* 5, 589-594). Exemplary protease cleavage sites include, but are not limited to the cleavage sites of potyvirus NIa proteases (*e.g.*, tobacco etch virus protease), potyvirus HC proteases, potyvirus P1 (P35) proteases, byovirus NIa proteases, byovirus RNA-2-encoded proteases, aphthovirus L proteases, enterovirus 2A proteases, rhinovirus 2A
15 proteases, picorna 3C proteases, comovirus 24K proteases, nepovirus 24K proteases, RTSV (rice tungro spherical virus) 3C-like protease, PYVF (parsnip yellow fleck virus) 3C-like protease, heparin, thrombin, factor Xa and enterokinase. Due to its high cleavage stringency, TEV (tobacco etch virus) protease cleavage sites are preferred in one embodiment, *e.g.*, EXXYXQ(G/S), for example, ENLYFQG (SEQ ID NO: 114) and ENLYFQS (SEQ ID NO:
20 115), wherein X represents any amino acid (cleavage by TEV occurs between Q and G or Q and S).

In particular embodiments, the polypeptide cleavage signal is a viral self-cleaving peptide or ribosomal skipping sequence.

Illustrative examples of ribosomal skipping sequences include, but are not limited to:
25 a 2A or 2A-like site, sequence or domain (Donnelly *et al.*, 2001. *J. Gen. Virol.* 82:1027-1041).

In a particular embodiment, the viral 2A peptide is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide. In one embodiment, the viral 2A peptide is selected from the group consisting of: a foot-and-mouth disease virus (FMDV) 2A
30 peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thosea asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.

Illustrative examples of 2A sites are provided in Table 1.

TABLE 2

SEQ ID NO: 116	GSGATNFSLLKQAGDVEENPGP
SEQ ID NO: 117	ATNFSLLKQAGDVEENPGP
SEQ ID NO: 118	LLKQAGDVEENPGP
SEQ ID NO: 119	GSGEGRGSLTTCGDVEENPGP
SEQ ID NO: 120	EGRGSLTTCGDVEENPGP
SEQ ID NO: 121	LLTCGDVEENPGP
SEQ ID NO: 122	GSGQCTNYALLKLAGDVESNPGP
SEQ ID NO: 123	QCTNYALLKLAGDVESNPGP
SEQ ID NO: 124	LLKLAGDVESNPGP
SEQ ID NO: 125	GSGVKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 126	VKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 127	LLKLAGDVESNPGP
SEQ ID NO: 128	LLNFDLLKLAGDVESNPGP
SEQ ID NO: 129	TLNFDLLKLAGDVESNPGP
SEQ ID NO: 130	LLKLAGDVESNPGP
SEQ ID NO: 131	NFDLLKLAGDVESNPGP
SEQ ID NO: 132	QLNFDLLKLAGDVESNPGP
SEQ ID NO: 133	APVKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 134	VTELLYRMKRAETCYCPRLAIHPTEARHKQKIVAPVKQT
SEQ ID NO: 135	LNFDLLKLAGDVESNPGP
SEQ ID NO: 136	LLAIHPTEARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 137	EARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP

In particular embodiments, the fusion protein comprises a polypeptide cleavage signal
5 that is a viral self-cleaving peptide or ribosomal skipping sequence.

In particular embodiments, the fusion protein comprises a polypeptide cleavage signal that is a viral 2A peptide. In particular embodiments, the fusion protein comprises a polypeptide cleavage signal that is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide. In particular embodiments, the fusion protein comprises a polypeptide cleavage signal

that is a viral 2A peptide is selected from the group consisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thossea asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.

5 In particular embodiments, the polypeptide cleavage signal is a viral self-cleaving peptide or ribosomal skipping sequence. In some embodiments, the polypeptide cleavage signal is a viral 2A peptide. In some embodiments, the polypeptide cleavage signal is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide. In some embodiments, the polypeptide cleavage signal is a viral 2A peptide selected from the group consisting of: a foot-and-mouth
10 disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thossea asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.

In various embodiments, the polypeptide cleavage signal comprises a self-cleaving peptide (*e.g.*, 2A peptide) and a GSG amino acid sequence immediately upstream (*i.e.*, N-term)
15 of the 2A peptide.

In various embodiments, the polypeptide cleavage signal further comprises a furin recognition site upstream of the polypeptide cleavage signal (*e.g.*, self-cleaving 2A peptide). In particular embodiments, the furin recognition site comprises the amino acid sequence as set forth in SEQ ID NO: 112.

20 In various embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 113-137. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 113. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 114. In some embodiments, the polypeptide cleavage signal comprises an
25 amino acid sequence as set forth in SEQ ID NO: 115. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 116. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 117. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 118. In some embodiments, the polypeptide cleavage
30 signal comprises an amino acid sequence as set forth in SEQ ID NO: 119. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 120. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence

as set forth in SEQ ID NO: 121. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 122. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 123. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 124. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 125. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 126. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 127. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 128. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 129. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 130. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 131. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 132. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 133. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 134. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 135. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 136. In some embodiments, the polypeptide cleavage signal comprises an amino acid sequence as set forth in SEQ ID NO: 137.

In various embodiments, the TCR β or TCR δ polypeptide is N-terminal of the TCR α or TCR γ polypeptide.

In various embodiments, the TCR α or TCR γ polypeptide is N-terminal of the TCR β or TCR δ polypeptide.

In particular embodiments, the fusion polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide comprises an amino acid sequence at least 85%, identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide comprises an amino acid sequence at least 90%, identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide

comprises an amino acid sequence at least 95%, identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide comprises an amino acid sequence at least 96%, identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide
5 comprises an amino acid sequence at least 97%, identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide comprises an amino acid sequence at least 98%, identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide comprises an amino acid sequence at least 99%, identical to an amino acid sequence as set forth
10 in any one of SEQ ID NOs: 91-97, 100, and 102.

In particular embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 91. In some
embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID
15 NO: 92. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 93. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 94. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 95. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 96. In some
20 embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 97. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 100. In some embodiments, the fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 102.

F. POLYNUCLEOTIDES

25 In particular embodiments, one or more polynucleotides encoding one or more TCR polypeptides, TCR α polypeptides, TCR β polypeptides, TCR γ polypeptides, TCR δ polypeptides, TCR fusion polypeptides, and fragments thereof is provided. As used herein, the terms “polynucleotide” or “nucleic acid” refer to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and DNA/RNA hybrids. Polynucleotides may be monocistronic or polycistronic,
30 single-stranded or double-stranded, and either recombinant, synthetic, or isolated. Polynucleotides include, but are not limited to: pre-messenger RNA (pre-mRNA), messenger RNA (mRNA), RNA, genomic DNA (gDNA), PCR amplified DNA, complementary DNA

(cDNA), synthetic DNA, or recombinant DNA. Polynucleotides refer to a polymeric form of nucleotides of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 5000, at least 10000, or at least 15000 or more nucleotides in length, either ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide, as well as all intermediate lengths. It will be readily understood that “intermediate lengths,” in this context, means any length between the quoted values, such as 6, 7, 8, 9, *etc.*, 101, 102, 103, *etc.*; 151, 152, 153, *etc.*; 201, 202, 203, *etc.* In particular embodiments, polynucleotides or variants have at least or about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a reference sequence.

As used herein, “isolated polynucleotide” refers to a polynucleotide that has been purified from the sequences which flank it in a naturally-occurring state, *e.g.*, a DNA fragment that has been removed from the sequences that are normally adjacent to the fragment. In particular embodiments, an “isolated polynucleotide” also refers to a complementary DNA (cDNA), a recombinant DNA, or other polynucleotide that does not exist in nature and that has been made by the hand of man. In particular embodiments, an isolated polynucleotide is a synthetic polynucleotide, a recombinant polynucleotide, a semi-synthetic polynucleotide, or a polynucleotide obtained or derived from a recombinant source.

In various embodiments, a polynucleotide comprises an mRNA encoding a polypeptide contemplated herein. In certain embodiments, the mRNA comprises a cap, one or more nucleotides, and a poly(A) tail.

In various embodiments, the polynucleotide is an mRNA that is introduced into a cell in order to transiently express a desired polypeptide.

As used herein, “transient” refers to expression of a non-integrated transgene for a period of hours, days or weeks, wherein the period of time of expression is less than the period of time for expression of the polynucleotide if integrated into the genome or contained within a stable plasmid replicon in the cell.

In particular embodiments, the mRNA encoding a polypeptide is an *in vitro* transcribed mRNA. As used herein, “*in vitro* transcribed RNA” refers to RNA, preferably mRNA that has been synthesized *in vitro*. Generally, the *in vitro* transcribed RNA is generated from an *in vitro*

transcription vector. The *in vitro* transcription vector comprises a template that is used to generate the *in vitro* transcribed RNA.

In particular embodiments, mRNAs may further comprise a 5' cap or modified 5' cap and/or a poly(A) sequence. As used herein, a 5' cap (also termed an RNA cap, an RNA 7-methylguanosine cap or an RNA m⁷G cap) is a modified guanine nucleotide that has been added to the 'front' or 5' end of a eukaryotic messenger RNA shortly after the start of transcription. The 5' cap comprises a terminal group which is linked to the first transcribed nucleotide and recognized by the ribosome and protected from RNases. The capping moiety can be modified to modulate functionality of mRNA such as its stability or efficiency of translation. In a particular embodiment, the mRNA comprises a poly(A) sequence of between about 50 and about 5000 adenines. In one embodiment, the mRNA comprises a poly(A) sequence of between about 100 and about 1000 bases, between about 200 and about 500 bases, or between about 300 and about 400 bases. In one embodiment, the mRNA comprises a poly(A) sequence of about 65 bases, about 100 bases, about 200 bases, about 300 bases, about 400 bases, about 500 bases, about 600 bases, about 700 bases, about 800 bases, about 900 bases, or about 1000 or more bases. poly(A) sequences can be modified chemically or enzymatically to modulate mRNA functionality such as localization, stability or efficiency of translation. In particular embodiments, polynucleotides may be codon-optimized. As used herein, the term "codon-optimized" refers to substituting codons in a polynucleotide encoding a polypeptide in order to increase the expression, stability and/or activity of the polypeptide. Factors that influence codon optimization include, but are not limited to one or more of: (i) variation of codon biases between two or more organisms or genes or synthetically constructed bias tables, (ii) variation in the degree of codon bias within an organism, gene, or set of genes, (iii) systematic variation of codons including context, (iv) variation of codons according to their decoding tRNAs, (v) variation of codons according to GC %, either overall or in one position of the triplet, (vi) variation in degree of similarity to a reference sequence for example a naturally occurring sequence, (vii) variation in the codon frequency cutoff, (viii) structural properties of mRNAs transcribed from the DNA sequence, (ix) prior knowledge about the function of the DNA sequences upon which design of the codon substitution set is to be based, (x) systematic variation of codon sets for each amino acid, and/or (xi) isolated removal of spurious translation initiation sites.

As used herein, the terms "polynucleotide variant" and "variant" and the like refer to polynucleotides displaying substantial sequence identity with a reference polynucleotide sequence or polynucleotides that hybridize with a reference sequence under stringent

conditions that are defined hereinafter. These terms include polynucleotides in which one or more nucleotides have been added or deleted or replaced with different nucleotides compared to a reference polynucleotide. In this regard, it is well understood in the art that certain alterations inclusive of mutations, additions, deletions and substitutions can be made to a
 5 reference polynucleotide whereby the altered polynucleotide retains the biological function or activity of the reference polynucleotide.

Polynucleotide variants include polynucleotide fragments that encode biologically active polypeptide fragments or variants. As used herein, the term “polynucleotide fragment” refers to a polynucleotide fragment at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
 10 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or more nucleotides in length that encodes a polypeptide variant that retains at least 100%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at
 15 least 10%, or at least 5% of the naturally occurring polypeptide activity. Polynucleotide fragments refer to a polynucleotide that encodes a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion or substitution of one or more amino acids of a naturally-occurring or recombinantly-produced polypeptide.

The recitations “sequence identity” or, for example, comprising a “sequence 50%
 20 identical to,” as used herein, refer to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a “percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, I) or the identical amino acid residue
 25 (*e.g.*, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Included are nucleotides and polypeptides having at least about 50%, 55%, 60%,
 30 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of the reference sequences described herein,

typically where the polypeptide variant maintains at least one biological activity of the reference polypeptide.

Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include “reference sequence,” “comparison window,” “sequence identity,” “percentage of sequence identity,” and “substantial identity”. A “reference sequence” is at least 12 but frequently 15 to 18 and often at least 25 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (*i.e.*, only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a “comparison window” to identify and compare local regions of sequence similarity. A “comparison window” refers to a conceptual segment of at least 6 contiguous positions, usually about 50 to about 100, more usually about 100 to about 150 in which a sequence is compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. The comparison window may comprise additions or deletions (*i.e.*, gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (*i.e.*, resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for example disclosed by Altschul *et al.*, 1997, Nucl. Acids Res. 25:3389. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley & Sons Inc, 1994-1998, Chapter 15.

Terms that describe the orientation of polynucleotides include: 5' (normally the end of the polynucleotide having a free phosphate group) and 3' (normally the end of the polynucleotide having a free hydroxyl (OH) group). Polynucleotide sequences can be annotated in the 5' to 3' orientation or the 3' to 5' orientation. For DNA and mRNA, the 5' to 3' strand is designated the “sense,” “plus,” or “coding” strand because its sequence is identical to the sequence of the premessenger (pre-mRNA) [except for uracil (U) in RNA,

instead of thymine (T) in DNA]. For DNA and mRNA, the complementary 3' to 5' strand which is the strand transcribed by the RNA polymerase is designated as “template,” “antisense,” “minus,” or “non-coding” strand. As used herein, the term “reverse orientation” refers to a 5' to 3' sequence written in the 3' to 5' orientation or a 3' to 5' sequence written in the 5' to 3' orientation.

Moreover, it will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide, or fragment of variant thereof, as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated in particular embodiments, for example polynucleotides that are optimized for human and/or primate codon selection. Further, alleles of the genes comprising the polynucleotide sequences provided herein may also be used. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides.

The term “nucleic acid cassette” or “expression cassette” as used herein refers to genetic sequences within the vector which can express an RNA, and subsequently a polypeptide. In one embodiment, the nucleic acid cassette contains a gene(s)-of-interest, *e.g.*, a polynucleotide(s)-of-interest. In another embodiment, the nucleic acid cassette contains one or more expression control sequences, *e.g.*, a promoter, enhancer, poly(A) sequence, and a gene(s)-of-interest, *e.g.*, a polynucleotide(s)-of-interest. Vectors may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleic acid cassettes. The nucleic acid cassette is positionally and sequentially oriented within the vector such that the nucleic acid in the cassette can be transcribed into RNA, and when necessary, translated into a protein or a polypeptide, undergo appropriate post-translational modifications required for activity in the transformed cell, and be translocated to the appropriate compartment for biological activity by targeting to appropriate intracellular compartments or secretion into extracellular compartments. Preferably, the cassette has its 3' and 5' ends adapted for ready insertion into a vector, *e.g.*, it has restriction endonuclease sites at each end. In a preferred embodiment, the nucleic acid cassette encodes one or more chains of a TCR. The cassette can be removed and inserted into a plasmid or viral vector as a single unit.

Polynucleotides include polynucleotide(s)-of-interest. As used herein, the term “polynucleotide-of-interest” refers to a polynucleotide encoding a polypeptide, polypeptide variant, or fusion polypeptide. A vector may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10

polynucleotides-of-interest. In certain embodiments, the polynucleotide-of-interest encodes a polypeptide that provides a therapeutic effect in the treatment or prevention of a disease or disorder. Polynucleotides-of-interest, and polypeptides encoded therefrom, include both polynucleotides that encode wild-type polypeptides, as well as functional variants and
5 fragments thereof. In particular embodiments, a functional variant has at least 80%, at least 90%, at least 95%, or at least 99% identity to a corresponding wild-type reference polynucleotide or polypeptide sequence. In certain embodiments, a functional variant or fragment has at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of a biological activity of a corresponding wild-type polypeptide.

10 The polynucleotides contemplated herein, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters and/or enhancers, untranslated regions (UTRs), signal sequences, Kozak sequences, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, internal ribosomal entry sites (IRES), recombinase recognition sites (*e.g.*, LoxP, FRT, and Att sites), termination
15 codons, transcriptional termination signals, and polynucleotides encoding self-cleaving polypeptides, epitope tags, as disclosed elsewhere herein or as known in the art, such that their overall length may vary considerably. It is therefore contemplated that a polynucleotide fragment of almost any length may be employed in particular embodiments, with the total length preferably being limited by the ease of preparation and use in the intended
20 recombinant DNA protocol.

Polynucleotides can be prepared, manipulated and/or expressed using any of a variety of well-established techniques known and available in the art. In order to express a desired polypeptide, a nucleotide sequence encoding the polypeptide, can be inserted into appropriate vector as discussed further below.

25 Illustrative examples of vectors include, but are not limited to plasmid, autonomously replicating sequences, and transposable elements, *e.g.*, piggyBac, Sleeping Beauty, Mos1, Tc1/mariner, Tol2, mini-Tol2, Tc3, MuA, Himar I, Frog Prince, and derivatives thereof.

Additional Illustrative examples of vectors include, without limitation, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosome (YAC),
30 bacterial artificial chromosome (BAC), or P1-derived artificial chromosome (PAC), bacteriophages such as lambda phage or M13 phage, and animal viruses.

Illustrative examples of viruses useful as vectors include, without limitation, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpesvirus (*e.g.*, herpes simplex virus), poxvirus, baculovirus, papillomavirus, and papovavirus (*e.g.*, SV40).

Illustrative examples of expression vectors include, but are not limited to, pCleo vectors (Promega) for expression in mammalian cells; pLenti4/V5-DEST™, pLenti6/V5-DEST™, and pLenti6.2/V5-GW/lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells. In particular embodiments, coding sequences of polypeptides disclosed herein can be ligated into such expression vectors for the expression of the polypeptides in mammalian cells.

In particular embodiments, the vector is an episomal vector or a vector that is maintained extrachromosomally. As used herein, the term “episomal” refers to a vector that is able to replicate without integration into host’s chromosomal DNA and without gradual loss from a dividing host cell also meaning that said vector replicates extrachromosomally or episomally.

The “control elements” or “regulatory sequences” present in an expression vector are those non-translated regions of the vector—origin of replication, selection cassettes, promoters, enhancers, translation initiation signals (Shine Dalgarno sequence or Kozak sequence) introns, a polyadenylation sequence, 5' and 3' untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including ubiquitous promoters and inducible promoters may be used.

In particular embodiments, vectors include, but are not limited to expression vectors and viral vectors, and will include exogenous, endogenous, or heterologous control sequences such as promoters and/or enhancers. An “endogenous” control sequence is one which is naturally linked with a given gene in the genome. An “exogenous” control sequence is one which is placed in juxtaposition to a gene by means of genetic manipulation (*i.e.*, molecular biological techniques) such that transcription of that gene is directed by the linked enhancer/promoter. A “heterologous” control sequence is an exogenous sequence that is from a different species than the cell being genetically manipulated.

The term “promoter” as used herein refers to a recognition site of a polynucleotide (DNA or RNA) to which an RNA polymerase binds. An RNA polymerase initiates and transcribes polynucleotides operably linked to the promoter. In particular embodiments,

promoters operative in mammalian cells comprise an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated and/or another sequence found 70 to 80 bases upstream from the start of transcription, a CNCAAT region where N may be any nucleotide.

5 The term “enhancer” refers to a segment of DNA which contains sequences capable of providing enhanced transcription and in some instances can function independent of their orientation relative to another control sequence. An enhancer can function cooperatively or additively with promoters and/or other enhancer elements. The term “promoter/enhancer” refers to a segment of DNA which contains sequences capable of providing both promoter
10 and enhancer functions.

 The term “operably linked”, refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. In one embodiment, the term refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, and/or enhancer) and a second polynucleotide sequence, *e.g.*, a
15 polynucleotide-of-interest, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

 As used herein, the term “constitutive expression control sequence” refers to a promoter, enhancer, or promoter/enhancer that continually or continuously allows for transcription of an operably linked sequence. A constitutive expression control sequence
20 may be a “ubiquitous” promoter, enhancer, or promoter/enhancer that allows expression in a wide variety of cell and tissue types or a “cell specific,” “cell type specific,” “cell lineage specific,” or “tissue specific” promoter, enhancer, or promoter/enhancer that allows expression in a restricted variety of cell and tissue types, respectively.

 Illustrative ubiquitous expression control sequences suitable for use in particular
25 embodiments include, but are not limited to, a cytomegalovirus (CMV) immediate early promoter, a viral simian virus 40 (SV40) (*e.g.*, early or late), a Moloney murine leukemia virus (MoMLV) LTR promoter, a Rous sarcoma virus (RSV) LTR, a herpes simplex virus (HSV) (thymidine kinase) promoter, H5, P7.5, and P11 promoters from vaccinia virus, an elongation factor 1-alpha (EF1a) promoter, early growth response 1 (EGR1), ferritin H
30 (FerH), ferritin L (FerL), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock 70kDa protein 5 (HSPA5), heat shock protein 90kDa beta, member 1 (HSP90B1), heat shock protein 70kDa (HSP70), β -kinesin (β -

KIN), the human ROSA 26 locus (Irions *et al.*, *Nature Biotechnology* 25, 1477 - 1482 (2007)), a Ubiquitin C promoter (UBC), a phosphoglycerate kinase-1 (PGK) promoter, a cytomegalovirus enhancer/chicken β -actin (CAG) promoter, a β -actin promoter and a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) U3 promoter (Haas *et al. Journal of Virology*. 2003;77(17): 9439-9450).

In one embodiment, a vector comprises an MNDU3 promoter.

In one embodiment, a vector comprises an EF1a promoter comprising the first intron of the human EF1a gene.

10 In one embodiment, a vector comprises an EF1a promoter that lacks the first intron of the human EF1a gene.

In a particular embodiment, it may be desirable to express a polynucleotide comprising an engineered TCR from a T cell specific promoter.

As used herein, "conditional expression" may refer to any type of conditional
15 expression including, but not limited to, inducible expression; repressible expression; expression in cells or tissues having a particular physiological, biological, or disease state, *etc.* This definition is not intended to exclude cell type or tissue specific expression. Certain embodiments provide conditional expression of a polynucleotide-of-interest, *e.g.*, expression is controlled by subjecting a cell, tissue, organism, *etc.*, to a treatment or condition that causes
20 the polynucleotide to be expressed or that causes an increase or decrease in expression of the polynucleotide encoded by the polynucleotide-of-interest.

Illustrative examples of inducible promoters/systems include, but are not limited to, steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionein promoter
25 (inducible by treatment with various heavy metals), MX-1 promoter (inducible by interferon), the "GeneSwitch" mifepristone-regulatable system (Sirin *et al.*, 2003, *Gene*, 323:67), the cumate inducible gene switch (WO 2002/088346), tetracycline-dependent regulatory systems, *etc.*

Conditional expression can also be achieved by using a site-specific DNA recombinase.
30 According to certain embodiments the vector comprises at least one (typically two) site(s) for recombination mediated by a site-specific recombinase. As used herein, the terms "recombinase" or "site specific recombinase" include excisive or integrative proteins, enzymes, co-factors or

associated proteins that are involved in recombination reactions involving one or more recombination sites (*e.g.*, two, three, four, five, seven, ten, twelve, fifteen, twenty, thirty, fifty, *etc.*), which may be wild-type proteins (*see* Landy, *Current Opinion in Biotechnology* 3:699-707 (1993)), or mutants, derivatives (*e.g.*, fusion proteins containing the recombination protein sequences or fragments thereof), fragments, and variants thereof. Illustrative examples of recombinases suitable for use in particular embodiments include, but are not limited to: Cre, Int, IHF, Xis, Flp, Fis, Hin, Gin, Φ C31, Cin, Tn3 resolvase, TndX, XerC, XerD, TnpX, Hjc, Gin, SpCCE1, and ParA.

The vectors may comprise one or more recombination sites for any of a wide variety of site-specific recombinases. It is to be understood that the target site for a site-specific recombinase is in addition to any site(s) required for integration of a vector, *e.g.*, a retroviral vector or lentiviral vector. As used herein, the terms “recombination sequence,” “recombination site,” or “site specific recombination site” refer to a particular nucleic acid sequence to which a recombinase recognizes and binds.

For example, one recombination site for Cre recombinase is loxP which is a 34 base pair sequence comprising two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence (see FIG. 1 of Sauer, B., *Current Opinion in Biotechnology* 5:521-527 (1994)). Other exemplary loxP sites include, but are not limited to: lox511 (Hoess *et al.*, 1996; Bethke and Sauer, 1997), lox5171 (Lee and Saito, 1998), lox2272 (Lee and Saito, 1998), m2 (Langer *et al.*, 2002), lox71 (Albert *et al.*, 1995), and lox66 (Albert *et al.*, 1995).

Suitable recognition sites for the FLP recombinase include, but are not limited to: FRT (McLeod, *et al.*, 1996), F₁, F₂, F₃ (Schlake and Bode, 1994), F₄, F₅ (Schlake and Bode, 1994), FRT(LE) (Senecoff *et al.*, 1988), FRT(RE) (Senecoff *et al.*, 1988).

Other examples of recognition sequences are the attB, attP, attL, and attR sequences, which are recognized by the recombinase enzyme λ Integrase, *e.g.*, ϕ C31. The ϕ C31 SSR mediates recombination only between the heterotypic sites attB (34 bp in length) and attP (39 bp64aposiength) (Groth *et al.*, 2000). attB and attP, named for the attachment sites for the phage integrase on the bacterial and phage genomes, respectively, both contain imperfect inverted repeats that are likely bound by ϕ C3164aposidimers (Groth *et al.*, 2000). The product sites, attL and attR, are effectively inert to further ϕ C31-mediated recombination (Belteki *et al.*, 2003), making the reaction irreversible. For catalyzing insertions, it has been found that attB-bearing DNA inserts into a genomic attP site more readily than an attP site into a genomic attB site

(Thyagarajan *et al.*, 2001; Belteki *et al.*, 2003). Thus, typical strategies position by homologous recombination an attP-bearing “docking site” into a defined locus, which is then partnered with an attB-bearing incoming sequence for insertion.

As used herein, an “internal ribosome entry site” or “IRES” refers to an element that promotes direct internal ribosome entry to the initiation codon, such as ATG, of a cistron (a protein encoding region), thereby leading to the cap-independent translation of the gene. *See, e.g.*, Jackson *et al.*, 1990. *Trends Biochem Sci* 15(12):477-83) and Jackson and Kaminski. 1995. *RNA* 1(10):985-1000. In particular embodiments, vectors include one or more polynucleotides-of-interest that encode one or more polypeptides. In particular embodiments, to achieve efficient translation of each of the plurality of polypeptides, the polynucleotide sequences can be separated by one or more IRES sequences or polynucleotide sequences encoding self-cleaving polypeptides. In one embodiment, the IRES used in polynucleotides contemplated herein is an EMCV IRES.

As used herein, the term “Kozak sequence” refers to a short nucleotide sequence that greatly facilitates the initial binding of mRNA to the small subunit of the ribosome and increases translation. The consensus Kozak sequence is (GCC)RCCATGG (SEQ ID NO: 139), where R is a purine (A or G) (Kozak, 1986. *Cell*. 44(2):283-92, and Kozak, 1987. *Nucleic Acids Res.* 15(20):8125-48). In particular embodiments, the vectors comprise polynucleotides that have a consensus Kozak sequence and that encode a desired polypeptide, *e.g.*, a TCR.

Elements directing the efficient termination and polyadenylation of the heterologous nucleic acid transcripts increases heterologous gene expression. Transcription termination signals are generally found downstream of the polyadenylation signal. In particular embodiments, vectors comprise a polyadenylation sequence 3' of a polynucleotide encoding a polypeptide to be expressed. The term “polyA site” or “polyA sequence” as used herein denotes a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript by RNA polymerase II. Polyadenylation sequences can promote mRNA stability by addition of a polyA tail to the 3' end of the coding sequence and thus, contribute to increased translational efficiency. Cleavage and polyadenylation is directed by a poly(A) sequence in the RNA. The core poly(A) sequence for mammalian pre-mRNAs has two recognition elements flanking a cleavage-polyadenylation site. Typically, an almost invariant AAUAAA hexamer lies 20-50 nucleotides upstream of a more variable element rich in U or GU residues. Cleavage of the nascent transcript occurs between these two elements and is coupled to the addition of up to 250 adenosines to the

5' cleavage product. In particular embodiments, the core poly(A) sequence is an ideal polyA sequence (*e.g.*, AATAAA, ATTAAG, AGTAAA). In particular embodiments, the poly(A) sequence is an SV40 polyA sequence, a bovine growth hormone polyA sequence (BGHpA), a rabbit β -globin polyA sequence (r β gpA), variants thereof, or another suitable heterologous or
5 endogenous polyA sequence known in the art.

In some embodiments, a polynucleotide or cell harboring the polynucleotide utilizes a suicide gene, including an inducible suicide gene to reduce the risk of direct toxicity and/or uncontrolled proliferation. In specific aspects, the suicide gene is not immunogenic to the host harboring the polynucleotide or cell. A certain example of a suicide gene that may be
10 used is caspase-9 or caspase-8 or cytosine deaminase. Caspase-9 can be activated using a specific chemical inducer of dimerization (CID).

In certain embodiments, a polycistronic polynucleotide encoding a fusion protein encoding a TCR is contemplated herein. In some embodiments, a polycistronic polynucleotide encoding a TCR comprising a TCR α polypeptide/chain and a TCR β
15 polypeptide/chain is introduced into a cell. In some embodiments, a polycistronic polynucleotide encoding a TCR comprising a TCR γ polypeptide/chain and a TCR δ polypeptide/chain is introduced into a cell.

In particular embodiments, the polycistronic polynucleotide comprises the TCR α polypeptide/chain 5' to the TCR β polypeptide/chain. In other embodiments, the polycistronic polynucleotide comprises the TCR β polypeptide/chain 5' to the TCR α polypeptide/chain. In
20 other embodiments, the polycistronic polynucleotide comprises the TCR δ polypeptide/chain 5' to the TCR γ polypeptide/chain. In other embodiments, the polycistronic polynucleotide comprises the TCR γ polypeptide/chain 5' to the TCR δ polypeptide/chain.

G. VECTORS

25 In particular embodiments, one or more polynucleotides encoding a TCR α polypeptide/chain and a TCR β polypeptide/chain are introduced into a cell (*e.g.*, an immune effector cell) by non-viral or viral vectors.

The term "vector" is used herein to refer to a nucleic acid molecule capable transferring or transporting another nucleic acid molecule. The transferred nucleic acid is generally linked to,
30 *e.g.*, inserted into, the vector nucleic acid molecule. A vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into

host cell DNA. In particular embodiments, non-viral vectors are used to deliver one or more polynucleotides contemplated herein to a T cell.

Illustrative examples of non-viral vectors include, but are not limited to mRNA, plasmids (*e.g.*, DNA plasmids or RNA plasmids), transposons, cosmids, and bacterial artificial
5 chromosomes. Other non-viral vectors are discussed above.

Illustrative methods of non-viral delivery of polynucleotides contemplated in particular embodiments include, but are not limited to: electroporation, sonoporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, nanoparticles, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions,
10 DEAE-dextran-mediated transfer, gene gun, and heat-shock.

Illustrative examples of non-viral / polynucleotide delivery systems suitable for use in particular embodiments contemplated in particular embodiments include, but are not limited to those provided by Amaxa Biosystems, Maxcyte, Inc., BTX Molecular Delivery Systems, and Copernicus Therapeutics Inc. Lipofection reagents are sold commercially (*e.g.*, Transfectam™
15 and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides have been described in the literature. See *e.g.*, Liu *et al.* (2003) *Gene Therapy*. 10:180–187; and Balazs *et al.* (2011) *Journal of Drug Delivery*. 2011:1-12. Antibody-targeted, bacterially derived, non-living nanocell-based delivery is also contemplated in particular embodiments.

20 In various embodiments, the polynucleotide is an mRNA that is introduced into a cell in order to transiently express a desired polypeptide. As used herein, “transient” refers to expression of a non-integrated transgene for a period of hours, days or weeks, wherein the period of time of expression is less than the period of time for expression of the polynucleotide if integrated into the genome or contained within a stable plasmid replicon in
25 the cell.

In particular embodiments, viral vectors are used to deliver one or more polynucleotides contemplated herein to a T cell.

Viral vectors comprising polynucleotides contemplated in particular embodiments can be delivered *in vivo* by administration to an individual patient, typically by systemic
30 administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application, as described below. Alternatively, vectors can be delivered to cells *ex vivo*, such as cells explanted from an individual patient (*e.g.*, mobilized peripheral

blood, lymphocytes, bone marrow aspirates, tissue biopsy, *etc.*) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient.

In one embodiment, viral vectors comprising nuclease variants and/or donor repair templates are administered directly to an organism for transduction of cells *in vivo*.

- 5 Alternatively, naked DNA can be administered. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular
- 10 composition, a particular route can often provide a more immediate and more effective reaction than another route.

Illustrative examples of viral vector systems suitable for use in particular embodiments contemplated in particular embodiments include, but are not limited to adeno-associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, and vaccinia virus vectors.

- 15 In certain embodiments, a polycistronic polynucleotide encoding a TCR comprising a TCR α polypeptide/chain and a TCR β polypeptide/chain is introduced into a cell by a non-viral or viral vector. In particular embodiments, the polycistronic polynucleotide comprises the TCR α polypeptide/chain 5' to the TCR β polypeptide/chain. In other embodiments, the polycistronic polynucleotide comprises the TCR β polypeptide/chain 5' to the TCR α
- 20 polypeptide/chain.

- In some embodiments, a polycistronic polynucleotide encoding a TCR comprising a TCR α polypeptide/chain and a TCR β polypeptide/chain is introduced into a cell by a non-viral or viral vector. In some embodiments, a polycistronic polynucleotide encoding a TCR comprising a TCR γ polypeptide/chain and a TCR δ polypeptide/chain is introduced into a cell
- 25 by a non-viral or viral vector.

- In certain embodiments, the polycistronic polynucleotide comprises the TCR α polypeptide/chain 5' to the TCR β polypeptide/chain. In other embodiments, the polycistronic polynucleotide comprises the TCR β polypeptide/chain 5' to the TCR α polypeptide/chain. In other embodiments, the polycistronic polynucleotide comprises the TCR δ polypeptide/chain 5' to the TCR γ polypeptide/chain. In other embodiments, the polycistronic polynucleotide comprises the TCR γ polypeptide/chain 5' to the TCR δ polypeptide/chain.
- 30

In various embodiments, one or more polynucleotides are introduced into an immune effector cell, *e.g.*, T cell, by transducing the cell with a recombinant adeno-associated virus (rAAV), comprising the one or more polynucleotides.

AAV is a small (~26 nm) replication-defective, primarily episomal, non-enveloped virus. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell. Recombinant AAV (rAAV) are typically composed of, at a minimum, a transgene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs). The ITR sequences are about 145 bp in length. In particular embodiments, the rAAV comprises ITRs and capsid sequences isolated from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10.

In some embodiments, a chimeric rAAV is used the ITR sequences are isolated from one AAV serotype and the capsid sequences are isolated from a different AAV serotype. For example, a rAAV with ITR sequences derived from AAV2 and capsid sequences derived from AAV6 is referred to as AAV2/AAV6. In particular embodiments, the rAAV vector may comprise ITRs from AAV2, and capsid proteins from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10. In a preferred embodiment, the rAAV comprises ITR sequences derived from AAV2 and capsid sequences derived from AAV6. In a preferred embodiment, the rAAV comprises ITR sequences derived from AAV2 and capsid sequences derived from AAV2.

In some embodiments, engineering and selection methods can be applied to AAV capsids to make them more likely to transduce cells of interest.

Construction of rAAV vectors, production, and purification thereof have been disclosed, *e.g.*, in U.S. Patent Nos. 9,169,494; 9,169,492; 9,012,224; 8,889,641; 8,809,058; and 8,784,799, each of which is incorporated by reference herein, in its entirety.

In various embodiments, one or more polynucleotides are introduced into an immune effector cell, *e.g.*, T cell, by transducing the cell with a retrovirus, *e.g.*, lentivirus, comprising the one or more polynucleotides.

As used herein, the term “retrovirus” refers to an RNA virus that reverse transcribes its genomic RNA into a linear double-stranded DNA copy and subsequently covalently integrates its genomic DNA into a host genome. Illustrative retroviruses suitable for use in particular embodiments, include, but are not limited to: Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine

mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma Virus (RSV)) and lentivirus.

As used herein, the term “lentivirus” refers to a group (or genus) of complex retroviruses. Illustrative lentiviruses include, but are not limited to: HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna-maedi virus (VMV) virus; the caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV). In one embodiment, HIV based vector backbones (*i.e.*, HIV cis-acting sequence elements) are preferred.

In various embodiments, a lentiviral vector contemplated herein comprises one or more LTRs, and one or more, or all, of the following accessory elements: a cPPT/FLAP, a Psi (Ψ) packaging signal, an export element, poly (A) sequences, and may optionally comprise a WPRE or HPRE, an insulator element, a selectable marker, and a cell suicide gene, as discussed elsewhere herein.

In particular embodiments, lentiviral vectors contemplated herein may be integrative or non-integrating or integration defective lentivirus. As used herein, the term “integration defective lentivirus” or “IDLV” refers to a lentivirus having an integrase that lacks the capacity to integrate the viral genome into the genome of the host cells. Integration-incompetent viral vectors have been described in patent application WO 2006/010834, which is herein incorporated by reference in its entirety.

Illustrative mutations in the HIV-1 pol gene suitable to reduce integrase activity include, but are not limited to: H12N, H12C, H16C, H16V, S81 R, D41A, K42A, H51A, Q53C, D55V, D64E, D64V, E69A, K71A, E85A, E87A, D116N, D116I, D116A, N120G, N120I, N120E, E152G, E152A, D35E, K156E, K156A, E157A, K159E, K159A, K160A, R166A, D167A, E170A, H171A, K173A, K186Q, K186T, K188T, E198A, R199c, R199T, R199A, D202A, K211A, Q214L, Q216L, Q221 L, W235F, W235E, K236S, K236A, K246A, G247W, D253A, R262A, R263A and K264H.

In one embodiment, the HIV-1 integrase deficient pol gene comprises a D64V, D116I, D116A, E152G, or E152A mutation; D64V, D116I, and E152G mutations; or D64V, D116A, and E152A mutations.

In one embodiment, the HIV-1 integrase deficient pol gene comprises a D64V mutation.

The term “long terminal repeat (LTR)” refers to domains of base pairs located at the ends of retroviral DNAs which, in their natural sequence context, are direct repeats and contain U3, R and U5 regions.

As used herein, the term “FLAP element” or “cPPT/FLAP” refers to a nucleic acid whose sequence includes the central polypurine tract and central termination sequences (cPPT and CTS) of a retrovirus, *e.g.*, HIV-1 or HIV-2. Suitable FLAP elements are described in U.S. Pat. No. 6,682,907 and in Zennou, *et al.*, 2000, *Cell*, 101:173. In another embodiment, a lentiviral vector contains a FLAP element with one or more mutations in the cPPT and/or CTS elements. In yet another embodiment, a lentiviral vector comprises either a cPPT or CTS element. In yet another embodiment, a lentiviral vector does not comprise a cPPT or CTS element.

As used herein, the term “packaging signal” or “packaging sequence” refers to psi [Ψ] sequences located within the retroviral genome which are required for insertion of the viral RNA into the viral capsid or particle, *see e.g.*, Clever *et al.*, 1995, *J. of Virology*, Vol. 69, No. 4; pp. 2101–2109.

The term “export element” refers to a cis-acting post-transcriptional regulatory element which regulates the transport of an RNA transcript from the nucleus to the cytoplasm of a cell. Examples of RNA export elements include, but are not limited to, the human immunodeficiency virus (HIV) rev response element (RRE) (*see e.g.*, Cullen *et al.*, 1991, *J. Virol.* 65: 1053; and Cullen *et al.*, 1991, *Cell* 58: 423), and the hepatitis B virus post-transcriptional regulatory element (HPRE).

In particular embodiments, expression of heterologous sequences in viral vectors is increased by incorporating posttranscriptional regulatory elements, efficient polyadenylation sites, and optionally, transcription termination signals into the vectors. A variety of posttranscriptional regulatory elements can increase expression of a heterologous nucleic acid at the protein, *e.g.*, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE; Zufferey *et al.*, 1999, *J. Virol.*, 73:2886); the posttranscriptional regulatory element present in hepatitis B virus (HPRE) (Huang *et al.*, *Mol. Cell. Biol.*, 5:3864); and the like (Liu *et al.*, 1995, *Genes Dev.*, 9:1766).

Lentiviral vectors preferably contain several safety enhancements as a result of modifying the LTRs. “Self-inactivating” (SIN) vectors refers to replication-defective vectors, *e.g.*, retroviral or lentiviral vectors, in which the right (3') LTR enhancer-promoter region, known as the U3 region, has been modified (*e.g.*, by deletion or substitution) to prevent viral

transcription beyond the first round of viral replication. Self-inactivation is preferably achieved through in the introduction of a deletion in the U3 region of the 3' LTR of the vector DNA, *i.e.*, the DNA used to produce the vector RNA. Thus, during reverse transcription, this deletion is transferred to the 5' LTR of the proviral DNA. In particular embodiments, it is
5 desirable to eliminate enough of the U3 sequence to greatly diminish or abolish altogether the transcriptional activity of the LTR, thereby greatly diminishing or abolishing the production of full-length vector RNA in transduced cells. In the case of HIV based lentivectors, it has been discovered that such vectors tolerate significant U3 deletions, including the removal of the LTR TATA box (e.g., deletions from -418 to -18), without significant reductions in vector
10 titers.

An additional safety enhancement is provided by replacing the U3 region of the 5' LTR with a heterologous promoter to drive transcription of the viral genome during production of viral particles. Examples of heterologous promoters which can be used include, for example, viral simian virus 40 (SV40) (*e.g.*, early or late), cytomegalovirus (CMV) (*e.g.*, immediate early),
15 Moloney murine leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoters.

The terms “pseudotype” or “pseudotyping” as used herein, refer to a virus whose viral envelope proteins have been substituted with those of another virus possessing preferable characteristics. For example, HIV can be pseudotyped with vesicular stomatitis virus G-protein
20 (VSV-G) envelope proteins, which allows HIV to infect a wider range of cells because HIV envelope proteins (encoded by the *env* gene) normally target the virus to CD4⁺ presenting cells.

In certain embodiments, lentiviral vectors are produced according to known methods. *See e.g.*, Kutner *et al.*, *BMC Biotechnol.* 2009;9:10. doi: 10.1186/1472-6750-9-10; Kutner *et al.* *Nat. Protoc.* 2009;4(4):495–505. doi: 10.1038/nprot.2009.22.

25 According to certain specific embodiments contemplated herein, most or all of the viral vector backbone sequences are derived from a lentivirus, *e.g.*, HIV-1. However, it is to be understood that many different sources of retroviral and/or lentiviral sequences can be used, or combined and numerous substitutions and alterations in certain of the lentiviral sequences may be accommodated without impairing the ability of a transfer vector to perform the functions
30 described herein. Moreover, a variety of lentiviral vectors are known in the art, *see* Naldini *et al.*, (1996a, 1996b, and 1998); Zufferey *et al.*, (1997); Dull *et al.*, 1998, U.S. Pat. Nos.

6,013,516; and 5,994,136, many of which may be adapted to produce a viral vector or transfer plasmid contemplated herein.

In various embodiments, one or more polynucleotides are introduced into an immune effector cell, by transducing the cell with an adenovirus comprising the one or more

5 polynucleotides.

Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Most adenovirus vectors are engineered such that a transgene replaces the Ad
10 E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues *in vivo*, including non-dividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity.

Generation and propagation of the current adenovirus vectors, which are replication
15 deficient, may utilize a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham *et al.*, 1977). Since the E3 region is dispensable from the adenovirus genome (Jones & Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham & Prevec, 1991). Adenovirus vectors
20 have been used in eukaryotic gene expression (Levrero *et al.*, 1991; Gomez-Foix *et al.*, 1992) and vaccine development (Grunhaus & Horwitz, 1992; Graham & Prevec, 1992). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld *et al.*, 1991; Rosenfeld *et al.*, 1992), muscle injection (Ragot *et al.*, 1993), peripheral intravenous injections (Herz & Gerard, 1993) and stereotactic inoculation into the brain (Le Gal
25 La Salle *et al.*, 1993). An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Stermann *et al.*, *Hum. Gene Ther.* 7:1083-9 (1998)).

In various embodiments, one or more polynucleotides are introduced into an immune effector cell by transducing the cell with a herpes simplex virus, *e.g.*, HSV-1, HSV-2, comprising
30 the one or more polynucleotides.

The mature HSV virion consists of an enveloped icosahedral capsid with a viral genome consisting of a linear double-stranded DNA molecule that is 152 kb. In one embodiment, the

HSV based viral vector is deficient in one or more essential or non-essential HSV genes. In one embodiment, the HSV based viral vector is replication deficient. Most replication deficient HSV vectors contain a deletion to remove one or more intermediate-early, early, or late HSV genes to prevent replication. For example, the HSV vector may be deficient in an immediate early gene
5 selected from the group consisting of: ICP4, ICP22, ICP27, ICP47, and a combination thereof. Advantages of the HSV vector are its ability to enter a latent stage that can result in long-term DNA expression and its large viral DNA genome that can accommodate exogenous DNA inserts of up to 25 kb. HSV-based vectors are described in, for example, U.S. Pat. Nos. 5,837,532, 5,846,782, and 5,804,413, and International Patent Applications WO 91/02788, WO 96/04394,
10 WO 98/15637, and WO 99/06583, each of which are incorporated by reference herein in its entirety.

H. GENETICALLY MODIFIED CELLS

In various embodiments, cells genetically modified to express an engineered TCR are contemplated herein. In some embodiments, the immune effector cells genetically modified
15 to express an engineered TCR as contemplated herein are used in preparation or manufacture of a medicament for the treatment of cancer.

As used herein, the term “genetically engineered” or “genetically modified” refers to the addition of extra genetic material in the form of DNA or RNA into the total genetic material in a cell. The terms, “genetically modified cells,” “modified cells,” and, “redirected cells,” are used
20 interchangeably. As used herein, the term “gene therapy” refers to the introduction of extra genetic material in the form of DNA or RNA into the total genetic material in a cell that restores, corrects, or modifies expression of a gene, or for the purpose of expressing a therapeutic polypeptide, *e.g.*, an engineered TCR.

In particular embodiments, a polynucleotide encoding an engineered TCR
25 contemplated herein is introduced into immune effector cells so as express the engineered TCR and to redirect the immune effector cells to target cells expressing a target antigen. An “immune effector cell,” is any cell of the immune system that has one or more effector functions (*e.g.*, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and/or CDC). Illustrative immune effector cells contemplated herein are T lymphocytes,
30 including but not limited to cytotoxic T cells (CTLs; CD8⁺ T cells), TILs, and helper T cells (HTLs; CD4⁺ T cells. In a particular embodiment, the cells comprise $\alpha\beta$ T cells. In a particular embodiment, the cells comprise $\gamma\delta$ T cells modified to express an $\alpha\beta$ TCR. In one embodiment,

immune effector cells include natural killer (NK) cells. In one embodiment, immune effector cells include natural killer T (NKT) cells.

Immune effector cells can be autologous/autogeneic (“self”) or non-autologous (“non-self,” *e.g.*, allogeneic, syngeneic or xenogeneic). “Autologous,” as used herein, refers to cells from the same subject. “Allogeneic,” as used herein, refers to cells of the same species that differ genetically to the cell in comparison. “Syngeneic,” as used herein, refers to cells of a different subject that are genetically identical to the cell in comparison. “Xenogeneic,” as used herein, refers to cells of a different species to the cell in comparison. In preferred embodiments, the cells are autologous.

Illustrative immune effector cells used with the engineered TCRs contemplated in particular embodiments include T lymphocytes. The terms “T cell” or “T lymphocyte” are art-recognized and are intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. A T cell can be a T helper (Th) cell, for example a T helper 1 (Th1) or a T helper 2 (Th2) cell. The T cell can be a helper T cell (HTL; CD4⁺ T cell) CD4⁺ T cell, a cytotoxic T cell (CTL; CD8⁺ T cell), CD4⁺CD8⁺ T cell, CD4⁺CD8⁻ T cell, or any other subset of T cells. Other illustrative populations of T cells suitable for use in particular embodiments include naïve T cells (T_N), T memory stem cells (T_{SCM}), central memory T cells (T_{CM}), effector memory T cells (T_{EM}), and effector T cells (T_{EFF}).

As would be understood by the skilled person, other cells may also be used as immune effector cells with the engineered TCRs contemplated herein. In particular, immune effector cells also include NK cells, NKT cells, neutrophils, and macrophages. Immune effector cells also include progenitors of effector cells wherein such progenitor cells can be induced to differentiate into an immune effector cells *in vivo* or *in vitro*. Thus, in particular embodiments, immune effector cell includes progenitors of immune effectors cells such as hematopoietic stem cells (HSCs) contained within the CD34⁺ population of cells derived from cord blood, bone marrow or mobilized peripheral blood which upon administration in a subject differentiate into mature immune effector cells, or which can be induced *in vitro* to differentiate into mature immune effector cells.

The term, “CD34⁺ cell,” as used herein refers to a cell expressing the CD34 protein on its cell surface. “CD34,” as used herein refers to a cell surface glycoprotein (*e.g.*, sialomucin protein) that often acts as a cell-cell adhesion factor and is involved in T cell entrance into

lymph nodes. The CD34⁺ cell population contains hematopoietic stem cells (HSC), which upon administration to a patient differentiate and contribute to all hematopoietic lineages, including T cells, NK cells, NKT cells, neutrophils and cells of the monocyte/macrophage lineage.

5 Methods for making the immune effector cells that express an engineered TCR contemplated herein are provided in particular embodiments. In one embodiment, the method comprises transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells express a polynucleotide or polycistronic message encoding an engineered TCR as contemplated herein or a fusion protein encoding an
10 engineered TCR contemplated herein. In particular embodiments, the transduced cells are subsequently cultured for expansion, prior to administration to a subject.

 In certain embodiments, the immune effector cells are isolated from an individual and genetically modified without further manipulation *in vitro*. Such cells can then be directly re-administered into the individual. In further embodiments, the immune effector cells are first
15 activated and stimulated to proliferate *in vitro* prior to being genetically modified to express an engineered TCR contemplated herein. In this regard, the immune effector cells may be cultured before and/or after being genetically modified.

 In particular embodiments, prior to *in vitro* manipulation or genetic modification of the immune effector cells described herein, the source of cells is obtained from a subject. In
20 particular embodiments, modified immune effector cells comprise T cells.

 In particular embodiments, PBMCs may be directly genetically modified to express a polycistronic message encoding an engineered TCR contemplated herein. In certain embodiments, after isolation of PBMC, T lymphocytes are further isolated and in certain
25 embodiments, both cytotoxic and helper T lymphocytes can be sorted into naïve, memory, and effector T cell subpopulations either before or after genetic modification and/or expansion.

 The immune effector cells, such as T cells, can be genetically modified following isolation using known methods, or the immune effector cells can be activated and expanded (or differentiated in the case of progenitors) *in vitro* prior to being genetically modified. In a
30 particular embodiment, the immune effector cells, such as T cells, are activated and stimulated for expansion and then genetically modified with the TCRs contemplated herein (*e.g.*, transduced with a viral vector comprising a nucleic acid encoding a polycistronic

message encoding an engineered TCR contemplated herein comprising. In various embodiments, T cells can be activated and expanded before or after genetic modification, using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.

In one embodiment, CD34⁺ cells are transduced with a nucleic acid construct contemplated herein. In certain embodiments, the transduced CD34⁺ cells differentiate into mature immune effector cells *in vivo* following administration into a subject, generally the subject from whom the cells were originally isolated. In another embodiment, CD34⁺ cells may be stimulated *in vitro* prior to exposure to or after being genetically modified with one or more of the following cytokines: Flt-3 ligand (FLT3), stem cell factor (SCF), megakaryocyte growth and differentiation factor (TPO), IL-3 and IL-6 according to the methods described previously (Asheuer *et al.*, 2004; Imren, *et al.*, 2004).

In particular embodiments, a population of modified immune effector cells for the treatment of cancer comprises an engineered TCR contemplated herein. For example, a population of modified immune effector cells are prepared from peripheral blood mononuclear cells (PBMCs) obtained from a patient diagnosed with B cell malignancy described herein (autologous donors). The PBMCs form a heterogeneous population of T lymphocytes that can be CD4⁺, CD8⁺, or CD4⁺ and CD8⁺.

The PBMCs also can include other cytotoxic lymphocytes such as NK cells or NKT cells. An expression vector carrying the coding sequence of an engineered TCR contemplated in particular embodiments is introduced into a population of human donor T cells, NK cells or NKT cells. In particular embodiments, successfully transduced T cells that carry the expression vector can be sorted using flow cytometry to isolate CD3 positive T cells and then further propagated to increase the number of these CAR protein expressing T cells in addition to cell activation using anti-CD3 antibodies and or anti-CD28 antibodies and IL-2 or any other methods known in the art as described elsewhere herein. Standard procedures are used for cryopreservation of T cells expressing the CAR protein T cells for storage and/or preparation for use in a human subject. In one embodiment, the *in vitro* transduction, culture and/or expansion of T cells are performed in the absence of non-human animal derived products such as fetal calf serum and fetal bovine serum. Since a heterogeneous population of PBMCs is genetically modified, the resultant

transduced cells are a heterogeneous population of modified cells comprising a BCMA targeting CAR as contemplated herein.

In a further embodiment, a mixture of, *e.g.*, one, two, three, four, five or more, different expression vectors can be used in genetically modifying a donor population of immune effector cells wherein each vector encodes a different chimeric antigen receptor protein as contemplated herein. The resulting modified immune effector cells forms a mixed population of modified cells.

Genetically engineered cells, including T cells, can be manufactured using various methods known in the art, see, *e.g.*, WO 2016/094304 which is incorporated herein by reference in its entirety.

I. COMPOSITIONS AND FORMULATIONS

The compositions contemplated herein may comprise one or more engineered TCR polypeptides, TCR α polypeptides, TCR β polypeptides, TCR γ polypeptides, TCR δ polypeptides, TCR fusion polypeptides, polynucleotides, vectors comprising same, genetically modified immune effector cells, etc., as contemplated herein. Compositions include, but are not limited to pharmaceutical compositions. In preferred embodiments, a composition comprises one or more cells modified to express an engineered TCR contemplated herein.

A “pharmaceutical composition” refers to a composition formulated in pharmaceutically-acceptable or physiologically-acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy. It will also be understood that, if desired, the compositions may be administered in combination with other agents as well, such as, *e.g.*, cytokines, growth factors, hormones, small molecules, chemotherapeutics, pro-drugs, drugs, antibodies, or other various pharmaceutically-active agents. There is virtually no limit to other components that may also be included in the compositions, provided that the additional agents do not adversely affect the ability of the composition to deliver the intended therapy. In preferred embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier, diluent or excipient, and one or more cells modified to express an engineered TCR as contemplated herein.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and

animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein “pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, 5 preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals. Exemplary pharmaceutically acceptable carriers include, but are not limited to, to sugars, such as lactose, glucose and sucrose; starches, such as corn starch and 10 potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffins, silicones, bentonites, silicic acid, zinc oxide; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, 15 such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and any other compatible substances employed in pharmaceutical formulations.

In particular embodiments, formulation of pharmaceutically-acceptable carrier 20 solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, enteral and parenteral, *e.g.*, intravascular, intravenous, intrarterial, intrarterial, intraosseously, intraventricular, intracerebral, intracranial, intraspinal, intrathecal, and intramedullary administration and formulation. It would be 25 understood by the skilled artisan that particular embodiments contemplated herein may comprise other formulations, such as those that are well known in the pharmaceutical art, and are described, for example, in *Remington: The Science and Practice of Pharmacy*, volume I and volume II. 22nd Edition. Edited by Loyd V. Allen Jr. Philadelphia, PA: Pharmaceutical Press; 2012, which is incorporated by reference herein, in its entirety.

30 In particular embodiments, compositions comprise an amount of immune effector cells expressing an engineered TCR contemplated herein. As used herein, the term “amount” refers to “an amount effective” or “an effective amount” of a genetically modified

therapeutic cell, *e.g.*, T cell, to achieve a beneficial or desired prophylactic or therapeutic result, including clinical results.

A “prophylactically effective amount” refers to an amount of a genetically modified therapeutic cells effective to achieve the desired prophylactic result. Typically, but not
5 necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount is less than the therapeutically effective amount.

A “therapeutically effective amount” of a genetically modified therapeutic cell may vary according to factors such as the disease state, age, sex, and weight of the individual,
10 and the ability of the stem and progenitor cells to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the virus or transduced therapeutic cells are outweighed by the therapeutically beneficial effects. The term “therapeutically effective amount” includes an amount that is effective to “treat” a subject (*e.g.*, a patient). When a therapeutic amount is indicated, the precise
15 amount of the compositions to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject).

It can generally be stated that a pharmaceutical composition comprising the T cells described herein may be administered at a dosage of 10^6 to 10^{13} cells/kg body weight,
20 preferably 10^8 to 10^{13} cells/kg body weight, including all integer values within those ranges. The number of cells will depend upon the ultimate use for which the composition is intended as will the type of cells included therein. For uses provided herein, the cells are generally in a volume of a liter or less, can be 500 mLs or less, even 250 mLs or 100 mLs or less. Hence the density of the desired cells is typically greater than 10^6 cells/ml and generally is greater
25 than 10^7 cells/ml, generally 10^8 cells/ml or greater. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} or 10^{13} cells. Compositions may be administered multiple times at dosages within these ranges. The cells may be allogeneic, syngeneic, xenogeneic, or autologous to the patient undergoing therapy. If desired, the treatment may also include
30 administration of mitogens (*e.g.*, PHA) or lymphokines, cytokines, and/or chemokines (*e.g.*, IFN- γ , IL-2, IL-12, TNF-alpha, IL-18, and TNF-beta, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1 α , *etc.*) as contemplated herein to enhance induction of the immune response.

Generally, compositions comprising the cells activated and expanded as contemplated herein may be utilized in the treatment and prevention of diseases that arise in individuals who are immunocompromised. In particular embodiments, compositions comprising immune effector cells modified to express an engineered TCR contemplated herein are used in the treatment of cancer. The modified immune effector cells may be administered either alone, or as a pharmaceutical composition in combination with carriers, diluents, excipients, and/or with other components such as IL-2 or other cytokines or cell populations. In particular embodiments, pharmaceutical compositions comprise an amount of genetically modified T cells, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.

Pharmaceutical compositions comprising an immune effector cell population modified to express an engineered TCR (*e.g.*, T cells), may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (*e.g.*, aluminum hydroxide); and preservatives.

Compositions are preferably formulated for parenteral administration, *e.g.*, intravascular (intravenous or intraarterial), intraperitoneal or intramuscular administration.

The liquid pharmaceutical compositions, whether they be solutions, suspensions or other like form, may include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, or isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. An injectable pharmaceutical composition is preferably sterile.

In one embodiment, the T cell compositions contemplated herein are formulated in a pharmaceutically acceptable cell culture medium. Such compositions are suitable for administration to human subjects. In particular embodiments, the pharmaceutically acceptable cell culture medium is a serum free medium.

Serum-free medium has several advantages over serum containing medium, including a simplified and better-defined composition, a reduced degree of contaminants, elimination of a potential source of infectious agents, and lower cost. In various embodiments, the serum-free medium is animal-free, and may optionally be protein-free.

- 5 Optionally, the medium may contain biopharmaceutically acceptable recombinant proteins. “Animal-free” medium refers to medium wherein the components are derived from non-animal sources. Recombinant proteins replace native animal proteins in animal-free medium and the nutrients are obtained from synthetic, plant or microbial sources. “Protein-free” medium, in contrast, is defined as substantially free of protein.

- 10 Illustrative examples of serum-free media used in particular compositions includes, but is not limited to QBSF-60 (Quality Biological, Inc.), StemPro-34 (Life Technologies), and X-VIVO 10.

In one preferred embodiment, compositions comprising immune effector cells contemplated herein are formulated in a solution comprising PlasmaLyte A.

- 15 In another preferred embodiment, compositions comprising immune effector cells contemplated herein are formulated in a solution comprising a cryopreservation medium. For example, cryopreservation media with cryopreservation agents may be used to maintain a high cell viability outcome post-thaw. Illustrative examples of cryopreservation media used in particular compositions includes, but is not limited to, CryoStor CS10, CryoStor
20 CS5, and CryoStor CS2.

In a more preferred embodiment, compositions comprising immune effector cells contemplated herein are formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10.

- 25 In a particular embodiment, compositions comprise an effective amount of genome edited immune effector cells modified to express an engineered TCR contemplated herein. Thus, the immune effector cell compositions may be administered alone or in combination with other known cancer treatments, such as radiation therapy, chemotherapy, transplantation, immunotherapy, hormone therapy, photodynamic therapy, etc. The compositions may also be administered in combination with antibiotics. Such therapeutic
30 agents may be accepted in the art as a standard treatment for a particular disease state as described herein, such as a particular cancer. Exemplary therapeutic agents contemplated in particular embodiments include cytokines, growth factors, steroids, NSAIDs, DMARDs,

anti-inflammatories, chemotherapeutics, radiotherapeutics, therapeutic antibodies, or other active and ancillary agents.

In certain embodiments, compositions comprising genome edited immune effector cells modified to express an engineered TCR contemplated herein may be administered in conjunction with any number of chemotherapeutic agents. A variety of other therapeutic agents may be used in conjunction with the compositions contemplated herein. In one embodiment, the composition comprising immune effector cells expressing an engineered TCR is administered with an anti-inflammatory agent.

In particular embodiments, a composition comprising immune effector modified to express an engineered TCR contemplated herein is administered with a therapeutic antibody (*e.g.*, mono or bispecific antibody or fragment thereof) and/or an immune cell engager (NK engager). Illustrative examples of therapeutic antibodies suitable for combination with the CAR modified T cells contemplated in particular embodiments, include but are not limited to, atezolizumab, avelumab, bavituximab, bevacizumab (avastin), bivatuzumab, blinatumomab, conatumumab, crizotinib, daratumumab, duligotumab, dacetuzumab, dalotuzumab, durvalumab, elotuzumab (HuLuc63), gemtuzumab, ibritumomab, indatuximab, inotuzumab, ipilimumab, lorvotuzumab, lucatumumab, milatuzumab, moxetumomab, nivolumab, ocaratuzumab, ofatumumab, pembrolizumab, rituximab, siltuximab, teprotumumab, and ublituximab.

J. THERAPEUTIC METHODS

The genetically modified immune effector cells expressing an engineered TCR contemplated herein provide improved methods of adoptive immunotherapy for use in the prevention, treatment, and amelioration cancers or for preventing, treating, or ameliorating at least one symptom associated with cancer.

In various embodiments, the genetically modified immune effector cells contemplated herein provide improved methods of adoptive immunotherapy for use in increasing the cytotoxicity in cancer cells in a subject or for use in decreasing the number of cancer cells in a subject.

In particular embodiments, the specificity of a primary immune effector cell is redirected to cells expressing a particular antigen, *e.g.*, cancer cells, by genetically modifying the primary immune effector cell with an engineered TCR as contemplated herein. In various embodiments, a viral vector is used to genetically modify an immune effector cell with a particular

polynucleotide encoding an engineered TCR. In some embodiments, the engineered TCR comprises (a) a TCR α polypeptide comprising a TCR α variable domain; (b) a TCR β polypeptide comprising a TCR β variable domain; and (c) one or more antigen-binding domains linked to the TCR α variable domain and/or TCR β variable domain. In some embodiments, the engineered

5 TCR comprises (a) a TCR γ polypeptide comprising a TCR γ variable domain; (b) a TCR δ polypeptide comprising a TCR δ variable domain; and (c) one or more antigen-binding domains linked to the TCR γ variable domain and/or TCR δ variable domain. In certain embodiments, the linker is a polypeptide linker. In particular embodiments, the polypeptide linker comprises an amino acid sequence as set forth in any one or more of SEQ ID NOs: 33-53.

10 In one embodiment, a type of cellular therapy where T cells are genetically modified to express an engineered TCR contemplated herein are infused to a recipient in need thereof is provided. The infused cell is able to kill disease causing cells in the recipient. Unlike antibody therapies, T cell therapies are able to replicate *in vivo* resulting in long-term persistence that can lead to sustained cancer therapy.

15 In one embodiment, T cells that express an engineered TCR contemplated herein can undergo robust *in vivo* T cell expansion and can persist for an extended amount of time. In another embodiment, T cells that express an engineered TCR contemplated herein evolve into specific memory T cells or stem cell memory T cells that can be reactivated to inhibit any additional tumor formation or growth.

20 In particular embodiments, modified immune effector cells that express an engineered TCR contemplated herein are used in the treatment of solid tumors or cancers.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, but not limited to: adrenal cancer, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, atypical

25 teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain/CNS cancer, breast cancer, bronchial tumors, cardiac tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal carcinoma in situ (DCIS) endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing's sarcoma, extracranial germ cell tumor,

30 extragonadal germ cell tumor, eye cancer, fallopian tube cancer, fibrous histiosarcoma, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor (GIST), germ cell tumors, glioma, glioblastoma, head and neck

cancer, hemangioblastoma, hepatocellular cancer, hypopharyngeal cancer, intraocular melanoma, kaposi sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, lip cancer, liposarcoma, liver cancer, lung cancer, non-small cell lung cancer, lung carcinoid tumor, malignant mesothelioma, medullary carcinoma, medulloblastoma, meningioma, melanoma, 5 Merkel cell carcinoma, midline tract carcinoma, mouth cancer, myxosarcoma, myelodysplastic syndrome, myeloproliferative neoplasms, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oligodendroglioma, oral cancer, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic islet cell tumors, papillary carcinoma, paraganglioma, parathyroid cancer, penile cancer, 10 pharyngeal cancer, pheochromocytoma, pinealoma, pituitary tumor, pleuropulmonary blastoma, primary peritoneal cancer, prostate cancer, rectal cancer, retinoblastoma, renal cell carcinoma, renal pelvis and ureter cancer, rhabdomyosarcoma, salivary gland cancer, sebaceous gland carcinoma, skin cancer, soft tissue sarcoma, squamous cell carcinoma, small cell lung cancer, small intestine cancer, stomach cancer, sweat gland carcinoma, synovioma, 15 testicular cancer, throat cancer, thymus cancer, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vascular cancer, vulvar cancer, and Wilms Tumor.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, without limitation, non-small cell lung carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic 20 cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, and oligodendroglioma.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, without limitation, non-small- 25 cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of glioblastoma.

In particular embodiments, the modified immune effector cells that express an 30 engineered TCR contemplated herein are used in the treatment of liquid cancers or hematological cancers.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of B-cell malignancies, including but not limited to: leukemias, lymphomas, and multiple myeloma.

In particular embodiments, the modified immune effector cells contemplated herein
5 are used in the treatment of liquid cancers including, but not limited to leukemias, lymphomas, and multiple myelomas: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and
10 polycythemia vera, Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, Burkitt lymphoma, small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, marginal zone lymphoma, mycosis fungoides, anaplastic large cell lymphoma, Sézary syndrome, precursor T-lymphoblastic
15 lymphoma, multiple myeloma, overt multiple myeloma, smoldering multiple myeloma, plasma cell leukemia, non-secretory myeloma, IgD myeloma, osteosclerotic myeloma, solitary plasmacytoma of bone, and extramedullary plasmacytoma.

In certain embodiments, the liquid or hematological cancer is selected from the group consisting of: acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), hairy
20 cell leukemia (HCL), multiple myeloma (MM), acute myeloid leukemia (AML), or chronic myeloid leukemia (CML).

In preferred embodiments, the liquid or hematological cancer is multiple myeloma (MM).

In preferred embodiments, the liquid or hematological cancer is relapsed/refractory multiple myeloma (MM).

25 In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of acute myeloid leukemia (AML).

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of lymphoma (*e.g.*, non-hodgkin's lymphoma or DLBCL).

30 As used herein, the terms "individual" and "subject" are often used interchangeably and refer to any animal that exhibits a symptom of a disease, disorder, or condition that can be treated with the gene therapy vectors, cell-based therapeutics, and methods contemplated elsewhere herein. In preferred embodiments, a subject includes any animal that exhibits

symptoms of a disease, disorder, or condition related to cancer that can be treated with the gene therapy vectors, cell-based therapeutics, and methods contemplated elsewhere herein. Suitable subjects (*e.g.*, patients) include laboratory animals (such as mouse, rat, rabbit, or guinea pig), farm animals, and domestic animals or pets (such as a cat or dog). Non-human
5 primates and, preferably, human patients, are included.

As used herein, the term “patient” refers to a subject that has been diagnosed with a particular disease, disorder, or condition that can be treated with the gene therapy vectors, cell-based therapeutics, and methods disclosed elsewhere herein.

As used herein “treatment” or “treating,” includes any beneficial or desirable effect on
10 the symptoms or pathology of a disease or pathological condition, and may include even minimal reductions in one or more measurable markers of the disease or condition being treated. Treatment can involve optionally either the reduction the disease or condition, or the delaying of the progression of the disease or condition. “Treatment” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms
15 thereof.

As used herein, “prevent,” and similar words such as “prevented,” “preventing” *etc.*, indicate an approach for preventing, inhibiting, or reducing the likelihood of the occurrence or recurrence of, a disease or condition. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease or
20 condition. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and/or burden of a disease or condition prior to onset or recurrence of the disease or condition.

As used herein, the phrase “ameliorating at least one symptom of” refers to decreasing one or more symptoms of the disease or condition for which the subject is being treated. In
25 particular embodiments, the disease or condition being treated is a cancer, wherein the one or more symptoms ameliorated include, but are not limited to, weakness, fatigue, shortness of breath, easy bruising and bleeding, frequent infections, enlarged lymph nodes, distended or painful abdomen (due to enlarged abdominal organs), bone or joint pain, fractures, unplanned weight loss, poor appetite, night sweats, persistent mild fever, and decreased urination (due to
30 impaired kidney function).

By “enhance” or “promote,” or “increase” or “expand” refers generally to the ability of a composition contemplated herein, *e.g.*, genetically modified T cells that express an

engineered TCR contemplated herein, to produce, elicit, or cause a greater physiological response (*i.e.*, downstream effects) compared to the response caused by either vehicle or a control molecule/composition. A measurable physiological response may include an increase in T cell expansion, activation, persistence, and/or an increase in cancer cell killing ability, among others apparent from the understanding in the art and the description herein. An “increased” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (*e.g.*, 500, 1000 times) (including all integers and decimal points in between and above 1, *e.g.*, 1.5, 1.6, 1.7, 1.8, *etc.*) the response produced by vehicle or a control composition.

By “decrease” or “lower,” or “lessen,” or “reduce,” or “abate” refers generally to the ability of composition contemplated herein to produce, elicit, or cause a lesser physiological response (*i.e.*, downstream effects) compared to the response caused by either vehicle or a control molecule/composition. A “decrease” or “reduced” amount is typically a “statistically significant” amount, and may include an decrease that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (*e.g.*, 500, 1000 times) (including all integers and decimal points in between and above 1, *e.g.*, 1.5, 1.6, 1.7, 1.8, *etc.*) the response (reference response) produced by vehicle, a control composition, or the response in a particular cell lineage.

By “maintain,” or “preserve,” or “maintenance,” or “no change,” or “no substantial change,” or “no substantial decrease” refers generally to the ability of a composition contemplated herein to produce, elicit, or cause a similar physiological response (*i.e.*, downstream effects) in a cell, as compared to the response caused by either vehicle, a control molecule/composition, or the response in a particular cell lineage. A comparable response is one that is not significantly different or measurable different from the reference response.

In one embodiment, a method of treating cancer in a subject in need thereof comprises administering an effective amount, *e.g.*, therapeutically effective amount of a composition comprising genetically modified immune effector cells contemplated herein. The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages may be determined by clinical trials.

In one embodiment, the amount of immune effector cells, *e.g.*, T cells that express an engineered TCR, in the composition administered to a subject is at least 1×10^7 cells, at least

0.5×10^8 cells, at least 1×10^8 cells, at least 0.5×10^9 cells, at least 1×10^9 cells, at least 1×10^{10} cells, at least 1×10^{11} cells, at least 1×10^{12} cells, at least 5×10^{12} cells, or at least 1×10^{13} cells.

In particular embodiments, about 1×10^7 T cells to about 1×10^{13} T cells, about 1×10^8 T cells to about 1×10^{13} T cells, about 1×10^9 T cells to about 1×10^{13} T cells, about 1×10^{10} T cells to about 1×10^{13} T cells, about 1×10^{11} T cells to about 1×10^{13} T cells, or about 1×10^{12} T cells to about 1×10^{13} T cells are administered to a subject.

In one embodiment, the amount of immune effector cells, *e.g.*, T cells that express an engineered TCR, in the composition administered to a subject is at least 0.1×10^4 cells/kg of bodyweight, at least 0.5×10^4 cells/kg of bodyweight, at least 1×10^4 cells/kg of bodyweight, at least 5×10^4 cells/kg of bodyweight, at least 1×10^5 cells/kg of bodyweight, at least 0.5×10^6 cells/kg of bodyweight, at least 1×10^6 cells/kg of bodyweight, at least 0.5×10^7 cells/kg of bodyweight, at least 1×10^7 cells/kg of bodyweight, at least 0.5×10^8 cells/kg of bodyweight, at least 1×10^8 cells/kg of bodyweight, at least 2×10^8 cells/kg of bodyweight, at least 3×10^8 cells/kg of bodyweight, at least 4×10^8 cells/kg of bodyweight, at least 5×10^8 cells/kg of bodyweight, or at least 1×10^9 cells/kg of bodyweight.

In particular embodiments, about 1×10^6 T cells/kg of bodyweight to about 1×10^8 T cells/kg of bodyweight, about 2×10^6 T cells/kg of bodyweight to about 0.9×10^8 T cells/kg of bodyweight, about 3×10^6 T cells/kg of bodyweight to about 0.8×10^8 T cells/kg of bodyweight, about 4×10^6 T cells/kg of bodyweight to about 0.7×10^8 T cells/kg of bodyweight, about 5×10^6 T cells/kg of bodyweight to about 0.6×10^8 T cells/kg of bodyweight, or about 5×10^6 T cells/kg of bodyweight to about 0.5×10^8 T cells/kg of bodyweight are administered to a subject.

One of ordinary skill in the art would recognize that multiple administrations of the compositions contemplated herein may be required to effect the desired therapy. For example a composition may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more times over a span of 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 5 years, 10 years, or more.

In certain embodiments, it may be desirable to administer activated immune effector cells to a subject and then subsequently redraw blood (or have an apheresis performed), activate immune effector cells therefrom, and reinfuse the patient with these activated and expanded immune effector cells. This process can be carried out multiple times every few weeks. In certain embodiments, immune effector cells can be activated from blood draws of from 10cc to 400cc. In certain embodiments, immune effector cells are activated from blood

draws of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, 100cc, 150cc, 200cc, 250cc, 300cc, 350cc, or 400cc or more. Not to be bound by theory, using this multiple blood draw/multiple reinfusion protocol may serve to select out certain populations of immune effector cells.

The administration of the compositions contemplated herein may be carried out in any
5 convenient manner, including by aerosol inhalation, injection, ingestion, transfusion,
implantation or transplantation. In a preferred embodiment, compositions are administered
parenterally. The phrases “parenteral administration” and “administered parenterally” as
used herein refers to modes of administration other than enteral and topical administration,
usually by injection, and includes, without limitation, intravascular, intravenous,
10 intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intratumoral, intracardiac,
intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular,
subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. In one
embodiment, the compositions contemplated herein are administered to a subject by direct
injection into a tumor, lymph node, or site of infection.

15 In one embodiment, a subject in need thereof is administered an effective amount of a
composition to increase a cellular immune response to a B cell related condition in the
subject. The immune response may include cellular immune responses mediated by
cytotoxic T cells capable of killing infected cells, regulatory T cells, and helper T cell
responses. Humoral immune responses, mediated primarily by helper T cells capable of
20 activating B cells thus leading to antibody production, may also be induced. A variety of
techniques may be used for analyzing the type of immune responses induced by the
compositions, which are well described in the art; *e.g.*, Current Protocols in Immunology,
Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach,
Warren Strober (2001) John Wiley & Sons, NY, N.Y.

25 In one embodiment, a method of treating a subject diagnosed with a cancer is
provided comprising removing immune effector cells from the subject, genetically modifying
said immune effector cells with a vector comprising a nucleic acid encoding an engineered
TCR contemplated herein, thereby producing a population of modified immune effector cells,
and administering the population of modified immune effector cells to the same subject. In a
30 preferred embodiment, the immune effector cells comprise T cells.

In certain embodiments, methods for stimulating an immune effector cell mediated
immune modulator response to a target cell population in a subject are provided comprising

the steps of administering to the subject an immune effector cell population expressing a nucleic acid construct encoding an engineered TCR contemplated herein.

The methods for administering the cell compositions contemplated in particular embodiments includes any method which is effective to result in reintroduction of *ex vivo* genetically modified immune effector cells that either directly express an engineered TCR contemplated herein in the subject or on reintroduction of the genetically modified progenitors of immune effector cells that on introduction into a subject differentiate into mature immune effector cells that express the TCR. One method comprises transducing peripheral blood T cells *ex vivo* with a nucleic acid construct contemplated herein and returning the transduced cells into the subject.

All publications, patent applications, and issued patents cited in this specification are herein incorporated by reference as if each individual publication, patent application, or issued patent were specifically and individually indicated to be incorporated by reference.

Although the foregoing embodiments have been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings contemplated herein that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

SEQUENCE LISTING

SEQ ID NO	NAME	SEQUENCE
1	anti-BCMA.1 scFV	DIVLTQSPPSLAMS LGKRATISCRASESVTILGSHLIHWYQQKP GQPPTLLIQLASNVQTVGVPARFSGSGSRTDFTLTIDPVEEDDVA VYYCLQSRITPRTFGGGTKLEIKGSTSGSGKPGSGEGSTKGQIQ LVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKW MGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLYKEDT ATYFCALDYSYAMDYWGQTSVTVSS
2	anti-BCMA.2 scFV	DIVLTQSPASLAVSLGERATINCRASESVSVIGAHLIHWYQQKP GQPPKLLIYLASNLETGVPARFSGSGSGTDFTLTISSLQAEDAA IYYCLQSRIFPRTFGGQTKLEIKGSTSGSGKPGSGEGSTKGQVQ LVQSGSELKKPGASVKVSCASGYTFTDYSINWVRQAPGQGLEW MGWINTETREPAYAYDFRGRFVFLDTSVSTAYLQISSLKAEDT AVYYCARDYSYAMDYWGQGLTVTVSS
3	anti-BCMA.3 scFV	DIQMTQSPSSLSASVGDRTITCRASQDIRNYLGWYQQKPGKAP KVLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC LQDYIYPWTFAGTKVEIKGGGGSGGGGSGGGGSGVQLVESGGG VQVPGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYD GRNKNYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR EGEATYYDILTGPFYWGQGLTVTVSS
4	anti-CD19 scFV	DIQMTQTTSSLSASLGDRVTISCRASQDISKYNLWYQQKPDGTV KLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFC QQGNTLPYTFGGGKLEITGGGGSGGGGSGGGGSEVKLQESGPG LVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGS ETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDDAIYYCAKH YYYGGSYAMDYWGQTSVTVSS
5	anti-CD20.1 scFV	EVQLQQSGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQG LEWIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTS EDSADYYCARSNYYGSSYWFDFVWGAGTTVTVSSGGGGSGGGGS GGGGSDIVLTQSPAILSASPGEKVTMTCRASSSVNYMDWYQKKP GSSPKPWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAA TYQCQWFSFNPPTFGGGTKLEIK
6	anti-CD20.2 scFV	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRG LEWIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTS EDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAGGGGSGGGGSG GGGQIVLSQSPAILSASPGEKVTMTCRASSSVYIHWGQKPG SSPKPWIYATSNLASGVPRFSGSGSGTSYSLTISRVEAEDAAT YYCQWTSNPPTFGGGTKLEIKR
7	anti-CD20.3 scFV	QVQLVQSGAEVKKPGSSVKVSCASGYAFSYSWINWVRQAPGQG LEWMGRIFPGDGD TDYNGKFKGRVTITADKSTSTAYMELSSLRS EDTAVYYCARNVFDGYWLVYWGQGLTVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLPVTGPGEPAISCRSSKSLLSHNGITYLYWYL QKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAE DVGYYCAQNLLELPYTFGGGKVEIKRTV
8	anti-CD22 scFV	QVQLQQSGPGLVKPSQTLSTCAISGDSVSSNSAANNWIRQSPS RGLEWLGRYYRSKYNDYAVSVKSRITINPDTSKNQFSLQLNS VTPEDTAVYYCAREVTGDLEDAFDIWGQGTMTVTVSSGGGGSDIQ MTQSPSSLSASVGDRTITCRASQTIWSYLNWYQQRPGKAPNLL IYAASSLQSGVPSRFSGRSGTDFTLTISSLQAEDFATYYCQQS YSIPQTFGGGKLEIK
9	anti-CD33 scFV	EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQ IPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQPED LAIYYCHQYLSRFTFGGQTKLEIKGGGGSGGGGSGGGGSGVQLQ QPGAENVKPGASVKMSCKASGYTFTSYIHWIKQTPGQGLEWVG

		VIYPGNDDISYNQKFQ GKATLTADKSSTTAYMQLSSLTSEDSAV YYCAREVRLRYFDVWGQGT TVTVSS
10	anti-CD79A scFV	DVLMTQIPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQK PGQSPKLLIYKVS NRFSGV PDRFSGSGSGTDFTLKISRVEAEDL GVYYCFQGSHPFTFGSGTKLEIKRGGGSGGGGSGGGGSGVQL QQSGPELVKPGASVKISCKASGYTFSTSWMNWVKRPGGLEWI GRIYPGDGTNYNGKFKGKATLTADKSSNTAYMQLSSLTSDSA VYFCERFYYWGTFAMDYWGQGT SVTVSS
11	anti-CD79B.1 scFV	QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMHVWKQAPGEG LKWMGWINTETGEPTYADDFKGRFAFSLETSASTAYLQINNKN EDTATYFCYGYGSGWQGT LVTVSAGGGGSGGGGSGGGGSDIVLT QSPASLAVSLGQRATISCKASQSVDDYDGDGYMDWYQKPGQPPK LLIFAASNLKSGIPARFSGSGSGTDFTLNHPVEEEDAATYYCQ QTNEYPTWTFGGGTKLEIK
12	anti-CD79B.2 scFV	DIQLTQSPSSLSASVGDRTITCKASQSVDEYEGDSFLNWKQK GKAPKLLIYAASNLES GVP SRFSGSGSGTDFTLTISLQPEDFA TYYCQSNEDPLTFGQGTKEIKRGGGSGGGGSGGGGSEVQLV ESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKLEWIG EILPGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAV YYCTRRVPIRLDYWGQGT LVTVSS
13	anti-B7H3 scFV	DIVMTQSHKFMSTSIGARVSITCKASQDVRTAVAWYQKPGQSP KLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYC QQHYGTTPWTFGGGTKLEIKGGGSGGGGSGGGGSEVQLVESGG GLVKPGGSLKLSCEASRFTFSSYAMSWVRQTPEKRLWVA AISG GGRYTYYPDSMKGRFTISRDNKNFLYLQMSSLRSEDAMYYCA RHYDGYLDYWGQGT TLTVSS
14	anti-Muc16 scFV	VKLQESGGGFVKPGGSLKVS CAASGFTFSSYAMSWRLSPERM LWVATISSAGGYIFYSDSVQGRFTISRDNKNLTLHLQMGSLRSG DTAMYYCARQGFGNYGDYAMDYWGQGT TVTVSSGGGGSGGGG GGGSDIELTQSPSSLAVSAGEKVTMSCKSSQSLNSTRKNQL AWYQKPGQSPPELLIYWASTRQSGVPDRFTGSGSGTDFTLTIS VQAEDLAVYYCQSYNLLTFGPGTKLEVKR
15	anti-HER2 scFV	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQKPGKAP KLLIYSASFYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYC QQHYTTPPTFGQGTKEIKGSTSGSGKPGSGGSEVQLVESGG GLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKLEWVARIYP TNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCS RWGGDGFYAMDYWGQGT LVTVSS
16	anti-EGFR scFV	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQRTNGSP RLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYC QQNNNWPTTFGAGTKLELKG GGGSGGGGSGGGGSGVQLKQSGPG LVQPSQSLITCTVSGFSLTNYGVHWVRQSPGKLEWLGVISG GNTDYNTPTFSLRSLINKDNKSQVFFKMNSLQSDTAIYYCARA LTYDYEFAYWGQGT LVTVSS
17	anti-FN-EDB scFV	EVQLLES GGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGK LEWVSSISGSGTTYADSVKGRFTISRDNKNLTLQMNSLRA EDTAVYYCAKPFYFDYWGQGT LVTVSSGDGSSGGSGGASEIVL TQSPGTLSPGERATLSCRASQSVSSSFLAWYQKPGQAPRLL IYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQT GRIPPTFGQGTKEIK
18	anti-CLDN18.2 scFV	QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGK LKWMGWINTNTGEPTYAEFKGRFAFSLETSASTAYLQINNKN EDTATYFCARLGFGNAMDYWGQGT SVTVSSGGGGSGGGGSGGGG SDIVMTQSPSSLTVTAGEKVTMSCKSSQSLNLSGNQKNYL TWYQ QKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAE DLAVYYCQNDYSYPLTFGAGTKLELK

19	anti-DLL3 scFV	QVQLQESGPGLVKPSSETLSLTCTVSGDSISSYYWTWIRQPPGKG LEWIGYIYYSGTTNYPNPSLKSRTISVDTSKQFSLKLSVTA DTAVYYCASIIVRGFFFDYWGQGLTVTVSSGGGGSGGGSGGGG SEIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQ APRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY YCQQYGTSPITFGGGTKVEIK
20	anti-FLT3.1 scFV	QVTLKESGPVLVKPTETLTCTVSGFSLINARMGVSWIRQPPG KALEWLAHIFSNAEKSYRTSLKSRLTISKDTSKSQVLTMTNMD PVDATYYCARIPGYGGNGDYHYYGMDVWGQGLTVTVSSGGGG GGGGSGGGSDIQMTQSPSSLSASLGDRVTITCRASQGIKNDLG WYQQKPGKAPKRLIYASSTLQSGVPSRFSGSGSGTEFTLTISL QPEDFATYYCLQHNNFPWTFGQGTKVEIK
21	anti-FLT3.2 scFV	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKG LEWVAVISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNSLRA EDTAVYYCANLAPWAAAYWGQGLTVTVSSGGGGSGGGSGGGSE IVLTQSPSLSPVTPGEPASISCRSSQSLLSNGYNYLDWYLQKP GQSPQLLIYLSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVG VYYCMQALQTPHTFGQGTKLEIK
22	anti-CD33.1 VHH	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAED TAVYYCNAHSFLDLVGAWGQGLTVTVKP
23	anti-CD33.2 VHH	EVQLVESGGGEVQPGGSLRLSCAASGRTFSGYIMGWFRQAPGKE RELVARISGNLSTEYAESVKGRFTISRDNKNTLYLQMSSLRA EDTAVYYCAAEDYSSGDFVYWGQGLTVTVKP
24	anti-CD33.3 VHH	EVQLVESGGGEVQPGGSLRLSCAASGSTLNIDHIGWYRQAPGKE RELGVISSGAGPNYAESVKGRFTISRDNKNTVYLQMSSLRAE DTAVYYCNAWIDYGSGLPQNYWGQGLTVTVKP
25	anti-CLL1.1 VHH	EVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKE REWVAGITNNGYSTAYAESVKGRFTISRDNKNTIYLQMSSLRA EDTAVYYCHADLTKAYDVEYAWGQGLTVTVKP
26	anti-CLL1.2 VHH	EVQLVESGGGEVQPGGSLRLSCAASGLLFSIYDMNWYRQAPGKE REWVAGITNNGYSTAYAESVKGRFTISRDNKNTVYLQMSSLRA EDTAVYYCHTDEWGREYWGQGLTVTVKP
27	anti-CD123.1 VHH	EVQLVESGGGEVQPGGSLRLSCTASGRAINMYAMGWFRQAPGKE REFVAAINWNGAYTQYAESVKGRFTISRDNKNTLYLQMSSLRA EDTAVYYCSADADYNTYVSPNKRVSYWGGQGLTVTVKP
28	anti-CD123.2 VHH	EVQLVESGGGLVQPGGSLRLSCAASGRAINAYNMGWFRQAPGKG REFVSAINWNAARTYYAESVKGRFTISRDNKNTLYLQMSSLRA EDTAVYYCAASGRWSAAVPSGEDQYNFWGGQGLTVTVKP
29	anti-CD20 VHH	QVQLQESGGGLVQAGGSLRLSCAASGRTFSNYNMGWFRQAPGKE REFVAAIDWGGSPYYAASVVRGRTISRDNAENTVYLQMNSLKP EDTAVYYCAAPLSYGSTWLADYWGQGTQVTVSS
30	anti-EGFR VHH	QVKLEESGGGSVQTGGSLRLTCAASGRTSRSYGMGWFRQAPGKE REFVSGISWRGDSTGYADSVKGRFTISRDNKNTVDLQMNSLKP EDTAIYYCAAAAGSAWYGTLYEYDYWGQGTQVTVSS
31	anti-BCMA.1 VHH	QVKLEESGGGLVQAGRSLRLSCAASEHTFSSHVMGWFRQAPGKE RESVAVIGWRDISTSYADSVKGRFTISRDNKNTLYLQMNSLKP EDTAVYYCAARRIDAADFDSWGQGTQVTVSS
32	anti-BCMA.2 VHH	EVQLVESGGGLVQAGGSLRLSCAASGRTFTMGWFRQAPGKEREF VAAISLSPTLAYYAESVKGRFTISRDNKNTVVLQMNSLKPEDT ALYYCAADRSVMSIRPDYWGQGTQVTVSS
33	yuTCR linker (uLNK)	LEKT

34	uLNK + G4S linker	LEKTGGGGS
35	1xG4S linker	GGGGS
36	2xG4S linker	GGGSGGGGS
37	3xG4S linker	GGGSGGGSGGGGS
38	4xG4S linker	GGGSGGGSGGGSGGGGS
39	5xG4S linker	GGGSGGGSGGGSGGGSGGGGS
40	linker	DGGGS
41	linker	TGEKP
42	linker	GGRR
43	linker	EGKSSGSGSESKVD
44	linker	KESGSVSSEQLAQFRSLD
45	linker	GGRRGGGS
46	linker	LRQRDGERP
47	linker	LRQKGGGGERP
48	linker	LRQKGGGSGGGSERP
49	linker	GSTSGSGKPGSGEGSTKG
50	linker	GSTSGSGKSSEGSSTKG
51	linker	GSTSGSGKSSEGGK
52	linker	GSTSGSGKPGSGEGS
53	linker	GGGS
54	NY-ESO-1.1 TCR α	QEVTTQIPAAALSVPEGENLVLNCSFTDSAIYNLQWFRQDPGKGLT SLLL IQSSQREQTSGRNLNASLDKSSGRSTLYIAASQPGDSATYL CAVRPTSGGSYIPTFGRGTS LIVHPY
55	NY-ESO-1.1 TCR β	GVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLI HYSVGAGITDQGEVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYF CASSYVGNTGELFFGEGSRLTVLE
56	NY-ESO-1.2 TCR α	QEVTTQIPAAALSVPEGENLVLNCSFTDSAIYNLQWFRQDPGKGLT SLLL IQSSQREQTSGRNLNASLDKSSGRSTLYIAASQPGDSATYL CAVRPLYGGSYIPTFGRGTS LIVH
57	NY-ESO-1.2 TCR β	GVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLI HYSVGAGITDQGEVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYF CASSYVGNTGELFFGEGSRLTVLE
58	PRAME TCR α	VEQSPQSLHVQEGDSTNFTCSFPSSNFYALHWYRWETAKSPEAL FVMTLNGDEKKGRI SATLNTKEGYSYLYIKGSQPEDSATYLCA LYNNNDMRFGAGTRLTVKPN
59	PRAME TCR β	GVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRQTMMRGLELL IYFNNNVPIDDSGMPEDRFS AKMPNASFSTLKI QPSEPRDSAVY FCASSPGSTDTQYFGPGTRLTVLE
60	TP53R175H TCR α	QRKEVEQDPGPFNVPEGATVAFNCTYSNSASQSFFWYRQDCRKE PKLLMSVYSSGNEDGRFTAQLNRASQYISLLIRDSKLSDSATYL CVVQPGGYQKVTFGTGTLQVIPD
61	TP53R175H TCR β	GVTQTPKFQVLKTGQSMTLQCAQDMNHNMSYWYRQDPGMGLRLI YYSASEGTTDKGEVPNGYNVSRNLNKRFSRLRESAAPSQTSVYF CASSEGLWQVGDEQYFGPGTRLTVTE

62	MAGE-A4 TCR α	QKITQTQPGMFVQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEM IFLIYQGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAM YFCAMSGGYTGGFKTIFGAGTRLFVKAN
63	MAGE-A4 TCR β	GVTQTPKHLITATGQRVTLRCSPRSGDL SVYWYQQSLDQGLQFL IQYYNGEERAKGNILERFSAQQFPDLHSELNLSLELGDSALYF CASSGGDGDEQFFGPGTRLTVLE
64	WT1 TCR α	VEQHPSTLSVQEGDSAVIKCTYSDSASNYFPWYKQELGKRPQLI IDIRSNVGEKKDQRIAVTLNKTAKHFSLHITETQPEDSAVYFCA ATEDYQLIWGAGTKLIIP
65	WT1 TCR β	GITQSPKYLFRKEGQNVTLSC EQNLNHDAMYWYRQDPGQGLRLI YYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYL CASSPGALYEQYFGPGTRLTVT
66	MR1.1 TCR α	GQNIDQPTMTATEGAIVQINCTYQTSGFNGLFWYQQHAGEAPT FLSYNVLDGLEEKGRFSSFLSRSGYSYLLKELQMKDSASYLC AVKDSNYQLIWGAGTKLIIPD
67	MR1.1 TCR β	NAGVTQTPKFQVLKTGQSMTLQCAQDMNHNSMYWYRQDPGMGLR LIYYSASEGTTDKGEVPNGYNVSRNLNREFSLRLESAAPSQTSV YFCASSVWTGEGSGELFFGEGSRLTVLE
68	MR1.2 TCR α	QTVTQSQPEMSVQEAETVTL SCTYDTSESDYYLFWYKQPPSRQM ILVIRQEAYKQNAENRFSVNFQKAASFSLKISDSQLGDAAM YFCAYRSAVNARLMFGDGTQLVVKPN
69	MR1.2 TCR β	DIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLI HYSYGVNSTEKGDLSSSESTVSRIRTEHFPLTLESARPSHTSQYL CASSEARGLAEFTDTQYFGPGTRLTVLE
70	CD1d+aGalCer TCR α	QVEQSPQSLIILEGKNCTLQCNVTVSPFSNLRWYKQDTGRGPVS LTIMTFSENTKSNGRYTATLDADTKQSSLHITASQLSDSASYIC VSDRGSTLGRLYFGRGTQLTVWPD
71	CD1d+aGalCer TCR β	DIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLI HYSYGVNSTEKGDLSSSESTVSRIRTEHFPLTLESARPSHTSQYL CASSGLRDRGLYEQYFGPGTRLTVTE
72	HPV16E7 TCR α	MLLEHLLIILWMQLTWVSGQQLNQSPQSMFIQEGEDVSMNCTSS SIFNTWLWYKQDPGEGPVLLIALYKAGELTSNGRLTAQFGITRK DSFLNISASIPSDVGIFYCAGHPSSNSGYALNFGKGTSLLVTPH
73	HPV16E7 TCR β	MGTSLLCWVVLGFLGTDHTGAGVSQSPRYKVTKRGQDVALRCDP ISGHVSLYWYRQALGQGPEFLTYFNIEAQDQKSGLPNDRFSAER PEGSISTLTIQRTREQDSAMYRCASSSQTGARTDTQYFGPGTRL TVLE
74	GP100 TCR α	MVKIRQFLLAILWLQLSCVSAAKNEVEQSPQNLTAEGEFITIN CSYSGISALHWLQQHPGGGIVSLFMLSSGKKKHGRLIATINI QEKHSSLHITASHPRDSAVYICAASLIQGAQKL VFGQGTSLTINP N
75	GP100 TCR β	MDSWTFCCVSLCILVAKHTDAGVIQSPRHEVTEMQEVTLRCKP ISGHNSLFWYRQTMMRGLELLIYFNNNVPIDDSGMPEDRFSAM PNASFSTLKIQSEPRDSAVYFCASSPGGNEQFFGPGTRLTVLE
76	MART-1 TCR α	MLLEHLLIILWMQLTWVSGQQLNQSPQSMFIQEGEDVSMNCTSS SIFNTWLWYKQDPGEGPVLLIALYKAGELTSNGRLTAQFGITRK DSFLNISASIPSDVGIFYCAGGTGNQFYFGTGTSLTVIPN
77	MART-1 TCR β	MGTRLFFYVALCLLWTGHMDAGITQSPRHKVETETGTPVTLRCHQ TENHRYMYWYRQDPGHGLRLIHYSYGVKDTDKGEVSDGYSVSRS KTEDFLLTLESATSSQTSVYFCAISEVGVGQPQHFQDGTSLIL E
78	a1To-HLA TCry	MGWALLVLLAFLSPASQKSSNLEGGTKSVTRPTRSSAEITCDLT VINAFYIHWYHLHQEGKAPQRLLYDVNSKDVLESGLSPGKYTT

		HTPRRWSWILILRNLIENDSGVYYCATWDRPEIYYKKLFGSGTT LVVT
79	a11o-HLA TCRδ	MVFSSLLCVFAFSYSGSSVAQKVTAQSSVSMPVRKAVTLNCL YETSWWSYIIFWYKQLPSKEMIIFLIRQGSDEQNAKSGRYSVNFK KAAKSVALTISALQLED SAKYFCALGDSYGGGPLYTDKLI FGKG TRVTVEPR
80	huTRBC1	DLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGF TSVSYQQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDF
81	huTRBC2	DLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGF TSESYQQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDS RG
82	huTRAC	IQNPDPVAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKSDVYIT DKTVLDMRSMDFKSN SAVAWSNKSD FACANAFNNSIIPEDTFFP SPESCDVKLVEKSFETDTNLNFQNL SVIGFRILLKLVAGFNLL MTLRLWSS
83	huTRGC1	DKQLDADVSPKPTIFLPSIAETKLQKAGTYLCLLEKFFPDVIKI HWQEKKSNTILGSQEGNTMKTNDTYMKFSWLTVPESL DKEHRC IVRHENNKNGVDQEIIFFPIKTDVITMDPKDNCSKDANDTLLQ LTNTSAYMYLLLLLLKSVVYFAIITCCLLRRTAFCCNGEKS
84	huTRGC2	DKQLDADVSPKPTIFLPSIAETKLQKAGTYLCLLEKFFPDIIKI HWQEKKSNTILGSQEGNTMKTNDTYMKFSWLTVPESL DKEHRC IVRHENNKNGIDQEIIFFPIKTDVTTVPKYNYSKDANDVITMD PKDNWSKDANDTLLQLTNTSAYTYLLLLLLKSVVYFAIITCCL LRRTAFCCNGEKS
85	huTRDC	SQPHTKPSVFMKNGTNVACL VKEFYPKDIRINLVSSKKITEFD PAIVISPSGKYNAVKLGKYEDSNSVTCSVQHDKNTVHSTDFEVK TDSTDHVKPKETENTKQPSK SCHKPKAIVHTEKVNMMSLTVLGL RMLFAKTAVAVNFLLTAKLFFL
86	mmTRBC1	DLNKVFPPEVAVFEP SKAEIAHTQKATLVCLATGFFPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDF
87	mmTRBC2	DLNKVFPPEVAVFEP SKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDS RG
88	mmTRAC	IQNPDPVAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKSDVYIT DKTVLDMRSMDFKSN SAVAWSNKSD FACANAFNNSIIPEDTFFP SSDVPCDVKLVEKSFETDTNLNFQNL LVIVLRILLKLVAGFNLL MTLRLWSS
89	MAGEA4 TCR	MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSP RSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSLELGD SALLYFCASSGGDGDEQFFGPGTRLTVLE DLNKVFPPEVAVFEP SKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDS RGRAKRGSGATNFSLLKQAGDVEENPGPMSLSLLKVVTASLWL GPGIAQKITQTQPGMFVQKEAVTLDCTYDTS DPSYGLFWYKQP SSGEMI FLIYQGSYDQQNATEGRYSLNFQKARKSANLVISASQL GDSAMYFCAMSGGYTGGFKTIFGAGTRLFVKANIQNPDPVAVYQL

		RDSKSSDKSVCLFTDFDSQTNVSQSKSDVYITDKTVLDMRSMD FKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSSDVPCDVKL EKSFETDTNLFQNLIVLRIILLKVAGFNLLMTLRLWSS
90	CD33 DARIC	MALPVTALLPLALLHAARPGSILWHEMWHEGLEEASRLYFGE RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEWC RKYMKSGNVKDLLQAWDLYYHVFRISKASAGTGSDIYIWAPLA GTCGVLLLSLVTMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCS CRFPEEEEGGCELRVKFSRSADAPAYQQGQNLYNELNLGRREE YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATN FSLLKQAGDVEENPGPSMETDTLLWVLLWVPGSTGEVQLVES GGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKERELVAEIS GVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTAVYYCN AHSFLDLVGAWGQGTLVTVKPGGGSGVQVETISPGDGRTFPCR GQTCVHYTGMLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGWEEG VAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVELLKL EGGRMALIVLGGVAGLLFI GLGIFFCVRCRHRRRRQ
91	CD33.VHH-mLNK- TRB-P2A-TRA	METPAQLLFLLLWL PDDTTGEVQLVESGGGEVQPGGSLRLSCAA SRSSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTV SRDNAKNTVYLQMSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLV TVKPLEKTD SGVTQTPKHLITATGQRVTLRCSPRSGDL SVYWYQ QSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLS LELGDSALYFCASSGGDGEQFFGPGTRLTVLEDLKNVFPPEVA VFEPKAEIAHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGV STDPQPLKEQPALNDSRYCLSSRLRVSATFWQNP RNHFRCQVQF YGLSENDEWTQDRAKPVTQIVSAEAWGRADCGITSASYHQGVLS ATILYEILLGKATLYAVLVSALVLMAMVKRKDSRGRAKRSGSAT NFSLLKQAGDVEENPGPMSLSSLLKVVTASLWLGPGIAQKITQT QPGMFVQKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMI FLIYQ GSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMS GGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVC LFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSN KSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLF QNLIVLRIILLKVAGFNLLMTLRLWSS
92	CD33.VHH- mLNK.1xG4S-TRB- P2A-TRA	METPAQLLFLLLWL PDDTTGEVQLVESGGGEVQPGGSLRLSCAA SRSSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTV SRDNAKNTVYLQMSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLV TVKPLEKTD SGVTQTPKHLITATGQRVTLRCSPRSGDL SVYWYQ QSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSE LNLSSLELGDSALYFCASSGGDGEQFFGPGTRLTVLEDLKNV PPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSWWVNGKE VHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNP RNHF RCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGITSASYH QGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRGRAKR GSGATNFSLLKQAGDVEENPGPMSLSSLLKVVTASLWLGPGIAQ KITQTQPGMFVQKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMI FLIYQGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMY FCAMSGGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSS DKSVCLFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSA VAWSNKSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFET DTNLFQNLIVLRIILLKVAGFNLLMTLRLWSS
93	TRB-P2A- CD33.VHH-mLNK- TRA	MGFRLLCCVAFCLLGAGPVD SGVTQTPKHLITATGQRVTLRCS RSGDL SVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSLELGDSALYFCASSGGDGEQFFGPGTRLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQ NP RNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGI TSASYHQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDS RGRAKRSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL P DDTTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAP

		GKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSL RAEDTAVYYCNAHSFLDLVGAWGQGLTVTKPLEKTAQKITQTQ PGMFVQEKEAVTLDCYDTSYGLFWYKQPSSGEMI FLIYQG SYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSG GYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCL FTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSNK SDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLF QNLLVIVLRILLKLVAGFNLLMTLRLWSS
94	TRB-P2A- CD33.VHH- mLNK.1xG4S-TRA	MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSP RSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSLELGDSALYFCASSGGDGDEQFFGPGTRLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVQFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDS RGRAKRGSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL P DTTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAP GKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSL RAEDTAVYYCNAHSFLDLVGAWGQGLTVTKPLEKTTGGGSAQK ITQTQPGMFVQEKEAVTLDCYDTSYGLFWYKQPSSGEMI F LIYQGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYF CAMSGGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSD KSVCLFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAV AWSNKSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETD TNLNFQNLLVIVLRILLKLVAGFNLLMTLRLWSS
95	TRB-P2A- CD33.VHH-1xG4S- TRA	MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSP RSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSLELGDSALYFCASSGGDGDEQFFGPGTRLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVQFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDS RGRAKRGSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL P DTTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAP GKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSL RAEDTAVYYCNAHSFLDLVGAWGQGLTVTKPGGGGSAQKITQT QPGMFVQEKEAVTLDCYDTSYGLFWYKQPSSGEMI FLIYQ GSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMS GGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVC LFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSN KSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLF QNLLVIVLRILLKLVAGFNLLMTLRLWSS
96	TRB-P2A- CD33.VHH-2xG4S- TRA	MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSP RSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSLELGDSALYFCASSGGDGDEQFFGPGTRLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVQFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQGVL SATILYEILLGKATLYAVLV SALVLMAMVKRKDS RGRAKRGSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL P DTTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAP GKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSL RAEDTAVYYCNAHSFLDLVGAWGQGLTVTKPGGGGSGGGGSAQ KITQTQPGMFVQEKEAVTLDCYDTSYGLFWYKQPSSGEMI FLIYQGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMY FCAMSGGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSS DKSVCLFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSA VAWSNKSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFET DTNLFQNLLVIVLRILLKLVAGFNLLMTLRLWSS

97	TRB-P2A-CLL1- CD33.VHH- mLNK.1xG4S-TRA	MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSP RSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSSLELGDSALYFCASSGGDGDEQFFGPGTRTLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQVLSATILYEILLGKATLYAVLVLSALVLMAMVVRKDS RGRAKRSGGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWLWP DTTGEVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQA PGKEREWVAGITNNGYSTAYAESVKGRFTISRDNAKNTIYLQMS SLRAEDTAVYYCHADLTAKAYDVEYAWGQGTLVTVKPGGGGSGGG GSEVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGK ERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLMSSSLRA EDTAVYYCNAHSFLDLVGAWGQGTLVTVKPLEKTGGGSAQKIT QTQPGMFVQEKEAVTLDCTYDTSYGLFWYKQPSGEMIFLI YQGSYDQQNATEGRYSLNFKARKSANLVISASQLGDSAMYFCA MSGGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKS VCLFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAW SNKSDFACANAFNNSIIPEDTFFPSSDVPDVKLVEKSFETDTN LNFQNLIVILRILLKLVAGFNLLMTLRLWSS
98	CLL1 DARIC	MALPVTALLPLALLHAARPGSILWHEMWHEGLEEASRLYFGE RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQWC RKYMKSGNVKDLLQAWDLYYHVFRISKASAGTGSDIYIWAPLA GTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCS CRFPEEEEGGCEL RVKFSRSADAPAYQQGNQLYNELNLGRREE YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGDGLYQGLSTATKDTYDALHMQALPPRSGSGATN FSLLKQAGDVEENPGPSMETDTLLWVLLWVPGSTGEVQLVES GGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKEREWVAGI TNNGYSTAYAESVKGRFTISRDNAKNTIYLQMSLRAEDTAVYY CHADLTAKAYDVEYAWGQGTLVTVKPGGGGSGVQVETISPGDGR T FPKRGQTCVVHYTGMLDGGKFDSSRDNRNPKFKFMLGKQEVIRG WEEGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVE LLKLEGGRMALIVLGGVAGLLFIGLGIFFCVRCHRRRQ
99	CLL1-CD33 tandem DARIC	MALPVTALLPLALLHAARPGSILWHEMWHEGLEEASRLYFGE RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQWC RKYMKSGNVKDLLQAWDLYYHVFRISKASAGTGSDIYIWAPLA GTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCS CRFPEEEEGGCEL RVKFSRSADAPAYQQGNQLYNELNLGRREE YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGDGLYQGLSTATKDTYDALHMQALPPRSGSGATN FSLLKQAGDVEENPGPSMETDTLLWVLLWVPGSTGEVQLVES GGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKEREWVAGI TNNGYSTAYAESVKGRFTISRDNAKNTIYLQMSLRAEDTAVYY CHADLTAKAYDVEYAWGQGTLVTVKPGGGGSGGGGSGGGGSEVQL VESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVA EISGVGDTNYAASLADRFTVSRDNAKNTVYLMSSSLRAEDTAVY YCNAHSFLDLVGAWGQGTLVTVKPGGGGSGVQVETISPGDGR TFPKRGQTCVVHYTGMLDGGKFDSSRDNRNPKFKFMLGKQEVIRG WEEGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDV EL LKLEGGRMALIVLGGVAGLLFIGLGIFFCVRCHRRRQ
100	TRB-P2A- BCMA.scFv-2xG4S- TRA	MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSP RSGDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF PDLHSELNLSSLELGDSALYFCASSGGDGDEQFFGPGTRTLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVFYGLSENDEWTQDRAKPVTVQIVSAEAWGRADCGI TSASYHQVLSATILYEILLGKATLYAVLVLSALVLMAMVVRKDS RGRAKRSGGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWLWP DTTGDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIHWY QQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEE

		DDVAVYYCLQSRITPRTFGGGTKLEIKGSTSGSGKPGSGEGSTK GQIQLVQSGPELKKPGETVKISCKASGYFTDYSINWVKRAPGK GLKWMGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLIK YEDTATYFCALDYSYAMDYWGQGTSVTVSSGGGSGGGGSAQKI TQTQPGMFVQEKEAVTLDCTYDTSYGLFWYKQPSSGEMIFL IYQGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFC AMSGGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDK SVCLFTDFDSQTNVSQSKSDSYITDKTVLDMRSMDFKNSAVA WSNKSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDT NLNFQNLVIVLRILLKLVAGFNLLMTLRLWSS
101	BCMA scFv CAR	MALPVTALLPLALLHAARPDIVLTQSPPSLAMSLGKRATISC RASESVTILGSHLIHWYQQKPGQPPTLLIQLASNVQGTGVPARFS GSGSRDFTLTIDPVEEDDVAVYYCLQSRITPRTFGGGTKLEIK GSTSGSGKPGSGEGSTKGQIQLVQSGPELKKPGETVKISCKASG YFTDYSINWVKRAPGKGLKWMGWINTETREPAYAYDFRGRFAF SLETSASTAYLQINNLIK YEDTATYFCALDYSYAMDYWGQGTSVT VSSAAATTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTR GLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQ PFMRPVQTTQEEDGCSCRFPSEEGGCELRVKFSRSADAPAYQQ GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQDKMAEAYSEIGMKGERRRRGKGDGLYQGLSTATKDTYDA LHMQUALPPR
102	TRB-P2A- CD19.scFv-2xG4S- TRA	MGFRLLCCVAFCLLGAGPVD SGVTQTPKHLITATGQRVTLRCS RSGDLSVYWYQQSLDQGLQFLIYYNGEERAKGNILERFSAQQF PDLHSELNLSSELGDSALYFCASSGGDGDEQFFGPGTRLTVLE DLKNVFPPEVAVFEPKAEIAHTQKATLVCLATGFYPDHVELSW WVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQN PRNHFRQCQVQFYGLSENDEWTQDRAKPVTVISAEAWGRADCGI TSASYHQVLSATILYEILLGKATLYAVLVLSALVLMAMVKRKDS RGRAKRGSGATNFSLLKQAGDVEENPGPMETPAQLLLFLLLWLP DTTGD IQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQK DGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIA TYFCQQGNTLPYTFGGGTKEITGGGGSGGGGSGGGGSEVKLQE SGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGV IWGSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDITAIIY CAKHYYYGGSYAMDYWGQGTSVTVSSGGGSGGGGSAQKITQTQ PGMFVQEKEAVTLDCTYDTSYGLFWYKQPSSGEMIFLIYQG SYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSG GYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCL FTDFDSQTNVSQSKSDSYITDKTVLDMRSMDFKNSAVAWSNK SDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLNF QNLVIVLRILLKLVAGFNLLMTLRLWSS
103	CD33.VHH-mLNK- TRB	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSLRAED TAVYYCNAHSFLDLVGAWGQGLTVTKPLEKTD SGVTQTPKHLI TATGQRVTLRCS PRSGDLSVYWYQQSLDQGLQFLIYYNGEERA KGNILERFSAQQFPDLHSELNLSSELGDSALYFCASSGGDGDE QFFGPGTRLTVLEDLKNVFPPEVAVFEPKAEIAHTQKATLVCL ATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCL SSRLRVSATFWQNP RNHFRCQVQFYGLSENDEWTQDRAKPVTVI VSAEAWGRADCGITSASYHQVLSATILYEILLGKATLYAVLVLS ALVLMAMVKRKDSRG
104	CD33.VHH- mLNK.1xG4S-TRB	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSLRAED TAVYYCNAHSFLDLVGAWGQGLTVTKPLEKTDGGGSDSGVTQT PKHLITATGQRVTLRCS PRSGDLSVYWYQQSLDQGLQFLIYYN GEERAKGNILERFSAQQFPDLHSELNLSSELGDSALYFCASSG GDGDEQFFGPGTRLTVLEDLKNVFPPEVAVFEPKAEIAHTQKA TLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALND SRYCLSSRLRVSATFWQNP RNHFRCQVQFYGLSENDEWTQDRAK

		PVTQIVSAEAWGRADCGITSASYHQVLSATILYEILLGKATLY AVLVSALVLMAMVKRKDSRG
105	CD33.VHH-mLNK- TRA	EVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAED TAVYYCNAHSFLDLVGAWGQGT LVTVKPLEKTAQKITQTQPGMF VQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIYQGSYDQ QNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSGGYTG GFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCLFTDF DSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFA CANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLNFQNL VIVLRILLKLVAGFNLLMTLRLWSS
106	CD33.VHH- mLNK.1xG4S-TRA	EVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAED TAVYYCNAHSFLDLVGAWGQGT LVTVKPLEKGGGSAQKITQT QPGMFVQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIYQ GSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMS GGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVC LFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSN KSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLN FQNLVIVLRILLKLVAGFNLLMTLRLWSS
107	CD33.VHH-1xG4S- TRA	EVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAED TAVYYCNAHSFLDLVGAWGQGT LVTVKPGGGGSAQKITQTQPGM FVQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIYQGSYD QQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSGGYT GGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCLFTD FDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFA CANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLNFQNL LVIVLRILLKLVAGFNLLMTLRLWSS
108	CD33.VHH-2xG4S- TRA	EVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKER ELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAED TAVYYCNAHSFLDLVGAWGQGT LVTVKPGGGGSGGGGSAQKITQ TQPGMFVQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIY QGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAM SGGYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSV CLFTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWS NKSDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNL NFQNLVIVLRILLKLVAGFNLLMTLRLWSS
109	CLL1-CD33.VHH- mLNK.1xG4S-TRA	EVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKE REWAGITNNGYSTAYAESVKGRFTISRDNAKNTIYLMSSLRAED TAVYYCHADLTKAYDVEYAWGQGT LVTVKPGGGGSGGGGSEV QLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKEREL VAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGT LVTVKPLEKGGGSAQKITQTQPG GMFVQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIYQGS YDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSGG YTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCLF TDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAVAWSNK DFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLNFQ NLLVIVLRILLKLVAGFNLLMTLRLWSS
110	BCMA.scFv-2xG4S- TRA	DIVLTQSPPSLAMS LGKRATISCRASESVTILGSHLIHWYQQKP GPPTLLIQLASNVQTGVPARFSGSGSRDFTLTIDPVEEDDVA VYYCLQSRTIPRTFGGKLEIKGSTSGSGKPGSGEGSTKGQIQ LVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKW MGWINTETREPAYAYDFRGRFAFSLETASTAYLQINNLYEDT ATYFCALDYSYAMDYWGQGTSVTVSSGGGSGGGGSAQKITQTQ PGMFVQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIYQ GSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSG GYTGGFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCL

		FTDFDSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAWAWSNK SDFACANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLF QNLLVIVLRILLKLVAGFNLLMTLRLWSS
111	CD19.ScFv-2xG4S- TRA	DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTV KLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFC QQGNTLPYTFGGGKLEITGGGGSGGGGSGGGGSEVKLQESGPG LVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVWGS ETTYNSALKSRLTIKDNSKSQVFLKMNSLQTDDTAIYYCAKH YYYGGSYAMDYWGQTSVTVSSGGGGSGGGGSAQKITQTQPGMF VQEKEAVTLDCTYDTS DPSYGLFWYKQPSSGEMIFLIYQGSYDQ QNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMSGGYTG GFKTIFGAGTRLFVKANIQNPDPAVYQLRDSKSSDKSVCLFTDF DSQTNVSQSKSDVYITDKTVLDMRSMDFKSNSAWAWSNKSDFA CANAFNNSIIPEDTFFPSSDVPCDVKLVEKSFETDTNLFQNLL VIVLRILLKLVAGFNLLMTLRLWSS
112	Furin cleavage site	RAKR

EXAMPLES

EXAMPLE 1

EVALUATION OF ENGINEERED TCRs

A MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) was embedded
5 with a VHH targeting human CD33 to produce an engineered dual-targeting TCR ("VHH-
TCR") (SEQ ID NO: 93) (**Figures 1A** and **1B**). This was evaluated for expression and
function compared to a TCR targeting MAGEA4 (SEQ ID NO: 89) and a DARIC
(Dimerizing Agent Regulated Immunoreceptor Complex, a controllable and adaptable
antigen recognizing system) targeting human CD33 (SEQ ID NO: 90) (the "comparators")
10 (**Figure 1A**). Dual-targeting TCR T cells were produced in a 10 Day process using G-REX®
flasks. Briefly, peripheral blood mononuclear cells (PBMC) were cultured in media
containing IL-2 (CellGenix, GmbH) and antibodies specific for CD3 and CD28 (Miltenyi
Biotec, Inc.). Lentiviruses encoding the test constructs were added one day after culture
initiation. On Day 3, CAR T cells were transferred from a 24-well plate, to a 24 well G-REX
15 flask, where cells were maintained until harvest on Day 10.

T cells were interrogated for cell surface VHH expression using flow cytometry. T
cells were stained using an iFlour488 labeled anti-Camelid VHH antibody (Genscript).
Surface VHH expression was higher in the VHH-TCR compared to CD33 DARIC (**Figure**
2A). Additionally, the biological activity of the T cells was assessed for interferon gamma
20 production in co-culture with tumor cell lines positive for CD33 (adherent A549 cell line that
was stably transduced with CD33). As shown in **Figure 2B**, the interferon gamma
production of VHH-TCR is >3-fold greater than the CD33-DARIC, which was activated by
including 1 nm Rapamycin during coculture. Live-cell imaging by IncuCyte was used to
analyze tumor cell growth of A549.CD33 stably transduced with red reporter. The A549
25 cells grew normally in the presence of UTD T cells and MAGEA4 TCR-T cells. Co-culture
with either VHH-TCR or CD33-DARIC resulted in tumor cell elimination, with VHH-TCR
achieving elimination more rapidly than the DARIC (**Figure 2C**).

Flow cytometry was performed to evaluate MAGEA4 tetramer/HLA-multimer
binding which was higher in VHH-TCR compared to the MAGEA4 TCR (**Figure 3A**).
30 Additionally, the biological activity of the T cells was assessed for interferon gamma

production in co-culture with tumor cell lines positive for MAGEA4 (adherent A549 cell line that was stably transduced with MAGEA4 and HLA-A2). As shown in **Figure 3B**, the interferon gamma production of VHH-TCR is ~3-fold greater than the MAGEA4 TCR.

Live-cell imaging by IncuCyte was used to analyze tumor cell growth of the adherent

5 A549.MAGEA4.HLA-A cell line that was stably transduced with a red reporter. The A549 cells grew normally in the presence of UTD T cells and CD33-DARIC cells. Co-culture of MAGEA4 TCR resulted in complete elimination of tumor cells, whereas VHH-TCR resulted in complete and more rapid elimination of tumor cells (**Figure 3C**).

The sensitivity of VHH-TCR was compared to the MAGEA4 TCR by setting up co-
10 cultures with A549 cells, that do not express MAGEA4, pulsed with a range of MAGEA4 peptide concentrations. As shown in **Figure 4A**, compared to the MAGEA4 TCR, the VHH-TCR demonstrates similar kinetics but superior interferon gamma release in co-culture with a range of MAGEA4 peptide expression. The sensitivity of VHH-TCR was compared to the CD33 DARIC by setting up co-cultures with A549 cells, that do not express CD33,
15 electroporated with a range of CD33 mRNA concentrations. As shown in **Figures 4B** and **4C**, compared to the CD33 DARIC activated with 1 nM Rapamycin, the VHH-TCR demonstrates similar kinetics but superior interferon gamma production in co-culture with a range of CD33 mRNA expression. Additionally, cocultures were set up with cell lines endogenously expressing varying levels of CD33; HL-60 has high CD33 expression,
20 Kasumi1 has moderate CD33 expression and OCI-AML3 has low CD33 expression. As shown in **Figures 5A-5C**, the VHH-TCR demonstrates superior interferon gamma upon coculture, most evident in OCI-AML3 that expresses low level of CD33.

EXAMPLE 2

EVALUATION OF ENGINEERED TCR CONFIGURATIONS

25 Four configurations were assessed: 1) a VHH was added to the TRB (T cell receptor beta chain) separated by a marsupial mu linker (LEKT) (SEQ ID NO: 91), 2) a VHH was added to the TRB separated by a mu linker + G4S (SEQ ID NO: 92), 3) a VHH was added to the TRA (T cell receptor alpha chain) separated by a mu linker (SEQ ID NO: 93), and 4) a VHH was added to the TRA separated by a mu linker + G4S (SEQ ID NO: 94)
30 (**Figure 6**). TCR T cells were produced as described in Example 1.

T cells were interrogated for cell surface VHH expression using flow cytometry. T cells were stained using an iFlour488 labeled anti-Camelid VHH antibody (Genscript). Surface VHH expression was higher in the VHH-TCR than the CD33 DARIC (SEQ ID NO: 90) and was comparable in all the orientations tested (**Figure 7A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for CD33 (adherent A549 cell line that was stably transduced with CD33). As shown in **Figure 7B**, the interferon gamma production of all VHH-TCRs is >2-fold greater than the CD33-DARIC activated with 1nM Rapamycin, and the VHH-TCR with VHH added to the TRA separated by a mu linker + G4S outperformed all the constructs assessed. Live-cell imaging by IncuCyte was used to analyze tumor cell growth of A549.CD33 stably transduced with red reporter. The A549 cells grew normally in the presence of UTD T cells and MAGEA4 TCR-T cells. Co-culture with all VHH-TCR or activated CD33-DARIC resulted in tumor cell elimination, with VHH-TCRs achieving elimination more rapidly than the DARIC (**Figure 7C**).

Flow cytometry was performed to evaluate MAGEA4 tetramer/HLA-multimer binding which was comparable in all VHH TCRs and to the MAGEA4 TCR (**Figure 8A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for MAGEA4 (adherent A549 cell line that was stably transduced with MAGEA4 and HLA-A2). As shown in **Figure 8B**, in comparison with the MAGEA4 TCR, the interferon gamma production of VHH-TCR with VHH embedded in TRB is lower, but slightly greater when VHH was added to the TRA separated by a mu linker, and ~3-fold greater when the VHH was added to the TRA separated by a mu linker + G4S. Live-cell imaging by IncuCyte was used to analyze tumor cell growth of the adherent A549.MAGEA4.HLA-A cell line that was stably transduced with a red reporter. The A549 cells grew normally in the presence of UTD T cells and CD33-DARIC cells. Co-culture with TCRs with VHH embedded in TRB had incomplete elimination of tumor cells. Co-culture with MAGEA4 TCR resulted in complete elimination of tumor cells and co-culture with VHH embedded in TRA resulted in complete and more rapid elimination of tumor cells (**Figure 8C**).

EXAMPLE 3

FURTHER EVALUATION OF LINKERS IN ENGINEERED TCRS

The significance of the linkers on the VHH was further assessed by comparing constructs where 1) a VHH was added to the TRA separated by a mu linker (LEKT) + G4S (SEQ ID NO: 94), 2) a VHH was added to the TRA separated by a 1xG4S (SEQ ID NO: 95), and 3) a VHH was added to the TRA separated by a 2xG4S (SEQ ID NO: 96) (**Figure 9**). TCR T cells were produced as described in Example 1.

T cells were interrogated for cell surface CD33 expression using flow cytometry. T cells were stained using a His labeled CD33-Fc reagent (Acros) and secondary staining was performed with APC labeled streptavidin. Surface CD33 expression was comparable in all the three assessed formats (**Figure 10A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for CD33 (adherent A549 cell line that was stably transduced with CD33). As shown in **Figure 10B**, the interferon gamma production of VHH-TCRs with mu linker + 1G4S and 1G4S was comparable and was highest in VHH-TCR with 2G4S. Live-cell imaging by IncuCyte was used to analyze tumor cell growth of A549.CD33 stably transduced with red reporter. The A549 cells grew normally in the presence of UTD T cells. Co-culture with all VHH-TCRs resulted in tumor cell elimination (**Figure 10C**).

Flow cytometry was performed to evaluate MAGEA4 tetramer/HLA-multimer binding which was comparable in all three assessed formats (**Figure 11A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for MAGEA4 (adherent A549 cell line that was stably transduced with MAGEA4 and HLA-A2). As shown in **Figure 11B**, the interferon gamma production of VHH-TCRs with mu linker + 1G4S and one G4S was comparable and highest in the VHH-TCR with two G4Ss. Live-cell imaging by IncuCyte was used to analyze tumor cell growth of the adherent A549.MAGEA4.HLA-A cell line that was stably transduced with a red reporter. The A549 cells grew normally in the presence of UTD T cells. Co-culture with all VHH-TCRs had complete elimination of tumor cells and it was fastest in VHH-TCR with two G4Ss (**Figure 11C**).

EXAMPLE 4

EVALUATION OF ENGINEERED MULTI-TARGETING TCRs WITH TANDEM BINDERS

A MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) was embedded with tandem VHHs targeting human CD33 and CLL1 (SEQ ID NO: 97) (**Figures 12A** and **12B**). This was evaluated for expression and function compared to a known TCR targeting MAGEA4 and a DARIC (Dimerizing Agent Regulated Immunoreceptor Complex, a controllable and adaptable antigen recognizing system) targeting human CD33 (SEQ ID NO: 90), CLL1 (SEQ ID NO: 98), and both CD33 and CLL1 in tandem (SEQ ID NO: 99) (the “comparators”) (**Figure 12A**). Dual targeting TCR T cells were produced in a 10 Day process using G-REX® flasks using the same protocol as Example 1.

T cells were interrogated for cell surface CD33 expression using flow cytometry. T cells were stained using a His labeled CD33-Fc reagent (Acros) and secondary staining with APC labeled streptavidin. Surface CD33 expression was higher in the CD33-CLL1-TCR compared to CD33 DARIC and CD33-CLL1 DARIC (**Figure 13A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for CD33 (adherent A549 cell line that was stably transduced with CD33). As shown in **Figure 13B**, the interferon gamma production of the CD33-CLL1-TCR is comparable to CD33-DARIC and CD33-CLL1 DARIC (the latter two were activated by addition of 1nM Rapamycin).

T cells were interrogated for cell surface CLL1 expression using flow cytometry. T cells were stained using a PE labeled CLL1-Fc reagent (Creative Biomart). Surface CLL1 expression was higher in the CD33-CLL1-TCR compared to CLL1 DARIC and CD33-CLL1 DARIC (**Figure 14A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for CLL1 (adherent A549 cell line that was stably transduced with CLL1). As shown in **Figure 14B**, the CD33-CLL1 TCR produces robust interferon gamma in co-culture with a CLL1 expressing cell line.

Flow cytometry was performed to evaluate MAGEA4 tetramer/HLA-multimer binding which was higher in CD33-CLL1-TCR compared to the MAGEA4 TCR (**Figure 15A**). Additionally, the biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for MAGEA4 (adherent A549 cell line

that was stably transduced with MAGEA4 and HLA-A2). As shown in **Figure 15B**, the interferon gamma production of CD33-CLL1-TCR is comparable to the MAGEA4 TCR.

EXAMPLE 5

EVALUATION OF VHH-BASED ENGINEERED TCRs

5 Two engineered TCRs were constructed, each with a MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) embedded with one of two anti-BCMA VHH. The same anti-BCMA VHHs were also formatted in a CAR format. These were evaluated for expression and function compared to a TCR targeting MAGEA4 and a known scFv-based CAR targeting BCMA (the “comparators”). T cells were produced in a 10 Day process using
10 G-REX® flasks using the same protocol as Example 1.

T cells were interrogated for cell surface CAR and TCR expression using flow cytometry and evaluated for MAGEA4 tetramer/HLA-multimer binding. T cells were stained using a PE labeled BCMA Fc reagent (AcroBio). Surface BCMA binder expression was detectable on all constructs having a BCMA binder (**Figure 16**). Both VHH TCR were
15 detected robustly by the MAGEA4 tetramer, and were comparable to the MAGE-A4 TCR.

The biological activity of the T cells was assessed for interferon gamma production in co-culture with tumor cell lines positive for MAGEA4 (adherent A375 cell line that endogenously expresses MAGEA4 and HLA-A2). As shown in **Figure 17**, the VHH TCRs expressed a very robust level of interferon gamma, and expression is comparable to the
20 MAGEA4 TCR.

The biological activity of the T cells was also assessed for interferon gamma production in co-culture with tumor cell lines positive for BCMA (the Toledo suspension cell line endogenously expresses low levels of BCMA). As shown in **Figure 18A**, the VHH TCRs produced interferon gamma comparable to or greater than the respective VHH CAR.
25 The biological activity of the T cells in co-culture with Toledo cells was further assessed for Interleukin 2 (IL2) production, which is a more sensitive assay. As shown in **Figure 18B**, none of the VHH CARs produced a detectable amount of IL2, whereas both VHH TCRs produced robust IL2. Antigen independent signaling of the T cells was assessed by interferon gamma production in co-culture without tumor cell lines. As shown in **Figure 19**, the VHH

CARs had detectable levels of interferon gamma production, but the VHH TCRs had low or no detectable interferon gamma production in the absence of tumor cells.

EXAMPLE 6

EVALUATION OF SCFV-BASED ENGINEERED TCRs

5 A MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) was embedded with an scFv targeting human BCMA (SEQ ID NO: 100) and a 2xG4S linker between the scFv and Va (**Figures 20A and 20B**). This was evaluated for expression and function compared to a TCR targeting MAGEA4 (SEQ ID NO: 89) and an scFv-based CAR targeting human BCMA (SEQ ID NO: 101) (the “comparators”) (**Figure 20A**). Dual targeting TCR T
10 cells were produced in the same manner as Example 1.

 T cells were interrogated for cell surface CAR expression using flow cytometry. T cells were stained using a PE labeled BCMA Fc reagent (AcroBio). Surface BCMA binder expression was comparable between the scFv-TCR and anti-BCMA CAR (**Figure 21A**). Additionally, the biological activity of the T cells was assessed for interferon gamma
15 production in co-culture with tumor cell lines expressing varying levels of BCMA (HT1080 engineered to overexpress high levels of BCMA, RPMI-8226: medium endogenous BCMA expression, Toledo: low endogenous expression). As shown in **Figure 21B**, the interferon gamma production of scFv-TCR is comparable to the anti-BCMA CAR in high BCMA expressing cell line, but greater in medium and low expressing cell lines. IL2 secretion of
20 scFv-TCR was greater than anti-BCMA CAR in coculture with medium and low BCMA expressing cell lines (**Figure 21C**). Secretion of tumor necrosis factor α , another sensitive assay, was assessed in **Figure 21D**, and this was greater in RPMI-8226 and Toledo, medium and low expressing BCMA cell lines. For Live-cell imaging by IncuCyte was used to analyze tumor cell growth of HT1080.BCMA stably transduced with red reporter. The
25 HT1080.BCMA cells grew in the presence of UTD T cells and MAGEA4 TCR-T cells. Co-culture with either scFv-TCR or anti-BCMA CAR resulted in tumor cell elimination, with the scFv-TCR achieving elimination more rapidly than the CAR (**Figure 21E**).

 Flow cytometry was performed to evaluate MAGEA4 tetramer/HLA-multimer binding which was comparable in scFv-TCR and the MAGEA4 TCR (**Figure 22A**).
30 Additionally, the biological activity of the T cells was assessed for interferon gamma

production, IL2 and tumor necrosis factor α in co-culture with tumor cell lines positive for MAGEA4 (adherent A375 cell line that endogenously expresses MAGEA4 and HLA-A2). As shown in **Figure 22B**, the interferon gamma and tumor necrosis factor α production of VHH-TCR is comparable to the MAGEA4 TCR.

5

EXAMPLE 7

EVALUATION OF ENGINEERED TCRS IN A CD33 ANTIGEN ONLY POSITIVE TUMOR MODEL

A MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) was embedded with a VHH targeting human CD33 to produce an engineered dual-targeting TCR ("VHH-TCR") (SEQ ID NO: 93) (**Figures 1A** and **1B**). Dual-targeting TCR T cells were produced
10 TCR") (SEQ ID NO: 93) (**Figures 1A** and **1B**). Dual-targeting TCR T cells were produced in the same manner as Example 1. Engineered T cells were evaluated for expression and *in vitro* function in the same manner as Example 1.

The ability of the VHH-TCR to recognize and function in the presence of VHH antigen was assessed *in vivo* using the systemic luciferase tagged HL-60 tumor model in
15 NSG mice. The HL-60 model expresses CD33 but not MAGEA4, therefore any observed anti-tumor activity would be a result of the VHH-TCR signaling following VHH recognition of CD33. Luciferase tagged HL-60 cells were transplanted intravenously into naïve female NSG mice and allowed to establish for five days. Mice were randomized into groups of 5 animals with similar means on study day -1 (D-1). On D0, animals were intravenously dosed
20 with either untransduced T cells, MAGE4 TCR T cells, CD33-DARIC T cells, or VHH-TcR T cells. T cell doses were normalized to 10E6 receptor positive cells/mouse; the untransduced T cell dose was normalized to match the highest total T cell dose. Animals treated with CD33-DARIC T cells were maintained on a Monday/Wednesday/Friday 0.1mg/kg rapamycin schedule starting on D0. As shown in **Figure 23**, tumor growth
25 continues unchecked in animals treated with either untransduced or MAGEA4 TCR T cells. Both the CD33-DARIC and VHH-TCR T cells demonstrate comparable tumor control.

EXAMPLE 8

EVALUATION OF ENGINEERED TCRS IN A TCR ANTIGEN ONLY POSITIVE TUMOR MODEL

A MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) was embedded
5 with a VHH targeting human CD33 to produce an engineered dual-targeting TCR ("VHH-
TCR") (SEQ ID NO: 93) (**Figures 1A** and **1B**). Dual-targeting TCR T cells were produced
in the same manner as Example 1. Engineered T cells were evaluated for expression and in
vitro function in the same manner as Example 1.

The ability of the VHH-TCR to recognize and function in the presence of TCR
10 antigen was assessed in vivo using the subcutaneous NCI-H2023 tumor model in NSG mice.
The NCI-H2023 model expresses MAGEA4 but not CD33, therefore any observed anti-
tumor activity would be a result of the VHH-TCR signaling following TCR recognition of
MAGEA4. NCI-H2023 cells were transplanted subcutaneously into naïve female NSG mice
and allowed to establish for twenty-one days. Mice were randomized into groups of 5
15 animals with similar means on study day -1 (D-1). On D0, animals were intravenously dosed
with either untransduced T cells, MAGE4 TCR T cells, CD33-DARIC T cells, or VHH-TCR
T cells. T cell doses were normalized to 10E6 receptor positive cells/mouse; the
untransduced T cell dose was normalized to match the highest total T cell dose. Animals
treated with CD33-DARIC T cells were maintained on a Monday/Wednesday/Friday
20 0.1mg/kg rapamycin schedule starting on D0. As shown in **Figure 24**, tumor growth
continues unchecked in animals treated with either untransduced or CD33-DARIC T cells.
Both the MAGEA4 TCR and VHH-TCR T cells initially demonstrate comparable tumor
control. Loss of tumor control occurs earlier in the animals treated with the VHH-TCR T
cells.

25

EXAMPLE 9

EVALUATION OF ENGINEERED TCR CONSTRUCTS COMPRISING A CD19 scFv

A MAGEA4-reactive, HLA-A2-restricted T-cell receptor (TCR) was embedded with
an scFv targeting human CD19 (SEQ ID NO: 102). This was evaluated for expression and
30 function compared to a MAGEA4-reactive, HLA-A2-restricted T-cell receptor

(TCR) embedded with an scFv targeting human BCMA (SEQ ID NO: 100). Dual-targeting TCR T cells were produced as described in Example 1.

5 T cells were interrogated for cell surface TCR expression using flow cytometry. T cells were stained using a PE-labeled anti-TCR Vb1 antibody (Miltenyi Biotech). Surface expression of the engineered constructs was comparable (**Figure 25A**). Additionally, the biological activity of the T cells was assessed by measuring interferon gamma production in co-cultures with suspension tumor cell line RPMI-8226 (endogenous BCMA expression, undetectable CD19 expression), and with suspension tumor cell line K562.CD19 (undetectable BCMA expression, stably transduced with CD19). As shown in **Figure 25B** and **Figure 25C**, CD19 ScFv TCR T cells produce interferon gamma in response to tumor cell lines positive for surface CD19 at comparable levels to the interferon gamma produced by BCMA ScFv TCR T cells in response to tumor cell lines positive for surface BCMA.

EXAMPLE 10

15 ILLUSTRATIVE ENGINEERED TCR CONSTRUCTS

As contemplated herein, antigen-binding domains (also referred to herein as “binders” or “antigen binders”), polypeptide linkers, and TCRs can be surprisingly combined to produce an engineered TCR having multi-specificity. In other words, the components can be combined without destroying the functionality of either the antigen-binding domain(s) or the TCR(s). Thus, the engineered TCRs contemplated herein surprisingly provide (1) multi-specificity, (2) increased sensitivity to non-MHC presented targets, and (3) the ability to simultaneously target both intracellular and extracellular targets.

25 Engineered TCRs can be constructed in multiple formats, and can be designed and constructed using known components (*e.g.*, antigen-binding domains, polypeptide linkers, and TCR α and TCR β chains) and techniques. For example, one or more antigen-binding domains (*e.g.*, one or more “A” components) can be linked to one or more TCR components (*e.g.*, one or more “C” components) with or without one or more polypeptide linkers (*e.g.*, with or without one or more “B” components) using standard cloning techniques. The “A” component can be linked to either the TCR α or TCR β polypeptide/chain or both; or the TCR γ

or TCR δ or both; of the “C” component. Illustrative general engineered TCR formulas are provided below:

A – C

A – B - C

5 The engineered TCRs contemplated herein can be designed and constructed using known components (*e.g.*, TCR α and TCR β chains, linkers, and antigen-binding domains) and techniques. **Table 3** provides an illustrative list of known antigen-binding domains. **Table 4** provides an illustrative list of known polypeptide linkers. **Table 5** provides an illustrative list of known TCRs. However, other known antigen-binding domains, linkers, and TCRs can be
10 found throughout the literature, *e.g.*, including but not limited to US20120082661, WO2016014789, WO2022046730, WO2016033570, US8147832B2, WO2014026054, WO2018145649, WO2014065961, WO2020123947, WO2013049254, WO2019241685, WO2019241688, WO2016049214, WO2018236870, WO2020102240, WO2018183888, US6217866B1, WO2008119566, WO2003055917, WO2018073680, WO2014146672,
15 WO2019200007, WO2016016859, WO2018119279, WO2020227072, WO2020227073, WO2020227071, WO2017153402, WO2007042289, WO2018028647, WO2005113595, US20180273602, WO2019067242, WO2020193767, US10538572B2, US11078252B2, WO2019140100, WO2015009606, WO2021195503, WO2007131092, US20190169260 each of which are incorporated by reference herein, in their entirety. Since other known antigen-
20 binding domains, linkers, and TCRs are well known in the literature, the invention is not intended to be limited to the illustrative components disclosed in **Tables 3-5**.

Table 3 - Illustrative Antigen-Binding Domains (“A” Components):

COMPONENT REFERENCE	TARGET	BINDER TYPE	SEQ ID NOS:
A1	BCMA	scFv	1, 2, AND/OR 3
A2	CD19	scFv	4
A3	CD20	scFv	5, 6, AND/OR 7
A4	CD22	scFv	8
A5	CD33	scFv	9
A6	CD79A	scFv	10
A7	CD79B	scFv	11 AND/OR 12
A8	B7H3	scFv	13
A9	Muc16	scFv	14

A10	HER2	scFv	15
A11	EGFR	scFv	16
A12	FN-EDB	scFv	17
A13	CLDN18.2	scFv	18
A14	DLL3	scFv	19
A15	FLT3	scFv	20 AND/OR 21
A16	CD33	VHH	22, 23, AND/OR 24
A17	CLL1	VHH	25 AND/OR 26
A18	CD123	VHH	27 AND/OR 28
A19	CD20	VHH	29
A20	EGFR	VHH	30
A21	BCMA	VHH	31 AND/OR 32

Table 4 - Illustrative Polypeptide Linkers (“B” Components):

COMPONENT REFERENCE	SEQUENCE	SEQ ID NO:
B1	LEKT	33
B2	LEKTGGGGS	34
B3	GGGGS	35
B4	GGGGSGGGGS	36
B5	GGGGSGGGGSGGGGS	37
B6	GGGGSGGGGSGGGGSGGGGS	38
B7	GGGGSGGGGSGGGGSGGGGSGGGGS	39
B8	DGGGS	40
B9	TGEKP	41
B10	GGRR	42
B11	EGKSSGSGSESKVD	43
B12	KESGSVSSEQLAQFRSLD	44
B13	GGRRGGGS	45
B14	LRQRDGERP	46
B15	LRQKDGGGGERP	47
B16	LRQKDGGGSGGGSERP	48
B17	GSTSGSGKPGSGEGSTKG	49
B18	GSTSGSGKSSEGSSTKG	50
B19	GSTSGSGKSSEGGK	51
B20	GSTSGSGKPGSGEGS	52
B21	GGGS	53

Table 5 – Illustrative TCRs (“C” Components):

COMPONENT REFERENCE	TARGET	TCR α CHAIN SEQ ID NO:	TCR β CHAIN SEQ ID NO:
C1	NY-ESO-1	54	55

C2	NY-ESO-1	56	57
C3	PRAME	58	59
C4	TP53R175H	60	61
C5	MAGE-A4	62	63
C6	WT1	64	65
C7	MR1	66	67
C8	MR1	68	69
C9	CD1d+aGalCer	70	71
C10	HPV16E7	72	73
C11	GP100	74	75
C12	MART-1	76	77
		TCR γ Chain SEQ ID NO:	TCR δ Chain SEQ ID NO:
C13	allo-HLA	78	79

As one example of an engineered TCR contemplated herein, an antigen-binding domain from **Table 3** (*e.g.*, an antigen-binding domain selected from Component A1) can be combined with one or more polypeptide linkers from **Table 4** (*e.g.*, Component B1) and one or both TCR variable domains of a TCR from **Table 5** (*e.g.*, Component C1), to produce a novel engineered TCR construct (*e.g.*, ATOMIC construct #1; see below). Additionally, as further shown and contemplated herein, multiple “A” components can be combined to produce multi-specific antigen-binding domains/regions (*e.g.*, tandem antigen-binding domains), and multiple polypeptide linkers can be combined to produce functional linkers.

Table 6 provides an illustrative, non-limiting list of engineered TCRs (*i.e.*, ATOMIC constructs) based on the antigen-binding domains, linkers, and TCRs provided in **Tables 3, 4, and 5**. One of skill in the art would understand that other combinations are possible, including combinations using other antigen-binding domains, linkers, and TCRs either known to or newly developed by the skilled artisan.

Table 6 – Illustrative Engineered TCRs (*i.e.*, ATOMICs):

ATOMIC CONSTRUCT #	“A” COMPONENT	“B” COMPONENT	“C” COMPONENT
1	A1	none or B1	C1
2	A2	none or B1	C1
3	A3	none or B1	C1
4	A4	none or B1	C1
5	A5	none or B1	C1

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
6	A6	none or B1	C1
7	A7	none or B1	C1
8	A8	none or B1	C1
9	A9	none or B1	C1
10	A10	none or B1	C1
11	A11	none or B1	C1
12	A12	none or B1	C1
13	A13	none or B1	C1
14	A14	none or B1	C1
15	A15	none or B1	C1
16	A16	none or B1	C1
17	A17	none or B1	C1
18	A18	none or B1	C1
19	A19	none or B1	C1
20	A20	none or B1	C1
21	A21	none or B1	C1
22	A1	B2	C1
23	A2	B2	C1
24	A3	B2	C1
25	A4	B2	C1
26	A5	B2	C1
27	A6	B2	C1
28	A7	B2	C1
29	A8	B2	C1
30	A9	B2	C1
31	A10	B2	C1
32	A11	B2	C1
33	A12	B2	C1
34	A13	B2	C1
35	A14	B2	C1
36	A15	B2	C1
37	A16	B2	C1
38	A17	B2	C1
39	A18	B2	C1
40	A19	B2	C1
41	A20	B2	C1
42	A21	B2	C1

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
43	A1	B3	C1
44	A2	B3	C1
45	A3	B3	C1
46	A4	B3	C1
47	A5	B3	C1
48	A6	B3	C1
49	A7	B3	C1
50	A8	B3	C1
51	A9	B3	C1
52	A10	B3	C1
53	A11	B3	C1
54	A12	B3	C1
55	A13	B3	C1
56	A14	B3	C1
57	A15	B3	C1
58	A16	B3	C1
59	A17	B3	C1
60	A18	B3	C1
61	A19	B3	C1
62	A20	B3	C1
63	A21	B3	C1
64	A1	B4	C1
65	A2	B4	C1
66	A3	B4	C1
67	A4	B4	C1
68	A5	B4	C1
69	A6	B4	C1
70	A7	B4	C1
71	A8	B4	C1
72	A9	B4	C1
73	A10	B4	C1
74	A11	B4	C1
75	A12	B4	C1
76	A13	B4	C1
77	A14	B4	C1
78	A15	B4	C1
79	A16	B4	C1

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
80	A17	B4	C1
81	A18	B4	C1
82	A19	B4	C1
83	A20	B4	C1
84	A21	B4	C1
85	A1	Any one of B5 through B21	C1
86	A2	Any one of B5 through B21	C1
87	A3	Any one of B5 through B21	C1
88	A4	Any one of B5 through B21	C1
89	A5	Any one of B5 through B21	C1
90	A6	Any one of B5 through B21	C1
91	A7	Any one of B5 through B21	C1
92	A8	Any one of B5 through B21	C1
93	A9	Any one of B5 through B21	C1
94	A10	Any one of B5 through B21	C1
95	A11	Any one of B5 through B21	C1
96	A12	Any one of B5 through B21	C1
97	A13	Any one of B5 through B21	C1
98	A14	Any one of B5 through B21	C1
99	A15	Any one of B5 through B21	C1
100	A16	Any one of B5 through B21	C1
101	A17	Any one of B5 through B21	C1
102	A18	Any one of B5 through B21	C1
103	A19	Any one of B5 through B21	C1
104	A20	Any one of B5 through B21	C1
105	A21	Any one of B5 through B21	C1
106	A1	none or B1	C2
107	A2	none or B1	C2
108	A3	none or B1	C2
109	A4	none or B1	C2
110	A5	none or B1	C2
111	A6	none or B1	C2
112	A7	none or B1	C2
113	A8	none or B1	C2
114	A9	none or B1	C2
115	A10	none or B1	C2
116	A11	none or B1	C2

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
117	A12	none or B1	C2
118	A13	none or B1	C2
119	A14	none or B1	C2
120	A15	none or B1	C2
121	A16	none or B1	C2
122	A17	none or B1	C2
123	A18	none or B1	C2
124	A19	none or B1	C2
125	A20	none or B1	C2
126	A21	none or B1	C2
127	A1	B2	C2
128	A2	B2	C2
129	A3	B2	C2
130	A4	B2	C2
131	A5	B2	C2
132	A6	B2	C2
133	A7	B2	C2
134	A8	B2	C2
135	A9	B2	C2
136	A10	B2	C2
137	A11	B2	C2
138	A12	B2	C2
139	A13	B2	C2
140	A14	B2	C2
141	A15	B2	C2
142	A16	B2	C2
143	A17	B2	C2
144	A18	B2	C2
145	A19	B2	C2
146	A20	B2	C2
147	A21	B2	C2
148	A1	B3	C2
149	A2	B3	C2
150	A3	B3	C2
151	A4	B3	C2
152	A5	B3	C2
153	A6	B3	C2

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
154	A7	B3	C2
155	A8	B3	C2
156	A9	B3	C2
157	A10	B3	C2
158	A11	B3	C2
159	A12	B3	C2
160	A13	B3	C2
161	A14	B3	C2
162	A15	B3	C2
163	A16	B3	C2
164	A17	B3	C2
165	A18	B3	C2
166	A19	B3	C2
167	A20	B3	C2
168	A21	B3	C2
169	A1	B4	C2
170	A2	B4	C2
171	A3	B4	C2
172	A4	B4	C2
173	A5	B4	C2
174	A6	B4	C2
175	A7	B4	C2
176	A8	B4	C2
177	A9	B4	C2
178	A10	B4	C2
179	A11	B4	C2
180	A12	B4	C2
181	A13	B4	C2
182	A14	B4	C2
183	A15	B4	C2
184	A16	B4	C2
185	A17	B4	C2
186	A18	B4	C2
187	A19	B4	C2
188	A20	B4	C2
189	A21	B4	C2
190	A1	Any one of B5 through B21	C2

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
191	A2	Any one of B5 through B21	C2
192	A3	Any one of B5 through B21	C2
193	A4	Any one of B5 through B21	C2
194	A5	Any one of B5 through B21	C2
195	A6	Any one of B5 through B21	C2
196	A7	Any one of B5 through B21	C2
197	A8	Any one of B5 through B21	C2
198	A9	Any one of B5 through B21	C2
199	A10	Any one of B5 through B21	C2
200	A11	Any one of B5 through B21	C2
201	A12	Any one of B5 through B21	C2
202	A13	Any one of B5 through B21	C2
203	A14	Any one of B5 through B21	C2
204	A15	Any one of B5 through B21	C2
205	A16	Any one of B5 through B21	C2
206	A17	Any one of B5 through B21	C2
207	A18	Any one of B5 through B21	C2
208	A19	Any one of B5 through B21	C2
209	A20	Any one of B5 through B21	C2
210	A21	Any one of B5 through B21	C2
211	A1	none or B1	C3
212	A2	none or B1	C3
213	A3	none or B1	C3
214	A4	none or B1	C3
215	A5	none or B1	C3
216	A6	none or B1	C3
217	A7	none or B1	C3
218	A8	none or B1	C3
219	A9	none or B1	C3
220	A10	none or B1	C3
221	A11	none or B1	C3
222	A12	none or B1	C3
223	A13	none or B1	C3
224	A14	none or B1	C3
225	A15	none or B1	C3
226	A16	none or B1	C3
227	A17	none or B1	C3

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
228	A18	none or B1	C3
229	A19	none or B1	C3
230	A20	none or B1	C3
231	A21	none or B1	C3
232	A1	B2	C3
233	A2	B2	C3
234	A3	B2	C3
235	A4	B2	C3
236	A5	B2	C3
237	A6	B2	C3
238	A7	B2	C3
239	A8	B2	C3
240	A9	B2	C3
241	A10	B2	C3
242	A11	B2	C3
243	A12	B2	C3
244	A13	B2	C3
245	A14	B2	C3
246	A15	B2	C3
247	A16	B2	C3
248	A17	B2	C3
249	A18	B2	C3
250	A19	B2	C3
251	A20	B2	C3
252	A21	B2	C3
253	A1	B3	C3
254	A2	B3	C3
255	A3	B3	C3
256	A4	B3	C3
257	A5	B3	C3
258	A6	B3	C3
259	A7	B3	C3
260	A8	B3	C3
261	A9	B3	C3
262	A10	B3	C3
263	A11	B3	C3
264	A12	B3	C3

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
265	A13	B3	C3
266	A14	B3	C3
267	A15	B3	C3
268	A16	B3	C3
269	A17	B3	C3
270	A18	B3	C3
271	A19	B3	C3
272	A20	B3	C3
273	A21	B3	C3
274	A1	B4	C3
275	A2	B4	C3
276	A3	B4	C3
277	A4	B4	C3
278	A5	B4	C3
279	A6	B4	C3
280	A7	B4	C3
281	A8	B4	C3
282	A9	B4	C3
283	A10	B4	C3
284	A11	B4	C3
285	A12	B4	C3
286	A13	B4	C3
287	A14	B4	C3
288	A15	B4	C3
289	A16	B4	C3
290	A17	B4	C3
291	A18	B4	C3
292	A19	B4	C3
293	A20	B4	C3
294	A21	B4	C3
295	A1	Any one of B5 through B21	C3
296	A2	Any one of B5 through B21	C3
297	A3	Any one of B5 through B21	C3
298	A4	Any one of B5 through B21	C3
299	A5	Any one of B5 through B21	C3
300	A6	Any one of B5 through B21	C3
301	A7	Any one of B5 through B21	C3

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
302	A8	Any one of B5 through B21	C3
303	A9	Any one of B5 through B21	C3
304	A10	Any one of B5 through B21	C3
305	A11	Any one of B5 through B21	C3
306	A12	Any one of B5 through B21	C3
307	A13	Any one of B5 through B21	C3
308	A14	Any one of B5 through B21	C3
309	A15	Any one of B5 through B21	C3
310	A16	Any one of B5 through B21	C3
311	A17	Any one of B5 through B21	C3
312	A18	Any one of B5 through B21	C3
313	A19	Any one of B5 through B21	C3
314	A20	Any one of B5 through B21	C3
315	A21	Any one of B5 through B21	C3
316	A1	none or B1	C4
317	A2	none or B1	C4
318	A3	none or B1	C4
319	A4	none or B1	C4
320	A5	none or B1	C4
321	A6	none or B1	C4
322	A7	none or B1	C4
323	A8	none or B1	C4
324	A9	none or B1	C4
325	A10	none or B1	C4
326	A11	none or B1	C4
327	A12	none or B1	C4
328	A13	none or B1	C4
329	A14	none or B1	C4
330	A15	none or B1	C4
331	A16	none or B1	C4
332	A17	none or B1	C4
333	A18	none or B1	C4
334	A19	none or B1	C4
335	A20	none or B1	C4
336	A21	none or B1	C4
337	A1	B2	C4
338	A2	B2	C4

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
339	A3	B2	C4
340	A4	B2	C4
341	A5	B2	C4
342	A6	B2	C4
343	A7	B2	C4
344	A8	B2	C4
345	A9	B2	C4
346	A10	B2	C4
347	A11	B2	C4
348	A12	B2	C4
349	A13	B2	C4
350	A14	B2	C4
351	A15	B2	C4
352	A16	B2	C4
353	A17	B2	C4
354	A18	B2	C4
355	A19	B2	C4
356	A20	B2	C4
357	A21	B2	C4
358	A1	B3	C4
359	A2	B3	C4
360	A3	B3	C4
361	A4	B3	C4
362	A5	B3	C4
363	A6	B3	C4
364	A7	B3	C4
365	A8	B3	C4
366	A9	B3	C4
367	A10	B3	C4
368	A11	B3	C4
369	A12	B3	C4
370	A13	B3	C4
371	A14	B3	C4
372	A15	B3	C4
373	A16	B3	C4
374	A17	B3	C4
375	A18	B3	C4

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
376	A19	B3	C4
377	A20	B3	C4
378	A21	B3	C4
379	A1	B4	C4
380	A2	B4	C4
381	A3	B4	C4
382	A4	B4	C4
383	A5	B4	C4
384	A6	B4	C4
385	A7	B4	C4
386	A8	B4	C4
387	A9	B4	C4
388	A10	B4	C4
389	A11	B4	C4
390	A12	B4	C4
391	A13	B4	C4
392	A14	B4	C4
393	A15	B4	C4
394	A16	B4	C4
395	A17	B4	C4
396	A18	B4	C4
397	A19	B4	C4
398	A20	B4	C4
399	A21	B4	C4
400	A1	Any one of B5 through B21	C4
401	A2	Any one of B5 through B21	C4
402	A3	Any one of B5 through B21	C4
403	A4	Any one of B5 through B21	C4
404	A5	Any one of B5 through B21	C4
405	A6	Any one of B5 through B21	C4
406	A7	Any one of B5 through B21	C4
407	A8	Any one of B5 through B21	C4
408	A9	Any one of B5 through B21	C4
409	A10	Any one of B5 through B21	C4
410	A11	Any one of B5 through B21	C4
411	A12	Any one of B5 through B21	C4
412	A13	Any one of B5 through B21	C4

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
413	A14	Any one of B5 through B21	C4
414	A15	Any one of B5 through B21	C4
415	A16	Any one of B5 through B21	C4
416	A17	Any one of B5 through B21	C4
417	A18	Any one of B5 through B21	C4
418	A19	Any one of B5 through B21	C4
419	A20	Any one of B5 through B21	C4
420	A21	Any one of B5 through B21	C4
421	A1	none or B1	C5
422	A2	none or B1	C5
423	A3	none or B1	C5
424	A4	none or B1	C5
425	A5	none or B1	C5
426	A6	none or B1	C5
427	A7	none or B1	C5
428	A8	none or B1	C5
429	A9	none or B1	C5
430	A10	none or B1	C5
431	A11	none or B1	C5
432	A12	none or B1	C5
433	A13	none or B1	C5
434	A14	none or B1	C5
435	A15	none or B1	C5
436	A16	none or B1	C5
437	A17	none or B1	C5
438	A18	none or B1	C5
439	A19	none or B1	C5
440	A20	none or B1	C5
441	A21	none or B1	C5
442	A1	B2	C5
443	A2	B2	C5
444	A3	B2	C5
445	A4	B2	C5
446	A5	B2	C5
447	A6	B2	C5
448	A7	B2	C5
449	A8	B2	C5

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
450	A9	B2	C5
451	A10	B2	C5
452	A11	B2	C5
453	A12	B2	C5
454	A13	B2	C5
455	A14	B2	C5
456	A15	B2	C5
457	A16	B2	C5
458	A17	B2	C5
459	A18	B2	C5
460	A19	B2	C5
461	A20	B2	C5
462	A21	B2	C5
463	A1	B3	C5
464	A2	B3	C5
465	A3	B3	C5
466	A4	B3	C5
467	A5	B3	C5
468	A6	B3	C5
469	A7	B3	C5
470	A8	B3	C5
471	A9	B3	C5
472	A10	B3	C5
473	A11	B3	C5
474	A12	B3	C5
475	A13	B3	C5
476	A14	B3	C5
477	A15	B3	C5
478	A16	B3	C5
479	A17	B3	C5
480	A18	B3	C5
481	A19	B3	C5
482	A20	B3	C5
483	A21	B3	C5
484	A1	B4	C5
485	A2	B4	C5
486	A3	B4	C5

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
487	A4	B4	C5
488	A5	B4	C5
489	A6	B4	C5
490	A7	B4	C5
491	A8	B4	C5
492	A9	B4	C5
493	A10	B4	C5
494	A11	B4	C5
495	A12	B4	C5
496	A13	B4	C5
497	A14	B4	C5
498	A15	B4	C5
499	A16	B4	C5
500	A17	B4	C5
501	A18	B4	C5
502	A19	B4	C5
503	A20	B4	C5
504	A21	B4	C5
505	A1	Any one of B5 through B21	C5
506	A2	Any one of B5 through B21	C5
507	A3	Any one of B5 through B21	C5
508	A4	Any one of B5 through B21	C5
509	A5	Any one of B5 through B21	C5
510	A6	Any one of B5 through B21	C5
511	A7	Any one of B5 through B21	C5
512	A8	Any one of B5 through B21	C5
513	A9	Any one of B5 through B21	C5
514	A10	Any one of B5 through B21	C5
515	A11	Any one of B5 through B21	C5
516	A12	Any one of B5 through B21	C5
517	A13	Any one of B5 through B21	C5
518	A14	Any one of B5 through B21	C5
519	A15	Any one of B5 through B21	C5
520	A16	Any one of B5 through B21	C5
521	A17	Any one of B5 through B21	C5
522	A18	Any one of B5 through B21	C5
523	A19	Any one of B5 through B21	C5

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
524	A20	Any one of B5 through B21	C5
525	A21	Any one of B5 through B21	C5
526	A1	none or B1	C6
527	A2	none or B1	C6
528	A3	none or B1	C6
529	A4	none or B1	C6
530	A5	none or B1	C6
531	A6	none or B1	C6
532	A7	none or B1	C6
533	A8	none or B1	C6
534	A9	none or B1	C6
535	A10	none or B1	C6
536	A11	none or B1	C6
537	A12	none or B1	C6
538	A13	none or B1	C6
539	A14	none or B1	C6
540	A15	none or B1	C6
541	A16	none or B1	C6
542	A17	none or B1	C6
543	A18	none or B1	C6
544	A19	none or B1	C6
545	A20	none or B1	C6
546	A21	none or B1	C6
547	A1	B2	C6
548	A2	B2	C6
549	A3	B2	C6
550	A4	B2	C6
551	A5	B2	C6
552	A6	B2	C6
553	A7	B2	C6
554	A8	B2	C6
555	A9	B2	C6
556	A10	B2	C6
557	A11	B2	C6
558	A12	B2	C6
559	A13	B2	C6
560	A14	B2	C6

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
561	A15	B2	C6
562	A16	B2	C6
563	A17	B2	C6
564	A18	B2	C6
565	A19	B2	C6
566	A20	B2	C6
567	A21	B2	C6
568	A1	B3	C6
569	A2	B3	C6
570	A3	B3	C6
571	A4	B3	C6
572	A5	B3	C6
573	A6	B3	C6
574	A7	B3	C6
575	A8	B3	C6
576	A9	B3	C6
577	A10	B3	C6
578	A11	B3	C6
579	A12	B3	C6
580	A13	B3	C6
581	A14	B3	C6
582	A15	B3	C6
583	A16	B3	C6
584	A17	B3	C6
585	A18	B3	C6
586	A19	B3	C6
587	A20	B3	C6
588	A21	B3	C6
589	A1	B4	C6
590	A2	B4	C6
591	A3	B4	C6
592	A4	B4	C6
593	A5	B4	C6
594	A6	B4	C6
595	A7	B4	C6
596	A8	B4	C6
597	A9	B4	C6

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
598	A10	B4	C6
599	A11	B4	C6
600	A12	B4	C6
601	A13	B4	C6
602	A14	B4	C6
603	A15	B4	C6
604	A16	B4	C6
605	A17	B4	C6
606	A18	B4	C6
607	A19	B4	C6
608	A20	B4	C6
609	A21	B4	C6
610	A1	Any one of B5 through B21	C6
611	A2	Any one of B5 through B21	C6
612	A3	Any one of B5 through B21	C6
613	A4	Any one of B5 through B21	C6
614	A5	Any one of B5 through B21	C6
615	A6	Any one of B5 through B21	C6
616	A7	Any one of B5 through B21	C6
617	A8	Any one of B5 through B21	C6
618	A9	Any one of B5 through B21	C6
619	A10	Any one of B5 through B21	C6
620	A11	Any one of B5 through B21	C6
621	A12	Any one of B5 through B21	C6
622	A13	Any one of B5 through B21	C6
623	A14	Any one of B5 through B21	C6
624	A15	Any one of B5 through B21	C6
625	A16	Any one of B5 through B21	C6
626	A17	Any one of B5 through B21	C6
627	A18	Any one of B5 through B21	C6
628	A19	Any one of B5 through B21	C6
629	A20	Any one of B5 through B21	C6
630	A21	Any one of B5 through B21	C6
631	A1	none or B1	C7
632	A2	none or B1	C7
633	A3	none or B1	C7
634	A4	none or B1	C7

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
635	A5	none or B1	C7
636	A6	none or B1	C7
637	A7	none or B1	C7
638	A8	none or B1	C7
639	A9	none or B1	C7
640	A10	none or B1	C7
641	A11	none or B1	C7
642	A12	none or B1	C7
643	A13	none or B1	C7
644	A14	none or B1	C7
645	A15	none or B1	C7
646	A16	none or B1	C7
647	A17	none or B1	C7
648	A18	none or B1	C7
649	A19	none or B1	C7
650	A20	none or B1	C7
651	A21	none or B1	C7
652	A1	B2	C7
653	A2	B2	C7
654	A3	B2	C7
655	A4	B2	C7
656	A5	B2	C7
657	A6	B2	C7
658	A7	B2	C7
659	A8	B2	C7
660	A9	B2	C7
661	A10	B2	C7
662	A11	B2	C7
663	A12	B2	C7
664	A13	B2	C7
665	A14	B2	C7
666	A15	B2	C7
667	A16	B2	C7
668	A17	B2	C7
669	A18	B2	C7
670	A19	B2	C7
671	A20	B2	C7

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
672	A21	B2	C7
673	A1	B3	C7
674	A2	B3	C7
675	A3	B3	C7
676	A4	B3	C7
677	A5	B3	C7
678	A6	B3	C7
679	A7	B3	C7
680	A8	B3	C7
681	A9	B3	C7
682	A10	B3	C7
683	A11	B3	C7
684	A12	B3	C7
685	A13	B3	C7
686	A14	B3	C7
687	A15	B3	C7
688	A16	B3	C7
689	A17	B3	C7
690	A18	B3	C7
691	A19	B3	C7
692	A20	B3	C7
693	A21	B3	C7
694	A1	B4	C7
695	A2	B4	C7
696	A3	B4	C7
697	A4	B4	C7
698	A5	B4	C7
699	A6	B4	C7
700	A7	B4	C7
701	A8	B4	C7
702	A9	B4	C7
703	A10	B4	C7
704	A11	B4	C7
705	A12	B4	C7
706	A13	B4	C7
707	A14	B4	C7
708	A15	B4	C7

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
709	A16	B4	C7
710	A17	B4	C7
711	A18	B4	C7
712	A19	B4	C7
713	A20	B4	C7
714	A21	B4	C7
715	A1	Any one of B5 through B21	C7
716	A2	Any one of B5 through B21	C7
717	A3	Any one of B5 through B21	C7
718	A4	Any one of B5 through B21	C7
719	A5	Any one of B5 through B21	C7
720	A6	Any one of B5 through B21	C7
721	A7	Any one of B5 through B21	C7
722	A8	Any one of B5 through B21	C7
723	A9	Any one of B5 through B21	C7
724	A10	Any one of B5 through B21	C7
725	A11	Any one of B5 through B21	C7
726	A12	Any one of B5 through B21	C7
727	A13	Any one of B5 through B21	C7
728	A14	Any one of B5 through B21	C7
729	A15	Any one of B5 through B21	C7
730	A16	Any one of B5 through B21	C7
731	A17	Any one of B5 through B21	C7
732	A18	Any one of B5 through B21	C7
733	A19	Any one of B5 through B21	C7
734	A20	Any one of B5 through B21	C7
735	A21	Any one of B5 through B21	C7
736	A1	none or B1	C8
737	A2	none or B1	C8
738	A3	none or B1	C8
739	A4	none or B1	C8
740	A5	none or B1	C8
741	A6	none or B1	C8
742	A7	none or B1	C8
743	A8	none or B1	C8
744	A9	none or B1	C8
745	A10	none or B1	C8

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
746	A11	none or B1	C8
747	A12	none or B1	C8
748	A13	none or B1	C8
749	A14	none or B1	C8
750	A15	none or B1	C8
751	A16	none or B1	C8
752	A17	none or B1	C8
753	A18	none or B1	C8
754	A19	none or B1	C8
755	A20	none or B1	C8
756	A21	none or B1	C8
757	A1	B2	C8
758	A2	B2	C8
759	A3	B2	C8
760	A4	B2	C8
761	A5	B2	C8
762	A6	B2	C8
763	A7	B2	C8
764	A8	B2	C8
765	A9	B2	C8
766	A10	B2	C8
767	A11	B2	C8
768	A12	B2	C8
769	A13	B2	C8
770	A14	B2	C8
771	A15	B2	C8
772	A16	B2	C8
773	A17	B2	C8
774	A18	B2	C8
775	A19	B2	C8
776	A20	B2	C8
777	A21	B2	C8
778	A1	B3	C8
779	A2	B3	C8
780	A3	B3	C8
781	A4	B3	C8
782	A5	B3	C8

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
783	A6	B3	C8
784	A7	B3	C8
785	A8	B3	C8
786	A9	B3	C8
787	A10	B3	C8
788	A11	B3	C8
789	A12	B3	C8
790	A13	B3	C8
791	A14	B3	C8
792	A15	B3	C8
793	A16	B3	C8
794	A17	B3	C8
795	A18	B3	C8
796	A19	B3	C8
797	A20	B3	C8
798	A21	B3	C8
799	A1	B4	C8
800	A2	B4	C8
801	A3	B4	C8
802	A4	B4	C8
803	A5	B4	C8
804	A6	B4	C8
805	A7	B4	C8
806	A8	B4	C8
807	A9	B4	C8
808	A10	B4	C8
809	A11	B4	C8
810	A12	B4	C8
811	A13	B4	C8
812	A14	B4	C8
813	A15	B4	C8
814	A16	B4	C8
815	A17	B4	C8
816	A18	B4	C8
817	A19	B4	C8
818	A20	B4	C8
819	A21	B4	C8

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
820	A1	Any one of B5 through B21	C8
821	A2	Any one of B5 through B21	C8
822	A3	Any one of B5 through B21	C8
823	A4	Any one of B5 through B21	C8
824	A5	Any one of B5 through B21	C8
825	A6	Any one of B5 through B21	C8
826	A7	Any one of B5 through B21	C8
827	A8	Any one of B5 through B21	C8
828	A9	Any one of B5 through B21	C8
829	A10	Any one of B5 through B21	C8
830	A11	Any one of B5 through B21	C8
831	A12	Any one of B5 through B21	C8
832	A13	Any one of B5 through B21	C8
833	A14	Any one of B5 through B21	C8
834	A15	Any one of B5 through B21	C8
835	A16	Any one of B5 through B21	C8
836	A17	Any one of B5 through B21	C8
837	A18	Any one of B5 through B21	C8
838	A19	Any one of B5 through B21	C8
839	A20	Any one of B5 through B21	C8
840	A21	Any one of B5 through B21	C8
841	A1	none or B1	C9
842	A2	none or B1	C9
843	A3	none or B1	C9
844	A4	none or B1	C9
845	A5	none or B1	C9
846	A6	none or B1	C9
847	A7	none or B1	C9
848	A8	none or B1	C9
849	A9	none or B1	C9
850	A10	none or B1	C9
851	A11	none or B1	C9
852	A12	none or B1	C9
853	A13	none or B1	C9
854	A14	none or B1	C9
855	A15	none or B1	C9
856	A16	none or B1	C9

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
857	A17	none or B1	C9
858	A18	none or B1	C9
859	A19	none or B1	C9
860	A20	none or B1	C9
861	A21	none or B1	C9
862	A1	B2	C9
863	A2	B2	C9
864	A3	B2	C9
865	A4	B2	C9
866	A5	B2	C9
867	A6	B2	C9
868	A7	B2	C9
869	A8	B2	C9
870	A9	B2	C9
871	A10	B2	C9
872	A11	B2	C9
873	A12	B2	C9
874	A13	B2	C9
875	A14	B2	C9
876	A15	B2	C9
877	A16	B2	C9
878	A17	B2	C9
879	A18	B2	C9
880	A19	B2	C9
881	A20	B2	C9
882	A21	B2	C9
883	A1	B3	C9
884	A2	B3	C9
885	A3	B3	C9
886	A4	B3	C9
887	A5	B3	C9
888	A6	B3	C9
889	A7	B3	C9
890	A8	B3	C9
891	A9	B3	C9
892	A10	B3	C9
893	A11	B3	C9

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
894	A12	B3	C9
895	A13	B3	C9
896	A14	B3	C9
897	A15	B3	C9
898	A16	B3	C9
899	A17	B3	C9
900	A18	B3	C9
901	A19	B3	C9
902	A20	B3	C9
903	A21	B3	C9
904	A1	B4	C9
905	A2	B4	C9
906	A3	B4	C9
907	A4	B4	C9
908	A5	B4	C9
909	A6	B4	C9
910	A7	B4	C9
911	A8	B4	C9
912	A9	B4	C9
913	A10	B4	C9
914	A11	B4	C9
915	A12	B4	C9
916	A13	B4	C9
917	A14	B4	C9
918	A15	B4	C9
919	A16	B4	C9
920	A17	B4	C9
921	A18	B4	C9
922	A19	B4	C9
923	A20	B4	C9
924	A21	B4	C9
925	A1	Any one of B5 through B21	C9
926	A2	Any one of B5 through B21	C9
927	A3	Any one of B5 through B21	C9
928	A4	Any one of B5 through B21	C9
929	A5	Any one of B5 through B21	C9
930	A6	Any one of B5 through B21	C9

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
931	A7	Any one of B5 through B21	C9
932	A8	Any one of B5 through B21	C9
933	A9	Any one of B5 through B21	C9
934	A10	Any one of B5 through B21	C9
935	A11	Any one of B5 through B21	C9
936	A12	Any one of B5 through B21	C9
937	A13	Any one of B5 through B21	C9
938	A14	Any one of B5 through B21	C9
939	A15	Any one of B5 through B21	C9
940	A16	Any one of B5 through B21	C9
941	A17	Any one of B5 through B21	C9
942	A18	Any one of B5 through B21	C9
943	A19	Any one of B5 through B21	C9
944	A20	Any one of B5 through B21	C9
945	A21	Any one of B5 through B21	C9
946	A1	none or B1	C10
947	A2	none or B1	C10
948	A3	none or B1	C10
949	A4	none or B1	C10
950	A5	none or B1	C10
951	A6	none or B1	C10
952	A7	none or B1	C10
953	A8	none or B1	C10
954	A9	none or B1	C10
955	A10	none or B1	C10
956	A11	none or B1	C10
957	A12	none or B1	C10
958	A13	none or B1	C10
959	A14	none or B1	C10
960	A15	none or B1	C10
961	A16	none or B1	C10
962	A17	none or B1	C10
963	A18	none or B1	C10
964	A19	none or B1	C10
965	A20	none or B1	C10
966	A21	none or B1	C10
967	A1	B2	C10

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
968	A2	B2	C10
969	A3	B2	C10
970	A4	B2	C10
971	A5	B2	C10
972	A6	B2	C10
973	A7	B2	C10
974	A8	B2	C10
975	A9	B2	C10
976	A10	B2	C10
977	A11	B2	C10
978	A12	B2	C10
979	A13	B2	C10
980	A14	B2	C10
981	A15	B2	C10
982	A16	B2	C10
983	A17	B2	C10
984	A18	B2	C10
985	A19	B2	C10
986	A20	B2	C10
987	A21	B2	C10
988	A1	B3	C10
989	A2	B3	C10
990	A3	B3	C10
991	A4	B3	C10
992	A5	B3	C10
993	A6	B3	C10
994	A7	B3	C10
995	A8	B3	C10
996	A9	B3	C10
997	A10	B3	C10
998	A11	B3	C10
999	A12	B3	C10
1000	A13	B3	C10
1001	A14	B3	C10
1002	A15	B3	C10
1003	A16	B3	C10
1004	A17	B3	C10

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1005	A18	B3	C10
1006	A19	B3	C10
1007	A20	B3	C10
1008	A21	B3	C10
1009	A1	B4	C10
1010	A2	B4	C10
1011	A3	B4	C10
1012	A4	B4	C10
1013	A5	B4	C10
1014	A6	B4	C10
1015	A7	B4	C10
1016	A8	B4	C10
1017	A9	B4	C10
1018	A10	B4	C10
1019	A11	B4	C10
1020	A12	B4	C10
1021	A13	B4	C10
1022	A14	B4	C10
1023	A15	B4	C10
1024	A16	B4	C10
1025	A17	B4	C10
1026	A18	B4	C10
1027	A19	B4	C10
1028	A20	B4	C10
1029	A21	B4	C10
1030	A1	Any one of B5 through B21	C10
1031	A2	Any one of B5 through B21	C10
1032	A3	Any one of B5 through B21	C10
1033	A4	Any one of B5 through B21	C10
1034	A5	Any one of B5 through B21	C10
1035	A6	Any one of B5 through B21	C10
1036	A7	Any one of B5 through B21	C10
1037	A8	Any one of B5 through B21	C10
1038	A9	Any one of B5 through B21	C10
1039	A10	Any one of B5 through B21	C10
1040	A11	Any one of B5 through B21	C10
1041	A12	Any one of B5 through B21	C10

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1042	A13	Any one of B5 through B21	C10
1043	A14	Any one of B5 through B21	C10
1044	A15	Any one of B5 through B21	C10
1045	A16	Any one of B5 through B21	C10
1046	A17	Any one of B5 through B21	C10
1047	A18	Any one of B5 through B21	C10
1048	A19	Any one of B5 through B21	C10
1049	A20	Any one of B5 through B21	C10
1050	A21	Any one of B5 through B21	C10
1051	A1	none or B1	C11
1052	A2	none or B1	C11
1053	A3	none or B1	C11
1054	A4	none or B1	C11
1055	A5	none or B1	C11
1056	A6	none or B1	C11
1057	A7	none or B1	C11
1058	A8	none or B1	C11
1059	A9	none or B1	C11
1060	A10	none or B1	C11
1061	A11	none or B1	C11
1062	A12	none or B1	C11
1063	A13	none or B1	C11
1064	A14	none or B1	C11
1065	A15	none or B1	C11
1066	A16	none or B1	C11
1067	A17	none or B1	C11
1068	A18	none or B1	C11
1069	A19	none or B1	C11
1070	A20	none or B1	C11
1071	A21	none or B1	C11
1072	A1	B2	C11
1073	A2	B2	C11
1074	A3	B2	C11
1075	A4	B2	C11
1076	A5	B2	C11
1077	A6	B2	C11
1078	A7	B2	C11

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1079	A8	B2	C11
1080	A9	B2	C11
1081	A10	B2	C11
1082	A11	B2	C11
1083	A12	B2	C11
1084	A13	B2	C11
1085	A14	B2	C11
1086	A15	B2	C11
1087	A16	B2	C11
1088	A17	B2	C11
1089	A18	B2	C11
1090	A19	B2	C11
1091	A20	B2	C11
1092	A21	B2	C11
1093	A1	B3	C11
1094	A2	B3	C11
1095	A3	B3	C11
1096	A4	B3	C11
1097	A5	B3	C11
1098	A6	B3	C11
1099	A7	B3	C11
1100	A8	B3	C11
1101	A9	B3	C11
1102	A10	B3	C11
1103	A11	B3	C11
1104	A12	B3	C11
1105	A13	B3	C11
1106	A14	B3	C11
1107	A15	B3	C11
1108	A16	B3	C11
1109	A17	B3	C11
1110	A18	B3	C11
1111	A19	B3	C11
1112	A20	B3	C11
1113	A21	B3	C11
1114	A1	B4	C11
1115	A2	B4	C11

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1116	A3	B4	C11
1117	A4	B4	C11
1118	A5	B4	C11
1119	A6	B4	C11
1120	A7	B4	C11
1121	A8	B4	C11
1122	A9	B4	C11
1123	A10	B4	C11
1124	A11	B4	C11
1125	A12	B4	C11
1126	A13	B4	C11
1127	A14	B4	C11
1128	A15	B4	C11
1129	A16	B4	C11
1130	A17	B4	C11
1131	A18	B4	C11
1132	A19	B4	C11
1133	A20	B4	C11
1134	A21	B4	C11
1135	A1	Any one of B5 through B21	C11
1136	A2	Any one of B5 through B21	C11
1137	A3	Any one of B5 through B21	C11
1138	A4	Any one of B5 through B21	C11
1139	A5	Any one of B5 through B21	C11
1140	A6	Any one of B5 through B21	C11
1141	A7	Any one of B5 through B21	C11
1142	A8	Any one of B5 through B21	C11
1143	A9	Any one of B5 through B21	C11
1144	A10	Any one of B5 through B21	C11
1145	A11	Any one of B5 through B21	C11
1146	A12	Any one of B5 through B21	C11
1147	A13	Any one of B5 through B21	C11
1148	A14	Any one of B5 through B21	C11
1149	A15	Any one of B5 through B21	C11
1150	A16	Any one of B5 through B21	C11
1151	A17	Any one of B5 through B21	C11
1152	A18	Any one of B5 through B21	C11

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1153	A19	Any one of B5 through B21	C11
1154	A20	Any one of B5 through B21	C11
1155	A21	Any one of B5 through B21	C11
1156	A1	none or B1	C12
1157	A2	none or B1	C12
1158	A3	none or B1	C12
1159	A4	none or B1	C12
1160	A5	none or B1	C12
1161	A6	none or B1	C12
1162	A7	none or B1	C12
1163	A8	none or B1	C12
1164	A9	none or B1	C12
1165	A10	none or B1	C12
1166	A11	none or B1	C12
1167	A12	none or B1	C12
1168	A13	none or B1	C12
1169	A14	none or B1	C12
1170	A15	none or B1	C12
1171	A16	none or B1	C12
1172	A17	none or B1	C12
1173	A18	none or B1	C12
1174	A19	none or B1	C12
1175	A20	none or B1	C12
1176	A21	none or B1	C12
1177	A1	B2	C12
1178	A2	B2	C12
1179	A3	B2	C12
1180	A4	B2	C12
1181	A5	B2	C12
1182	A6	B2	C12
1183	A7	B2	C12
1184	A8	B2	C12
1185	A9	B2	C12
1186	A10	B2	C12
1187	A11	B2	C12
1188	A12	B2	C12
1189	A13	B2	C12

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1190	A14	B2	C12
1191	A15	B2	C12
1192	A16	B2	C12
1193	A17	B2	C12
1194	A18	B2	C12
1195	A19	B2	C12
1196	A20	B2	C12
1197	A21	B2	C12
1198	A1	B3	C12
1199	A2	B3	C12
1200	A3	B3	C12
1201	A4	B3	C12
1202	A5	B3	C12
1203	A6	B3	C12
1204	A7	B3	C12
1205	A8	B3	C12
1206	A9	B3	C12
1207	A10	B3	C12
1208	A11	B3	C12
1209	A12	B3	C12
1210	A13	B3	C12
1211	A14	B3	C12
1212	A15	B3	C12
1213	A16	B3	C12
1214	A17	B3	C12
1215	A18	B3	C12
1216	A19	B3	C12
1217	A20	B3	C12
1218	A21	B3	C12
1219	A1	B4	C12
1220	A2	B4	C12
1221	A3	B4	C12
1222	A4	B4	C12
1223	A5	B4	C12
1224	A6	B4	C12
1225	A7	B4	C12
1226	A8	B4	C12

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1227	A9	B4	C12
1228	A10	B4	C12
1229	A11	B4	C12
1230	A12	B4	C12
1231	A13	B4	C12
1232	A14	B4	C12
1233	A15	B4	C12
1234	A16	B4	C12
1235	A17	B4	C12
1236	A18	B4	C12
1237	A19	B4	C12
1238	A20	B4	C12
1239	A21	B4	C12
1240	A1	Any one of B5 through B21	C12
1241	A2	Any one of B5 through B21	C12
1242	A3	Any one of B5 through B21	C12
1243	A4	Any one of B5 through B21	C12
1244	A5	Any one of B5 through B21	C12
1245	A6	Any one of B5 through B21	C12
1246	A7	Any one of B5 through B21	C12
1247	A8	Any one of B5 through B21	C12
1248	A9	Any one of B5 through B21	C12
1249	A10	Any one of B5 through B21	C12
1250	A11	Any one of B5 through B21	C12
1251	A12	Any one of B5 through B21	C12
1252	A13	Any one of B5 through B21	C12
1253	A14	Any one of B5 through B21	C12
1254	A15	Any one of B5 through B21	C12
1255	A16	Any one of B5 through B21	C12
1256	A17	Any one of B5 through B21	C12
1257	A18	Any one of B5 through B21	C12
1258	A19	Any one of B5 through B21	C12
1259	A20	Any one of B5 through B21	C12
1260	A21	Any one of B5 through B21	C12
1261	A1	none or B1	C13
1262	A2	none or B1	C13
1263	A3	none or B1	C13

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1264	A4	none or B1	C13
1265	A5	none or B1	C13
1266	A6	none or B1	C13
1267	A7	none or B1	C13
1268	A8	none or B1	C13
1269	A9	none or B1	C13
1270	A10	none or B1	C13
1271	A11	none or B1	C13
1272	A12	none or B1	C13
1273	A13	none or B1	C13
1274	A14	none or B1	C13
1275	A15	none or B1	C13
1276	A16	none or B1	C13
1277	A17	none or B1	C13
1278	A18	none or B1	C13
1279	A19	none or B1	C13
1280	A20	none or B1	C13
1281	A21	none or B1	C13
1282	A1	B2	C13
1283	A2	B2	C13
1284	A3	B2	C13
1285	A4	B2	C13
1286	A5	B2	C13
1287	A6	B2	C13
1288	A7	B2	C13
1289	A8	B2	C13
1290	A9	B2	C13
1291	A10	B2	C13
1292	A11	B2	C13
1293	A12	B2	C13
1294	A13	B2	C13
1295	A14	B2	C13
1296	A15	B2	C13
1297	A16	B2	C13
1298	A17	B2	C13
1299	A18	B2	C13
1300	A19	B2	C13

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1301	A20	B2	C13
1302	A21	B2	C13
1303	A1	B3	C13
1304	A2	B3	C13
1305	A3	B3	C13
1306	A4	B3	C13
1307	A5	B3	C13
1308	A6	B3	C13
1309	A7	B3	C13
1310	A8	B3	C13
1311	A9	B3	C13
1312	A10	B3	C13
1313	A11	B3	C13
1314	A12	B3	C13
1315	A13	B3	C13
1316	A14	B3	C13
1317	A15	B3	C13
1318	A16	B3	C13
1319	A17	B3	C13
1320	A18	B3	C13
1321	A19	B3	C13
1322	A20	B3	C13
1323	A21	B3	C13
1324	A1	B4	C13
1325	A2	B4	C13
1326	A3	B4	C13
1327	A4	B4	C13
1328	A5	B4	C13
1329	A6	B4	C13
1330	A7	B4	C13
1331	A8	B4	C13
1332	A9	B4	C13
1333	A10	B4	C13
1334	A11	B4	C13
1335	A12	B4	C13
1336	A13	B4	C13
1337	A14	B4	C13

ATOMIC CONSTRUCT #	"A" COMPONENT	"B" COMPONENT	"C" COMPONENT
1338	A15	B4	C13
1339	A16	B4	C13
1340	A17	B4	C13
1341	A18	B4	C13
1342	A19	B4	C13
1343	A20	B4	C13
1344	A21	B4	C13
1345	A1	Any one of B5 through B21	C13
1346	A2	Any one of B5 through B21	C13
1347	A3	Any one of B5 through B21	C13
1348	A4	Any one of B5 through B21	C13
1349	A5	Any one of B5 through B21	C13
1350	A6	Any one of B5 through B21	C13
1351	A7	Any one of B5 through B21	C13
1352	A8	Any one of B5 through B21	C13
1353	A9	Any one of B5 through B21	C13
1354	A10	Any one of B5 through B21	C13
1355	A11	Any one of B5 through B21	C13
1356	A12	Any one of B5 through B21	C13
1357	A13	Any one of B5 through B21	C13
1358	A14	Any one of B5 through B21	C13
1359	A15	Any one of B5 through B21	C13
1360	A16	Any one of B5 through B21	C13
1361	A17	Any one of B5 through B21	C13
1362	A18	Any one of B5 through B21	C13
1363	A19	Any one of B5 through B21	C13
1364	A20	Any one of B5 through B21	C13
1365	A21	Any one of B5 through B21	C13

As would be apparent to one skilled in the art, certain engineered TCR constructs (ATOMICs) comprising multiple A and B components are contemplated, and are surprisingly effective (see Examples 2-9).

Additionally, the engineered TCRs (ATOMICs) contemplated herein may also
5 include a native or engineered TCR constant domain. For example, the constant domain can be a native or engineered TCR α , TCR β , TCR γ , or TCR δ constant domain. Moreover, any

TCR variable domain can be combined with any TCR constant domain. For example, a TCR α variable domain can be combined with any one of the TCR α , TCR β , TCR γ , or TCR δ constant domains; a TCR β variable domain can be combined with any one of the TCR α , TCR β , TCR γ , or TCR δ constant domains; a TCR γ variable domain can be combined with any one of the TCR α , TCR β , TCR γ , or TCR δ constant domains; and a TCR δ variable domain can be combined with any one of the TCR α , TCR β , TCR γ , or TCR δ constant domains. Illustrative native and pairing enhanced TCR constant domains are provided in **Table 7** below. For other examples of TCR constant domains, see also WO2021195503A1, which is incorporated by reference herein, in its entirety.

Table 7 – TCR constant domains:

NAME	SEQ ID NO:
human beta constant 1 (huTRBC1)	80
human beta constant 2 (huTRBC2)	81
human alpha constant (huTRAC)	82
human gamma constant 1 (huTRGC1)	83
human gamma constant 2 (huTRGC2)	84
human delta constant (huTRDC)	85
pairing enhanced beta constant 1 (mmTRBC1)	86
pairing enhanced beta constant 2 (mmTRBC2)	87
pairing enhanced alpha constant (mmTRAC)	88

In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

CLAIMS

What is claimed is:

1. An engineered T cell receptor (TCR) comprising:
 - a) a TCR α polypeptide comprising a TCR α variable domain;
 - b) a TCR β polypeptide comprising a TCR β variable domain; and
 - c) one or more antigen-binding domains linked to the TCR α variable domain and/or TCR β variable domain.
2. An engineered T cell receptor (TCR) comprising:
 - a) a TCR γ polypeptide comprising a TCR γ variable domain;
 - b) a TCR δ polypeptide comprising a TCR δ variable domain; and
 - c) one or more antigen-binding domains linked to the TCR γ variable domain and/or TCR δ variable domain.
3. The engineered TCR of claim 1, wherein the TCR α polypeptide comprises a TCR α constant domain and the TCR β polypeptide comprises a TCR β constant domain.
4. The engineered TCR of claim 2, wherein the TCR γ polypeptide comprises a TCR γ constant domain and the TCR δ polypeptide comprises a TCR δ constant domain.
5. The engineered TCR of any one of claims 1-4, wherein the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR α or TCR γ variable domain.
6. The engineered TCR of any one of claims 1-5, wherein the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR β or TCR δ variable domain.
7. The engineered TCR of any one of claims 1-6, wherein the one or more antigen-binding domains comprise: (i) a first antigen-binding domain linked to the TCR α or TCR γ variable domain, and (ii) a first antigen-binding domain linked to the TCR β or TCR δ variable domain.

8. The engineered TCR of any one of claims 5-7, wherein the first antigen-binding domains are linked to the N-terminus of the variable domains.
9. The engineered TCR of any one of claims 5-8, wherein the first antigen-binding domains are the same or different, and/or bind to the same or different target antigens.
10. The engineered TCR of any one of claims 5-9, wherein the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α or TCR γ variable domain.
11. The engineered TCR of any one of claims 5-10, wherein the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR β or TCR δ variable domain.
12. The engineered TCR of any one of claims 5-11, wherein the one or more antigen-binding domains comprises: (i) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α or TCR γ variable domain, and (ii) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR β or TCR δ variable domain.
13. The engineered TCR of any one of claims 10-12, wherein the second antigen-binding domains are linked to the N-terminus of the first antigen-binding domain.
14. The engineered TCR of claim 12 or claim 13, wherein the second antigen-binding domains are the same or different, and/or bind to the same or different target antigens.
15. The engineered TCR of any one of claims 5-14, wherein the first and second antigen-binding domains are the same or different, and/or bind to the same or different target antigens.
16. The engineered TCR of any one of claims 1-15, wherein the one or more antigen-binding domains bind a target antigen selected from the group consisting of: alpha folate receptor (FR α), $\alpha_v\beta_6$ integrin, ADGRE2, BACE2, B cell maturation antigen (BCMA),

B7-H3 (CD276), B7-H4, B7-H6, CA19.9, carbonic anhydrase IX (CAIX), CCR1, CD7, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CD244, carcinoembryonic antigen (CEA), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), CLDN6, cMET, chondroitin sulfate proteoglycan 4 (CSPG4), CLDN18.2, cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), DLL3, epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), EGFR806, epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), EPHB2, ERBB4, epithelial cell adhesion molecule (EPCAM), ephrin type-A receptor 2 (EPHA2), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AChR), FLT3, FN, FN-EDB, FRBeta, ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), HER2p95, EGFRv3, IL-10R α , IL-13R α 2, Kappa, cancer/testis antigen 2 (LAGE-1A), K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, LY6G6GD, melanoma antigen recognized by T cells 1 (MelanA or MART1), Mesothelin (MSLN), MMP10, MUC1, MUC16, MHC class I chain related proteins A (MICA), MHC class I chain related proteins B (MICB), neural cell adhesion molecule (NCAM), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X breakpoint 2 (SSX2), Survivin, tumor associated glycoprotein 72 (TAG72), transmembrane activator and CAML interactor (TACI), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), TIM3, trophoblast glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, and vascular endothelial growth factor receptor 2 (VEGFR2).

17. The engineered TCR of any one of claims 1-16, wherein the one or more antigen-binding domains bind a target polypeptide derived from a protein selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase

(hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

18. The engineered TCR of any one of claims 1-17, wherein the one or more antigen-binding domains bind CD33, CLL1, CD19, CD20, CD22, CD79A, CD79B, or BCMA.

19. The engineered TCR of any one of claims 1-17, wherein the one or more antigen-binding domains bind CD19, CD20, CD22, CD33, CD79A, CD79B, B7H3, Muc16, Her2, EGFR, FN-EDB, CLDN18.2, DLL3, FLT3, CLL1, CD123, or BCMA.

20. The engineered TCR of any one of claims 1-17, wherein the one or more antigen-binding domains comprises an amino acid sequence at least 95% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32.

21. The engineered TCR of any one of claims 1-20, wherein the one or more antigen-binding domains comprise an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')₂ fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein ("scFv"), a bis-scFv, (scFv)₂, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein ("dsFv"), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

22. The engineered TCR of any one of claims 1-21, wherein the one or more antigen-binding domains comprise one or more single-chain variable fragments (scFv).
23. The engineered TCR of any one of claims 1-22, wherein the one or more antigen-binding domains comprise one or more single domain antibodies (sdAb).
24. The engineered TCR of claim 23, wherein the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb).
25. The engineered TCR of claim 23, wherein the sdAb is a camelid VHH.
26. The engineered TCR of any one of claims 21-25, wherein antibody or antigen binding fragment thereof is human or humanized.
27. The engineered TCR of any one of claims 1-19, wherein the one or more antigen-binding domains comprise a ligand.
28. The engineered TCR of any one of claims 1-27, wherein the one or more antigen-binding domain are linked to the TCR variable domains by one or more polypeptide linkers.
29. The engineered TCR of claim 28, wherein the one or more polypeptide linkers comprise a linker from about 2 to about 25 amino acids long.
30. The engineered TCR of claim 28 or claim 29, wherein the one or more polypeptide linkers comprise a linker from about 4 to about 15 amino acids long.
31. The engineered TCR of any one of claims 28-30, wherein the one or more polypeptide linkers comprise a linker from about 4 to about 10 amino acids long.
32. The engineered TCR of any one of claims 28-31, wherein the one or more polypeptide linkers comprise a linker of about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15 amino acids long.

33. The engineered TCR of any one of claims 28-32, wherein the one or more polypeptide linkers comprise a linker of about 9 or about 10 amino acids long.

34. The engineered TCR of any one of claims 28-33 wherein the one or more polypeptide linkers comprise a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), a linker from a marsupial $\gamma\mu$ TCR (*e.g.*, LEKT; SEQ ID NO: 33), and any combination thereof.

35. The engineered TCR of claims 28-34, wherein the one or more polypeptide linkers comprises a linker from a marsupial $\gamma\mu$ TCR, comprising an amino acid sequence as set forth in SEQ ID NO: 33.

36. The engineered TCR of claims 28-35, wherein the one or more polypeptide linkers comprise a GGGGS (SEQ ID NO: 35) linker (G4S).

37. The engineered TCR of claims 28-36, wherein the one or more polypeptide linkers comprise a marsupial $\gamma\mu$ TCR linker and a G4S linker as set forth in SEQ ID NO: 34.

38. The engineered TCR of claims 28-37, wherein the one or more polypeptide linkers comprise two GGGGS linkers (2xG4S) (SEQ ID NO: 36).

39. The engineered TCR of claims 28-38, wherein the one or more polypeptide linkers comprise three GGGGS linkers (3xG4S) (SEQ ID NO: 37).

40. The engineered TCR of claims 28-39, wherein the one or more polypeptide linkers comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

41. The engineered TCR of any one of claims 10-40, wherein the first and second antigen-binding domains are separated by a second polypeptide linker.

42. The engineered TCR of claim 41, wherein the second polypeptide linker is about 2 to about 25 amino acids long.

43. The engineered TCR of claim 41 or claim 42, wherein the second polypeptide linker is about 4 to about 15 amino acids long.

44. The engineered TCR of any one of claims 41-43, wherein the second polypeptide linker comprises a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), and any combination thereof.

45. The engineered TCR of any one of claims 41-44, wherein the second polypeptide linker comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

46. The engineered TCR of any one of claims 1-45, wherein the TCR variable domains bind a target polypeptide presented by an MHC complex.

47. The engineered TCR of any one of the claims 1-46, wherein the TCR variable domains bind a target polypeptide derived from a protein selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X

8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

48. The engineered TCR of any one of the claims 1-47, wherein the TCR variable domains bind a target polypeptide derived from MAGE-A4, PRAME, K-Ras, TP53R175H, PSA, or IGF2BP3.

49. The engineered TCR of any one of the claims 1-48, wherein the TCR variable domains bind a target polypeptide derived from MAGE-A4.

50. The engineered TCR of any one of claims 1-49, wherein the TCR α constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88, and/or the TCR β constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87.

51. The engineered TCR of any one of claims 1-49, wherein the TCR γ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84, and/or the TCR δ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NO: 85.

52. The engineered TCR of any one of claims 1-51, wherein the TCR α or TCR γ polypeptide comprises (i) an amino acid sequence as set forth in any one of SEQ ID NOs: 105-111, or (ii) a TCR α or TCR γ variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 62, 64, 66, 68, 70, 72, 74, 76, and 78.

53. The engineered TCR of any one of claims 1-52, wherein the TCR β or TCR δ polypeptide comprises (i) an amino acid sequence as set forth in SEQ ID NO: 103 or 104, or (ii) a TCR β or TCR δ variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 63, 65, 67, 69, 71, 73, 75, 77, and 79.

54. A fusion polypeptide comprising:
- a) a TCR β polypeptide comprising a TCR β variable domain;
 - b) a polypeptide cleavage signal; and
 - c) a TCR α polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR α variable domain.
55. A fusion polypeptide comprising:
- a) a TCR β polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR β variable domain;
 - b) a polypeptide cleavage signal; and
 - c) a TCR α polypeptide comprising a TCR α variable domain.
56. A fusion polypeptide comprising:
- a) a TCR β polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR β variable domain;
 - b) a polypeptide cleavage signal; and
 - c) a TCR α polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR α variable domain.
57. A fusion polypeptide comprising:
- a) a TCR γ polypeptide comprising a TCR γ variable domain;
 - b) a polypeptide cleavage signal; and
 - c) a TCR δ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR δ variable domain.
58. A fusion polypeptide comprising:
- a) a TCR γ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR γ variable domain;
 - b) a polypeptide cleavage signal; and
 - c) a TCR δ polypeptide comprising a TCR δ variable domain.

59. A fusion polypeptide comprising:
- a) a TCR γ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR γ variable domain;
 - b) a polypeptide cleavage signal; and
 - c) a TCR δ polypeptide comprising one or more antigen-binding domains, a polypeptide linker, and a TCR δ variable domain.
60. The fusion polypeptide of any one of claims 54-56, wherein the TCR β polypeptide comprises TCR β constant domain, and the TCR α polypeptide comprises a TCR α constant domain.
61. The fusion polypeptide of any one of claims 57-59, wherein the TCR γ polypeptide comprises TCR γ constant domain, and the TCR δ polypeptide comprises a TCR δ constant domain.
62. The fusion polypeptide of any one of claims 54-61, wherein the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR α or TCR γ variable domain.
63. The fusion polypeptide of any one of claims 54-62, wherein the one or more antigen-binding domains comprises a first antigen-binding domain linked to the TCR β or TCR δ variable domain.
64. The fusion polypeptide of any one of claims 54-63, wherein the one or more antigen-binding domains comprise: (i) a first antigen-binding domain linked to the TCR α or TCR γ variable domain, and (ii) a first antigen-binding domain linked to the TCR β or TCR δ variable domain.
65. The fusion polypeptide of any one of claims 62-64, wherein the first antigen-binding domains are linked to the N-terminus of the variable domains.
66. The fusion polypeptide of any one of claims 62-65, wherein the first antigen-binding domains are the same or different, and/or bind to the same or different target antigens.

67. The fusion polypeptide of any one of claims 62-66, wherein the one or more antigen-binding domains comprises a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α or TCR γ variable domain.

68. The fusion polypeptide of any one of claims 62-67, wherein the one or more antigen-binding domains comprises a second antigen-binding domain is linked to the first antigen-binding domain linked to the TCR β or TCR δ variable domain.

69. The fusion polypeptide of any one of claims 62-68, wherein the one or more antigen-binding domains comprises: (i) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR α or TCR γ variable domain, and (ii) a second antigen-binding domain linked to the first antigen-binding domain linked to the TCR β or TCR δ variable domain.

70. The fusion polypeptide of any one of claims 67-69, wherein the second antigen-binding domains are linked to the N-terminus of the first antigen-binding domain.

71. The fusion polypeptide of claim 69 or claim 70, wherein the second antigen-binding domains are the same or different, and/or bind to the same or different target antigens.

72. The fusion polypeptide of any one of claims 67-71, wherein the first and second antigen-binding domains are the same or different, and/or bind to the same or different target antigens.

73. The fusion polypeptide of any one of claims 54-72, wherein the one or more antigen-binding domains bind a target antigen selected from the group consisting of: alpha folate receptor (FR α), $\alpha_v\beta_6$ integrin, ADGRE2, BACE2, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H4, B7-H6, CA19.9, carbonic anhydrase IX (CAIX), CCR1, CD7, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CD244, carcinoembryonic antigen (CEA), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), CLDN6, cMET, chondroitin sulfate proteoglycan 4 (CSPG4), CLDN18.2, cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), DLL3, epidermal growth factor receptor (EGFR), epidermal growth factor

receptor variant III (EGFRvIII), EGFR806, epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), EPHB2, ERBB4, epithelial cell adhesion molecule (EPCAM), ephrin type-A receptor 2 (EPHA2), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AchR), FLT3, FN, FN-EDB, FRBeta, ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), HER2p95, EGFRv3, IL-10R α , IL-13R α 2, Kappa, cancer/testis antigen 2 (LAGE-1A), K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, LY6G6GD, melanoma antigen recognized by T cells 1 (MelanA or MART1), Mesothelin (MSLN), MMP10, MUC1, MUC16, MHC class I chain related proteins A (MICA), MHC class I chain related proteins B (MICB), neural cell adhesion molecule (NCAM), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X breakpoint 2 (SSX2), Survivin, tumor associated glycoprotein 72 (TAG72), transmembrane activator and CAML interactor (TACI), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), TIM3, trophoblast glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, and vascular endothelial growth factor receptor 2 (VEGFR2).

74. The fusion polypeptide of any one of claims 54-73, wherein the one or more antigen-binding domains bind a target polypeptide derived from a protein selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1),

Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

75. The fusion polypeptide of claims 54-74, wherein the one or more antigen-binding domains bind CD33, CLL1, CD19, CD20, CD22, CD79A, CD79B, or BCMA.

76. The engineered TCR of any one of claims 54-74, wherein the one or more antigen-binding domains bind CD19, CD20, CD22, CD33, CD79A, CD79B, B7H3, Muc16, Her2, EGFR, FN-EDB, CLDN18.2, DLL3, FLT3, CLL1, CD123, or BCMA.

77. The engineered TCR of any one of claims 54-74, wherein the one or more antigen-binding domains comprises an amino acid sequence at least 95% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 1-32.

78. The fusion polypeptide of any one of claims 54-77, wherein the one or more antigen-binding domains comprise an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')₂ fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein ("scFv"), a bis-scFv, (scFv)₂, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein ("dsFv"), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

79. The fusion polypeptide of any one of claims 54-78, wherein the one or more antigen-binding domains comprise one or more single-chain variable fragments (scFv).

80. The fusion polypeptide of any one of claims 54-79, wherein the one or more antigen-binding domains comprise one or more single domain antibodies (sdAb).

81. The fusion polypeptide of claim 80, wherein the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb).

82. The fusion polypeptide of claim 80, wherein the sdAb is a camelid VHH.
83. The fusion polypeptide of any one of claims 74-82, wherein the antibody or antigen binding fragment thereof is human or humanized.
84. The fusion polypeptide of any one of claims 54-76, wherein the one or more antigen-binding domains comprise a ligand.
85. The fusion polypeptide of any one of claims 54-84, wherein the one or more antigen-binding domains are linked to the TCR variable domains by one or more polypeptide linkers.
86. The fusion polypeptide of claim 85, wherein the one or more polypeptide linkers comprise a linker from about 2 to about 25 amino acids long.
87. The fusion polypeptide of claim 85 or claim 86, wherein the one or more polypeptide linkers comprise a linker from about 4 to about 15 amino acids long.
88. The fusion polypeptide of any one of claims 85-87, wherein the one or more polypeptide linkers comprise a linker from about 4 to about 10 amino acids long.
89. The fusion polypeptide of any one of claims 85-88, wherein the one or more polypeptide linkers comprise a linker of about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15 amino acids long.
90. The fusion polypeptide of any one of claims 85-89, wherein the one or more polypeptide linkers comprise a linker of about 9 or about 10 amino acids long.
91. The fusion polypeptide of any one of claims 85-90 wherein the one or more polypeptide linkers comprise a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), a linker from a marsupial $\gamma\mu$ TCR (*e.g.*, LEKT; SEQ ID NO: 33), and any combination thereof.

92. The fusion polypeptide of claims 85-91, wherein the one or more polypeptide linkers comprises a linker from a marsupial $\gamma\mu$ TCR, comprising an amino acid sequence as set forth in SEQ ID NO: 33.

93. The fusion polypeptide of claims 85-92, wherein the one or more polypeptide linkers comprise a GGGGS (SEQ ID NO: 35) linker (G4S).

94. The fusion polypeptide of claims 85-93, wherein the one or more polypeptide linkers comprise a marsupial $\gamma\mu$ TCR linker and a G4S linker as set forth in SEQ ID NO: 34.

95. The fusion polypeptide of claims 85-94, wherein the one or more polypeptide linkers comprise two GGGGS linkers (2xG4S) (SEQ ID NO: 36).

96. The fusion polypeptide of claims 85-95, wherein the one or more polypeptide linkers comprise three GGGGS linkers (3xG4S) (SEQ ID NO: 37).

97. The fusion polypeptide of claims 85-96, wherein the one or more polypeptide linkers comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

98. The fusion polypeptide of any one of claims 67-97, wherein the first and second antigen-binding domains are separated by a second polypeptide linker.

99. The fusion polypeptide of claim 98, wherein the second polypeptide linker is about 2 to about 25 amino acids long.

100. The fusion polypeptide of claim 98 or claim 99, wherein the one or more polypeptide linkers comprise a linker from about 4 to about 15 amino acids long.

101. The fusion polypeptide of any one of claims 98-100, wherein the second polypeptide linker comprises a linker selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, GGS, GGGS (SEQ ID NO: 53), (GGGS)₁₋₅ polypeptide (SEQ ID NOs: 35-39), and any combination thereof.

102. The fusion polypeptide of any one of claims 98-101, wherein the second polypeptide linker comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 33-53.

103. The fusion polypeptide of any one of claims 54-102, wherein the TCR variable domains bind a target polypeptide presented by an MHC complex.

104. The fusion polypeptide of any one of the claims 54-103, wherein the TCR variable domains bind a target polypeptide derived from a protein selected from the group consisting of: α -fetoprotein (AFP), ASCL2, B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, EPHB2, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, IGF2BP1, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), LY6G6D, Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, PAP, PIK3CA, PIK3CA H1047R, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Prostate specific antigen PSA, Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, TP53 R175H, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, UBD, Wilms tumor protein (WT-1), Wnt10A, X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

105. The fusion polypeptide of any one of the claims 54-104, wherein the TCR variable domains bind a target polypeptide derived from MAGE-A4, PRAME, K-Ras, TP53R175H, PSA, or IGF2BP3.

106. The fusion polypeptide of any one of the claims 54-105, wherein the TCR variable domains bind a target polypeptide derived from MAGE-A4.

107. The engineered TCR of any one of claims 54-106, wherein the TCR α constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NOs: 82 or 88, and/or the TCR β constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 80, 81, 86, or 87.

108. The engineered TCR of any one of claims 54-106, wherein the TCR γ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 83 or 84, and/or the TCR δ constant domain comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NO: 85.

109. The fusion polypeptide of any one of claims 54-108, wherein the TCR α or TCR γ polypeptide comprises (i) an amino acid sequence as set forth in any one of SEQ ID NOs: 105-111, or (ii) a TCR α or TCR γ variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 62, 64, 66, 68, 70, 72, 74, 76, and 78.

110. The fusion polypeptide of any one of claims 54-109, wherein the TCR β or TCR δ polypeptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 103 or 104, or (ii) a TCR β or TCR δ variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 63, 65, 67, 69, 71, 73, 75, 77, and 79.

111. The fusion polypeptide of any one of claims 54-110, wherein the polypeptide cleavage signal is a viral self-cleaving peptide or ribosomal skipping sequence.

112. The fusion polypeptide of any one of claims 54-111, wherein the polypeptide cleavage signal is a viral 2A peptide.

113. The fusion polypeptide of any one of claims 54-112, wherein the polypeptide cleavage signal is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide.

114. The fusion polypeptide of any one of claims 54-113, wherein the polypeptide cleavage signal is a viral 2A peptide selected from the group consisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thossea asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.

115. The fusion polypeptide of any one of claims 111-114, wherein the polypeptide cleavage signal comprises a furin recognition site upstream of the self-cleaving peptide, optionally wherein the furin recognition site comprises the amino acid sequence as set forth in SEQ ID NO: 112.

116. The fusion polypeptide of any one of claims 54-115, wherein the polypeptide cleavage signal comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 113-137.

117. The fusion polypeptide of any one of claims 54-116, wherein the TCR β or TCR δ polypeptide is N-terminal of the TCR α or TCR γ polypeptide.

118. The fusion polypeptide of any one of claims 54-116, wherein the TCR α or TCR γ polypeptide is N-terminal of the TCR β or TCR δ polypeptide.

119. The fusion polypeptide of any one of claims 54-118, wherein the TCR α and TCR β polypeptides each comprise an N-terminal signal sequence.

120. The fusion polypeptide of any one of claims 54-119, wherein the TCR γ and TCR δ polypeptides each comprises an N-terminal signal sequence.

121. The fusion polypeptide of claim 119 or claim 120, wherein the signal sequences are the same or different.

122. The fusion polypeptide of any one of claims 119-121, wherein the signal sequence is an IgK or TCR α signal sequence.

123. The fusion polypeptide of any one of claims 54-122, wherein the fusion polypeptide comprises an amino acid sequence at least 90% identical to an amino acid sequence as set forth in any one of SEQ ID NOs: 91-97, 100, and 102.
124. A polynucleotide encoding the TCR polypeptides of the engineered TCR according to any one of claims 1-51, or the fusion polypeptide of any one of claims 54-123.
125. A vector comprising the polynucleotide of claim 124.
126. The vector of claim 125, wherein the vector is an expression vector, retroviral vector, or a lentiviral vector.
127. A cell comprising the engineered TCR according to any one of claims 1-53, the fusion polypeptide of any one of claims 54-123, the polynucleotide of claim 124, or the vector of claim 125 or claim 126.
128. The cell of claim 127, wherein the cell is a hematopoietic cell.
129. The cell of claim 127 or claim 128, wherein the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell.
130. The cell of any one of claims 127-129, wherein the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell.
131. The cell of any one of claims 127-130, wherein the cell is an immune effector cell.
132. The cell of any one of claims 127-131, wherein the cell is a cytotoxic T lymphocytes (CTLs), a tumor infiltrating lymphocytes (TILs), or a helper T cell.
133. The cell of any one of claims 127-132, wherein the cell is a T cell, a natural killer (NK) cell, or a natural killer T (NKT) cell.

134. The cell of any one of claims 127-133, wherein the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.

135. The cell of any one of claims 127-134, wherein the cell is an isolated non-natural cell.

136. The cell of any one of claims 127-135, wherein the cell is obtained from a subject.

137. The cell of any one of claims 127-136, wherein the cell is a human cell.

138. A composition comprising the engineered TCR according to any one of claims 1-53, the fusion polypeptide of any one of claims 54-123, the polynucleotide of claim 124, or the vector of claim 125 or claim 126, or the cell of any one of claims 127-137.

139. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the engineered TCR according to any one of claims 1-53, the fusion polypeptide of any one of claims 54-123, the polynucleotide of claim 124, or the vector of claim 125 or claim 126, or the cell of any one of claims 127-137.

140. A method of treating a subject in need thereof comprising administering the subject an effective amount of the cell of any one of claims 127-137, the composition of claim 138, or the pharmaceutical composition of claim 139.

141. A method of treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith, comprising administering to the subject an effective amount of the cell of any one of claims 127-137, the composition of claim 138, or the pharmaceutical composition of claim 139.

142. A method of treating a solid cancer comprising administering to the subject an effective amount of the cell of any one of claims 127-137, the composition of claim 138, or the pharmaceutical composition of claim 139.

143. The method of claim 142, wherein the solid cancer is selected from the group consisting of: lung cancer, squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, brain cancer, or sarcoma.

144. The method of claim 142, wherein the solid cancer is a non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, oligodendroglioma, sarcoma, or osteosarcoma.

145. A method of treating a hematological malignancy comprising administering to the subject an effective amount of the cell of any one of claims 127-137, the composition of claim 138, or the pharmaceutical composition of claim 139.

146. The method of claim 145, wherein the hematological malignancy is a leukemia, lymphoma, or multiple myeloma.

147. The method of claim 145 or claim 146, wherein the hematological malignancy is selected from the group consisting of non-Hodgkin's lymphoma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL).